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Summary 
In both the male and the female, normal reproductive function depends on the optimal 
function of the hypothalamo-pituitary-gonadal axis. The hypothalamic gonadotropin-
releasing hormone (GnRH) elicits the release of the gonadotropins luteinising hormone 
(LH) and follicle stimulating hormone (FSH) by the pituitary gonadotrophs. LH is 
responsible for sex steroid production while FSH regulates gametogenesis. In turn, 
gonadal sex steroids such as 17-β-estradiol (E2) alter gonadotropin secretion through a 
feedback loop at the level of the hypothalamus and the pituitary.  
In the past, many in vitro studies have been conducted using primary pituitary cell 
cultures and tissue explants to study regulatory effects of E2 at the pituitary level. 
However, data interpretation is complex, as gonadotrophs interact with other pituitary 
cell types. Furthermore, these cells only represent 10% of the total pituitary cell 
population. 
In the beginning of the nineties, two immortalised gonadotropic cell lineages of murine 
origin, namely the LβT2 and the αT3-1 cell lines, were developed by the group of P. 
Mellon using targeted oncogenesis to the pituitary of transgenic mice. Although both 
cell lines express a functional GnRH receptor and the common α-gonadotropin subunit 
(α-GSU), they differ in their degree of differentiation. The LβT2 cell line has been 
shown to exhibit structural and functional characteristics of normal pituitary 
gonadotrophs, including expression of both LHβ- and FSHβ-subunits, together with the 
corresponding gonadotropin secretion. In contrast, the αT3-1 cell line is less 
differentiated as gonadotropin β-subunit expression appeared to be absent, hereby 
lacking ability to produce LH and FSH.  
Since its development, the LβT2 cell line served as a golden standard for the in vitro 
analysis of regulatory mechanisms involved in gonadotropin synthesis. 
In the present project, we have analysed the effects of estrogens and (anti-) 
estrogenic-active compounds at the level of the pituitary gonadotrophs using the LβT2 
and αT3-1 cell lineages. 
The first chapter of our experimental work (chapter 4.1) describes the analysis of the 
regulatory effects of E2 on GnRH-enhanced LH synthesis and secretion in the LβT2 cells. 
We have demonstrated that the LH secretory response was dose-dependently enhanced 
by GnRH, except on the first treatment day. This may indicate that the well-described 
self priming effect of GnRH on gonadotrophs in vivo remained preserved in the LβT2 
cell line. However, LH secretion diminished following daily repeated exposure to high 
concentrations of GnRH. This was not be explained by GnRH receptor down regulation 
or desensitisation, as LHβ-su gene expression was dose-dependently enhanced by 
GnRH, even at high concentrations of GnRH. Other factors such as alteration of post-
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translational processes or vesicle storage may be responsible for this diminished LH 
secretory response following exposure to high concentrations of GnRH.  
In contrast to limited literature data, E2 was not able to alter GnRH-enhanced LH 
release in the LβT2 cell line. Analysis of receptor expression revealed that LβT2 cells 
lack a functional estrogen receptor α (ERα). Even following ERα overexpression, we 
were not able to demonstrate any ER-mediated effect, hereby indicating disturbed ER 
signalling. This is further emphasized by the relative strong expression of an ERα 
messenger RNA splicing variant in comparison to the full length ERα message. This 
splicing variant (theoretically) encodes for a receptor protein which lacks almost the 
complete ligand binding domain and may possibly interfere with normal ER signalling in 
LβT2 cells. 
According to our findings, the gonadotropic LβT2 cell line was not a suitable in vitro 
model for the study of estrogenic regulatory effects at the level of the pituitary 
gonadotrophs. For this reason, we have chosen for the less differentiated αT3-1 cell 
line. These data are presented in chapter 4.2. Proliferation experiments and transient 
transfection studies with an estrogen-responsive reporter plasmid have demonstrated 
the presence of a functional ERα in αT3-1 cells. Although E2 showed rather modest 
effects on cell proliferation, the selective estrogen receptor modulator (SERM) 4-
hydroxy-tamoxifen and the pure anti-estrogen ICI 182,780 (fulvestrant) strongly 
repressed basal cell proliferation and ERα-mediated gene transcription. This 
unexpected result may be explained by cross-talk between ERα and the insulin-like 
growth factor I (IGF-I) receptor in our αT3-1 cell line. IGF-I enhanced ERα-mediated 
gene expression dose-dependently. Furthermore, exposure to raising concentrations of 
this growth factor reversed anti-estrogen-induced inhibition of basal cell proliferation 
and ERα-mediated gene expression. Another interesting observation was the fact that 
both IGF-I and E2 stimulated ERα phosphorylation at serine residue 118, a prerequisite 
for the ERα transcriptional activity. Our data suggest the involvement of IGF-I in the 
regulation of ERα-mediated effects at the level of the pituitary gonadotrophs. These 
findings are supported by limited literature data, showing modulatory effects of IGF-I 
on LH secretion by the pituitary gonadotrophs. Nevertheless, more research is required 
to further elucidate this complex mechanism of action. 
In contrast to the LβT2 cell line, showing lack of any estrogenic response, the less 
differentiated αT3-1 cell line appears to be an interesting in vitro model for the study 
of estrogenic effects at the level of the pituitary gonadotrophs. This offers interesting 
opportunities to screen and unravel the mechanisms of action of estrogenic-active 
compounds in gonadotrophs. The importance of such studies is emphasized by the use 
of phytoestrogens as an alternative for hormone replacement therapy. Accumulating 
evidence also suggests that exposure to xenoestrogens (estrogenic-active chemicals 
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present in the environment) may be responsible for reported increased prevalence of 
fertility disorders. In addition, the pharmaceutical industry is interested in the 
development of SERMs for the treatment of estrogen-dependent diseases such as 
osteoporosis and breast cancer.  
For these reasons, it is important to analyse the effects of phytoestrogens, 
xenoestrogens and (anti-)estrogenic pharmaceutical drugs at the level of the pituitary 
gonadotrophs, as these cells may be an important target of these compounds. 
At present, ongoing research in our laboratory focuses on the effects of phytoestrogens 
in the αT3-1 cell line. An example of such experiments has been presented in the 
discussion chapter (chapter 5.9). 
In conclusion, the mature gonadotropic LβT2 cell line, being the golden standard for 
molecular endocrinological research in pituitary gonadotrophs, was not a suitable 
model for our purposes because of the demonstrated lack of estrogenic response. In 
contrast, the less-differentiated αT3-1 cell line showed expression of a functional ERα, 
as demonstrated using cell proliferation assays and transient transfection assays. In 
addition, the growth inhibitory effects of SERMs and pure anti-estrogens may be 
explained by interactions between ERα and the IGF-IR. These data suggest that IGF-I 
may play an important role in the regulation of ER-mediated effects at the level of the 
pituitary gonadotrophs. According to our results, the αT3-1 cell line is a promising in 
vitro tool for the assessment of phytoestrogens, xenoestrogens and SERMs in order to 
unravel their complex mechanisms of action at the level of the pituitary gonadotrophs. 
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Samenvatting 
Bij man en vrouw wordt het fysiologische proces dat verantwoordelijk is voor de 
vruchtbaarheid gereguleerd door de hypothalamo-hypofysaire gonadale as. Het 
gonadotropine-releasing hormoon (GnRH) stimuleert de productie van de 
gonadotropines follikel stimulerend hormoon (FSH) en luteïniserend hormoon (LH) door 
de hypofysaire gonadotropen. LH is verantwoordelijk voor de synthese van de 
geslachtshormonen ter hoogte van de gonaden, terwijl FSH de gametogenese 
moduleert. Via een feedback terugkoppeling naar de hypothalamus en de hypofyse, 
controleren de gonadale geslachtshormonen, waaronder het 17-β-estradiol (E2), op hun 
beurt de gonadotropine secretie. 
Voor de studie van oestrogene effecten ter hoogte van de hypofyse werd vroeger 
gebruik gemaakt van primaire hypofysaire celculturen en weefselexplanten. De 
interpretatie van de bekomen data wordt echter bemoeilijkt omdat gonadotropen 
kunnen interageren met andere hypofysaire celtypes. Een andere beperking is het feit 
dat gonadotropen slechts 10% uitmaken van de totale hypofysaire celpopulatie.  
In het begin van de jaren negentig heeft de groep van P. Mellon twee 
geïmmortaliseerde, gonadotrope cellijnen ontwikkeld door middel van gerichte 
oncogenese in transgene muizen. Deze LβT2 en αT3-1 gonadotrope cellijnen brengen 
de gemeenschappelijke α-gonadotropine subunit en een functionele GnRH receptor tot 
expressie, maar verschillen in differentiatiegraad. De LβT2 cellijn vertoont structurele 
en functionele karakteristieken van volwassen hypofysaire gonadotropen. De αT3-1 
cellijn daarentegen is minder gedifferentieerd door de afwezigheid van gonadotropine 
β-subunits. Dit heeft als gevolg dat αT3-1 cellen niet in staat zijn om LH en FSH te 
secreteren. 
Sinds zijn ontwikkeling diende de LβT2 cellijn als gouden standaard in het onderzoek 
naar de moleculaire mechanismen die betrokken zijn bij gonadotropine productie.  
In het huidige project hebben we gebruik gemaakt van de αT3-1 en LβT2 cellijnen om 
de effecten van oestrogenen en (anti-)oestrogene componenten ter hoogte van de 
hypofysaire gonadotropen te bestuderen.  
In het eerste luik van ons experimenteel onderzoek (hoofdstuk 4.1) beschrijven we de 
effecten van E2 op GnRH-gemedieerde LH productie in de LβT2 cellijn. GnRH 
stimuleerde LH secretie op een dosisafhankelijke manier, behalve op de eerste 
behandelingsdag. Dit suggereert dat het “self-priming” effect van GnRH in 
gonadotropen bewaard is gebleven in de LβT2 cellijn. Dagelijks herhaalde blootstelling 
aan hoge concentraties GnRH zorgde echter voor een gedaalde LH vrijstelling. Dit kon 
niet verklaard worden door GnRH receptor downregulatie of desensitisatie, aangezien 
de expressie van het LHβ-subunit gen dosis-afhankelijk werd gestimuleerd, ook door 
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hogere concentraties van GnRH. Andere factoren, zoals post-translationele processen 
of opslag in de vesikels kunnen verstoord zijn in de LβT2 cellijn. 
In tegenstelling tot beperkte literatuurgegevens, bleek E2 geen invloed te hebben op 
GnRH-gestimuleerde LH secretie. Dit kan verklaard worden door de afwezigheid van 
een functionele oestrogeen receptor α (ERα) in de LβT2 cellijn. Bovendien blijkt ERα-
gestuurde signaaltransductie verstoord te zijn, aangezien E2-gemedieerde effecten 
afwezig bleven na overexpressie van de oestrogeen receptor. Dit wordt verder 
bevestigd door de relatief sterke expressie van een ERα messenger RNA splicing variant 
in vergelijking met normale ERα expressie. Theoretisch gezien codeert deze splice 
variant voor een receptoreiwit waarvan het ligand bindende domein quasi volledig 
ontbreekt. Een mogelijke hypothese is het feit dat deze variant kan interfereren met 
normale ER-gestuurde signaaltransductie in de LβT2 cellijn. 
Uit bovenstaande bevindingen kunnen we afleiden dat de gonadotrope LβT2 cellijn niet 
geschikt is voor in vitro studies naar oestrogene effecten ter hoogte van de hypofysaire 
gonadotropen. Daarom ging de voorkeur uit naar de minder gedifferentieerde αT3-1 
cellijn. Deze data zijn voorgesteld in chapter 4.2. Proliferatiestudies en transfecties 
met een oestrogeen-responsief reporter plasmide hebben aangetoond dat αT3-1 cellen 
een functionele ERα tot expressie brengen. Ondanks de eerder matige effecten van E2 
op αT3-1 celgroei zorgden de selectieve oestrogeenreceptor modulator (SERM) 4-
hydroxy-tamoxifen en het pure anti-oestrogeen ICI 182,780 (fulvestrant) voor een 
sterke inhibitie van zowel basale celgroei als van ERα-gestuurde gentranscriptie. Dit 
eerder onverwachte resultaat kan verklaard worden door interacties tussen ERα en de 
insulin-like growth factor I (IGF-I) receptor in de αT3-1 cellijn. Dit wordt bevestigd 
door het feit dat IGF-I in staat was om ERα-gestuurde genexpressie dosis-afhankelijk te 
stimuleren. De anti-oestrogeen-geïnduceerde inhibitie van basale celgroei en ERα-
gemedieerde genexpressie werd bovendien geblokkeerd door het toevoegen van 
stijgende concentraties IGF-I. Een andere belangrijke factor is het feit dat IGF-I in 
staat was om ERα fosforylatie ter hoogte van serine residue 118 te stimuleren. Deze 
fosforylatie is namelijk één van de sleutelvoorwaarden voor een optimale ERα 
transcriptionele activiteit. Uit deze data kunnen we afleiden dat IGF-I een invloed kan 
hebben op ERα-gemedieerde signaaltransductie in hypofysaire gonadotropen. Dit wordt 
bevestigd door een beperkt aantal rapporten in de literatuur, waarin beschreven wordt 
dat IGF-I LH secretie kan beïnvloeden. Extra onderzoek is dus noodzakelijk om dit 
complexe mechanisme verder uit te pluizen. 
Uit bovenstaande resultaten is gebleken dat de minder gedifferentieerde αT3-1 cellijn 
kan aangewend worden als een in vitro model voor de studie van oestrogene effecten 
in hypofysaire gonadotropen. In de gedifferentieerde LβT2 cellijn daarentegen bleken 
oestrogenen geen invloed te vertonen op LH en FSH productie. Het bestaan van een 
 
10
  
oestrogeen-responsieve gonadotrope cellijn opent veel mogelijkheden voor het 
onderzoek naar de mechanismen van oestrogeen-actieve componenten ter hoogte van 
de gonadotropen. De laatste jaren is er namelijk verhoogde interesse naar het gebruik 
van fyto-oestrogenen (plantaardige oestrogene stoffen) als alternatief voor de klassieke 
hormonale substitutietherapie. Meer en meer studies tonen ook aan dat blootstelling 
aan xeno-oestrogenen (oestrogeen-actieve chemicaliën aanwezig in het milieu) de 
vruchtbaarheid negatief kunnen beïnvloeden. Vanuit de farmaceutische industrie wordt 
bovendien sterk geïnvesteerd in de ontwikkeling van SERMs voor de behandeling van 
oestrogeen-afhankelijke aandoeningen zoals osteoporose en borstkanker. 
Aangezien gonadotropen een sleutelrol spelen in de regulatie van de vruchtbaarheid, 
vormen ze dus een mogelijk doelwit voor dergelijke stoffen. Momenteel wordt in ons 
laboratorium de αT3-1 cellijn aangewend voor de analyse van fyto-oestrogeen 
geïnduceerde effecten ter hoogte van gonadotropen. In hoofdstuk 5.9 tonen we een 
voorbeeld van een dergelijk experiment. 
Uit onze studie kunnen we concluderen dat de gedifferentieerde gonadotrope LβT2 
cellijn niet geschikt is voor ons onderzoek omwille van de aangetoonde afwezigheid van 
enige oestrogene respons. Daarentegen blijkt de minder gedifferentieerde αT3-1 cellijn 
een bruikbaar in vitro model te zijn door de aanwezigheid van een functionele ERα, 
zoals aangetoond door middel van proliferatie- en transfectiestudies. De geobserveerde 
inhibitie van groei- en ERα-gestuurde genexpressie kan mogelijk verklaard worden door 
interacties tussen ERα en de IGF-I receptor. Deze data suggereren dat IGF-I een 
belangrijke rol kan spelen in de regulatie van ERα-gestuurde effecten ter hoogte van 
hypofysaire gonadotropen. Vanuit dit standpunt kunnen we concluderen dat de αT3-1 
een geschikt in vitro model is voor het onderzoeken van oestrogeen-actieve 
componenten zoals fyto-oestrogenen, xeno-oestrogenen en SERMs met als finaal doel 
het moleculaire werkingsmechanisme van deze stoffen ter hoogte van de gonadotropen 
verder uit te spitten. 
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Research objectives 
The endogenous sex steroid 17-β-estradiol (E2) is a key mediator of different 
physiologic processes, including reproduction, bone metabolism, cardiovascular 
function and neuroprotection. Its action is strictly regulated in a complex manner, 
whereby multiple genetic and environmental factors determine the final outcome 
following receptor activation.  
Reproduction is under control of the hypothalamo-pituitary-gonadal axis, whereby 
estrogens regulate gonadotropin secretion through a negative feedback system at the 
level of the hypothalamus and/or the pituitary. The gonadotropins luteinising hormone 
(LH) and follicle stimulating hormone (FSH) are secreted by the pituitary gonadotrophs 
following stimulus by the hypothalamic gonadotropin-releasing hormone (GnRH) and 
are key mediators of reproduction in both the male and the female. We were 
interested in the potential effects of compounds with (anti)estrogenic properties on 
gonadotropin regulation in the pituitary gonadotrophs. Indeed, the latter may not only 
be the target of endogenous estrogens.  
During recent years, there has been growing interest for the use of phytoestrogens 
(plant-derived estrogenic compounds) as an alternative for postmenopausal hormone 
replacement therapy. However, such compounds may have both beneficial as well as 
adverse clinical effects, including the potential for increased as well as reduced risk for 
malignancies. 
The pharmaceutical industry also focuses on the development of drugs with a selective 
profile of biological activity, such as selective estrogen modulators (SERMs) to use as 
postmenopausal substitution therapy or for the treatment of hormone-related diseases 
such as hormone-responsive cancers and osteoporosis.  
In addition, there has been growing public and scientific concern about the raising 
number of fertility disorders, including decreased sperm quality, urogenital tract 
abnormalities and hormone-dependent cancers. Many studies suggest that exposure to 
xenoestrogens (being estrogenic-active chemicals present in the environment) may 
contribute to the development of these disorders.  
In other words, gonadotrophs, which are a major player in the regulation of 
reproduction, are a potential target for a variety of estrogenic compounds. 
Nevertheless, little information is available on this topic in the literature. Therefore, 
the aim of the present study was to analyse estrogen receptor-mediated effects in 
immortalised gonadotropic cell lines to gain insight in their potential as models for the 
study of the effects on gonadotrophs of substances with (anti)estrogenic properties.  
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In the past, studies of estrogenic effects on gonadotropin regulation has been 
extensively studied in vivo in primates, rodents and a variety of other mammalian 
species such as sheep. These studies allow for the study of estrogenic effects on 
gonadotropin secretion in a physiological context. There are also obvious practical 
limitations inherent to in vivo animal studies and interpretation of findings is always 
complex, which makes them less suitable for screening of effects on gonadotropin 
regulation of the numerous natural and synthetic compounds with (anti)estrogenic 
properties. Other approaches are the in vitro study in pituitary explants or primary cell 
cultures. However, gonadotrophs represent 10% of the total pituitary cell population, 
and although presence of other cell types in the culture may offer the advantage of 
allowing for potentially important cell-cell interactions, this also complicates data 
analysis. Moreover, standardisation of primary cell cultures is difficult.  
 
The study of gonadotroph-specific biochemical and molecular processes was facilitated 
by the development of immortalised, gonadotropic cell lines. In the present study, the 
murine LβT2 cell line was our primary choice because of its characteristics of mature 
gonadotrophs in vivo, including gonadotropin-releasing hormone receptor (GnRH-R) 
expression and gonadotropin secretion. Furthermore, a limited number of publications 
reported estrogen-responsiveness of the LβT2 cell line. 
The murine αT3-1 cell line reflects an early stage of gonadotroph differentiation as 
these cells express gonadotroph-specific markers but lack gonadotropin β-subunit 
expression and corresponding gonadotropin secretion. In addition, several reports 
describe the presence of a functional estrogen receptor. 
As both LβT2 and αT3-1 cell lines differ in their stage of differentiation, analysis of 
estrogenic effects in these cells might provide useful information concerning the role 
of estrogens during embryonic development of pituitary gonadotrophs 
 
Following the introductory chapter and a methodology section, we describe our 
experimental work on the effects of E2 on LH synthesis and secretion in the LβT2 cell 
line. In view of the selective lack of functional estrogen receptor (ER) expression in 
these cells, the ER-positive αT3-1 cell line served as an alternative in vitro model to 
study the response to estrogens, SERMs and growth factors on gonadotroph function; 
The ER-mediated effects in the αT3-1 cells are, at least in part, modulated by growth 
factors such as insulin-like growth factor I (IGF-1).The observations are reported in 
chapter 4.2. We conclude with a summary of our findings, general discussion and 
perspectives.  
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Chapter 1 Introduction 
1.1 The Hypothalamo-Pituitary-Gonadal axis 
1.1.1 Introduction  
In mammals, reproductive competence depends on the normal functioning of the 
hypothalamic-pituitary-gonadal axis. The episodic release of the hypothalamic 
gonadotropin-releasing hormone (GnRH) results in the pulsatile secretion of the 
gonadotropins luteinising hormone (LH) and follicle stimulating hormone (FSH) by the 
pituitary gonadotrophs (Belchetz et al., 1978; Clarke and Cummins, 1982; Moenter et 
al., 2003). In the gonads, these gonadotropins regulate gametogenesis and sex steroid 
synthesis. In turn, sex steroids and peptidergic gonadal secretory products can interact 
with the hypothalamus and/or the pituitary through a feedback loop to modulate 
gonadotropin secretion (Wildt et al., 1981; Bousfield et al., 1994; Haisenleder et al., 
1994; Burger et al., 2004; Bilezikjian et al., 2006).  
In the present work, we have focused on the effects of estrogens at the level of the 
pituitary gonadotrophs. In this chapter, we describe the hypothalamic-pituitary 
interactions which are responsible for the regulation of gonadotropin secretion. 
 
1.1.2 The Hypothalamus 
1.1.2.1 Physiology  
The hypothalamus is located below the thalamus, forming the major portion of the 
ventral region of the diencephalon and functioning to regulate certain metabolic 
processes and other autonomic activities (McClellan et al., 2006). As a consequence of 
neonatal steroid exposure, the hypothalamus in rodents is sexually dimorphic, showing 
clear differences in both structure and function between males and females (Beyer et 
al., 1994; Arai et al., 1996; Tobet, 2002). 
The hypothalamus links the nervous system to the endocrine system through the 
pituitary gland by synthesizing and secreting neurohormones, among which the so-
called releasing hormones, controlling synthesis and secretion of hormones from the 
anterior pituitary gland, including GnRH (Sherwood et al., 1993), on which we will 
focus in this chapter. 
 
1.1.2.2 Gonadotropin-releasing hormone (GnRH) 
Mammalian GnRH (GnRH-I), also called luteinising hormone-releasing hormone (LHRH), 
belongs to a group of seven distinct decapeptide hormones and is responsible for the 
release of the gonadotropins LH and FSH from the anterior pituitary. GnRH is 
synthesised as a larger precursor in specific, hypothalamic neurosecretory cells. 
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Following intracellular processing of this prohormone, GnRH is stored in neurosecretory 
granules, present in the nerve terminals of the median eminence. GnRH is then 
released into the hypophyseal portal circulation and transferred to the pituitary 
gonadotrophs, where it activates its own receptor (GnRH-R), located in the 
gonadotroph cell membrane (Sherwood et al., 1993; Hadley, 1996c). 
In all vertebrates, GnRH secretion shows an intermittent pulsatile pattern, entrained 
by a yet to be fully elucidated neural oscillator, often referred to as the “GnRH pulse 
generator”. The intermittent character of GnRH release is essential for the 
maintenance of its hypophysiotropic action. Adequate functioning of the “GnRH pulse 
generator” and GnRH secretion is a prerequisite for normal reproductive function, 
including gametogenesis and sex steroid production in both the male and the female.  
The regulation of GnRH secretion is complex and involves direct and indirect influences 
on GnRH-neurons. Neurotransmitters originating from the adrenergic system, excitatory 
amino acids (e.g. glutamate), various hypothalamic neuropeptides (e.g. the opioidergic 
system, GnRH degradation products) and feedback signals from systemic sex steroids 
and peptide hormones (e.g. inhibin B) may affect GnRH release. Furthermore, stress, 
metabolic factors and exteroceptive stimuli (e.g. season variation) may also alter the 
GnRH secretion pattern. For review, see for example Brann and Mahesh, 1994; 
Goodman et al., 1995; Clarkson and Herbison, 2006; Jawor et al., 2006; Maeda and 
Tsukamura, 2006. 
 
1.1.3 The Adenohypophysis 
1.1.3.1 Physiology  
The pituitary consists of an anterior lobe, the adenohypophysis which accounts for 80% 
of the pituitary’s gland weight, an intermediary lobe and a posterior lobe 
(neurohypophysis). The adenohypophysis is functionally connected to the hypothalamus 
by the portal circulation in the stalk that also contains nerve cell projections. 
The anterior lobe of the pituitary produces six main hormones through specific 
secretory cells. The somatotrophs are responsible for growth hormone (GH) production, 
which regulates growth and physical development. Thyrotrophs secrete thyroid-
stimulating hormone (TSH), which regulates thyroid gland function. Corticotrophs 
secrete adrenocorticotropic hormone (ACTH), which controls glucocorticoid and 
succeeded sex steroid production by the adrenal cortex. The gonadotrophs are 
responsible for gonadotropin (FSH and LH) secretion, which regulate gonadal function. 
The lactotrophs produce prolactin, which is involved in lactation. The anterior and 
intermediary lobes secrete melanocyte-stimulating hormone and other secretory 
products such as endorphins (Hadley, 1996b). 
As mentioned above, gonadotropin secretion is episodic and depends on the frequency 
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and amplitude of the hypothalamic GnRH pulses (Wildt et al., 1981). 
 
1.1.3.2 Gonadotrophs 
In this chapter, we discuss the regulation of gonadotropin synthesis and secretion by 
GnRH. First, we look at receptor signalling and the corresponding impact on 
gonadotropin gene production, together with gonadotropin packaging and secretion. 
 
1.1.3.2.1 The GnRH-receptor 
GnRH exerts its effects through specific high-affinity receptors on the membrane of the 
pituitary gonadotrophs. The GnRH-R belongs to the super family of the rhodopsin-like 
heptahelical G-protein-coupled receptors (GPCRs) and has been cloned from a wide 
range of vertebrate species. Other variants of the GnRH-R have also been identified but 
their role in reproduction remains to be determined for any species (Ruf et al., 2003).  
The mammalian GnRH-R is unique among rhodopsin-family receptors in lacking a 
carboxyl-terminal domain, which results in a relatively slow receptor internalisation, 
the lack of G-protein receptor kinase phosphorylation, and lack of rapid desensitisation 
(Chi et al., 1993; McArdle et al., 1995; McArdle et al., 2002). Many studies have 
demonstrated that the GnRH-R activates phospholipase C (PLC) through Gq/11 family G-
proteins in gonadotropic cell lines and in rodent pituitary primary cultures (Ruf et al., 
2003). In either Gαq or Gα11 knockout mice, GnRH injection enhances LH release, hereby 
suggesting that both G-proteins can substitute each other in GnRH receptor signalling 
(Stanislaus et al., 1998). The GnRH-R has also been proposed to activate Gi and Gs 
subtype G-proteins (Hawes et al., 1993; Imai et al., 1996). 
Agonist-binding results in the activation of PLC through the recruitment of the Gαq/11 G-
proteins. PLC catalyzes the hydrolysis of phosphatidylinositol 4, 5-bisphosphate to (1, 
4, 5) inositol trisphosphate (IP3) and diacylglycerol (DAG); IP3 mobilizes intracellular 
calcium which activates conventional protein kinase C (PKC) isoforms, of which α and 
βII have been identified in gonadotropic cell lines. The generation of DAG is likely to 
lead to the activation of novel PKC isoforms (McArdle et al., 1992; Hadley, 1996a; 
McArdle et al., 2002). The initial phase of calcium mobilisation originates from 
intracellular calcium stores, whereas the plateau phase depends on external calcium 
influx through L-type voltage-sensitive Ca2+ channels. 
 
1.1.3.2.2 Gonadotropin synthesis and secretion 
Gonadotropins are heterodimeric glycoprotein hormones, consisting of two subunits, 
namely an α glycoprotein hormone subunit (α-GSU), which is common for LH, FSH, 
human chorionic hormone (hCG) and TSH and a hormone-specific β-subunit, which 
determines the biological activity of the hormone (Gharib et al., 1990). 
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Gonadotropin production strongly depends on the amplitude and frequency of the 
GnRH pulses and is further regulated by feedback from androgens and estrogens, as 
well as peptidergic gonadal secretion products, in particular inhibin B. 
In general, the α-GSU responds to constant exposure or high pulse frequency (10 min), 
whereas the LHβ subunit (LHβ-su) promoter responds best to lower frequency pulses 
(30–60 min) and the FSHβ-subunit (FSHβ-su) to even lower frequencies. Furthermore, in 
vivo production of the LHβ-su and FSHβ-su is down regulated by continuous GnRH 
exposure (Wildt et al., 1981; Crowley et al., 1985; Haisenleder et al., 1991; Burger et 
al., 2002). 
The connections between the signalling network and each gonadotropin subunit 
promoter are unique. The common α-GSU functions as a primary gene, whereby its 
GnRH-induced transcription is mediated by the activation of preformed transcription 
factors. In contrast, the LHβ-su gene has a complex promoter that requires 
simultaneous activation by existing and de novo synthesised transcription factors for 
activation. The differences between both promoters within the signalling network of 
the gonadotrophs suggest mechanisms for their differential sensitivity to patterns of 
receptor stimulation. Furthermore, the need for newly synthesised and preformed 
transcription factors and their modulation by phosphorylation, might contribute to the 
known frequency-decoding behaviour of the LHβ-su (Ruf et al., 2003).  
The mechanisms underlying the effects of GnRH on the induction of FSHβ are less well 
defined than those of the common α-GSU or the LHβ su genes. Although the role of 
GnRH in stimulating expression of FSHβ expression is well known, the in vivo effects 
are mainly indirect and result from the induction of transforming growth factor β 
(TGFβ) family members (Burger et al., 2004). 
Gonadotropin subunit expression results in the formation of precursor polypeptides, 
which undergo complex cotranslational processes at the level of the endoplasmic 
reticulum. Finally, post-translational changes at the level of the Golgi apparatus result 
in the final production of mature gonadotropins, which are stored in specific secretory 
granules (Ulloa-Aguirre et al., 2001).  
Gonadotrophs are reported to be bihormonal but under certain physiological and 
experimental conditions, monohormonal cells have been identified. Despite the 
bihormonal nature of gonadotrophs, these cells are able to differentially regulate 
gonadotropin secretion. LH is stored intracellularly and released mainly in response to 
pulses of GnRH through a regulated secretory pathway, although minimal release does 
occur constitutively. FSH is largely secreted through a constitutive pathway; however it 
can also be released by an alternative regulated pathway. At the sub-cellular level, 
specialised secretory granules have been identified in the murine LβT2 cell line (Nicol 
et al., 2004). 
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The differential secretion of LH and FSH has been attributed to changes in the total 
number of granules and in the proportion of each type of granule. Furthermore, these 
granules also contain acidic soluble proteins from the granin family. At low pH and high 
calcium concentrations, conditions which are found in the Golgi apparatus, these 
proteins aggregate and are involved in the packaging of the gonadotropins into the 
secretory granules. In the rodent pituitary, three different granin proteins have been 
identified, namely, secretogranin II (SgII) and chromogranin (Cg) A and B. Several 
studies have demonstrated that LH is associated to SgII while FSH is linked to CgA. It 
has been hypothesised that the differences in the gonadotropin secretion pattern may 
be related to their different storage into specific secretory granules (Nicol et al., 2002; 
Nicol et al., 2004). 
 
1.1.3.2.3 Feedback regulation of gonadotropin secretion 
Gonadotropin secretion by pituitary gonadotrophs is regulated through a complex 
feedback mechanism, whereby sex steroids, activins, inhibins, follistatin and several 
neuropeptides will determine the final response to GnRH.  
In mammals, LH is responsible for sex steroid production at the gonadal level. In turn, 
androgens and estrogens regulate gonadotropin secretion at the hypothalamic and/or 
the pituitary level. In the male, testicular steroids alter the GnRH pulse frequency at 
the level of the hypothalamus, being the major site of negative feedback action of 
androgens. However, there may be species-specific differences in the pathways that 
mediate feedback responses and how steroids regulate GnRH gene expression. The 
actions of testosterone (T) can be mediated either directly or following conversion to 
E2 or dihydrotestosterone (DHT), but the relative importance of each remains to be 
determined. In the human male, estrogens do play a major role in the negative 
feedback regulation of LH secretion. Indirect evidence indicates that circulating 
estrogen levels, rather than local aromatisation in the hypothalamic and pituitary 
tissues, are responsible for this action (Raven et al., 2006; T'Sjoen et al., 2005). 
Testicular steroids act to regulate GnRH neurons through neuronal systems that are 
largely unknown but include endogenous opioid peptides and gamma amino butyric acid 
(GABA) (Hadley, 1996d; Kaufman, 1996). 
In the female, estrogens exert a negative feedback on LH release for the greater part 
of the ovarian cycle, at least in part through direct actions at the pituitary level. This 
inhibitory action is transiently reversed into marked facilitation of pituitary LH 
secretion during the mid-cycle gonadotropin surge (Messinis, 2006). The exact 
mechanisms at the pituitary level of this remarkable shift in responsiveness are yet to 
be fully elucidated. In rodents, but not in higher primates, the occurrence of a GnRH 
surge is a prerequisite for a normal preovulatory gonadotropin surge. 
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The feedback regulation of FSH is controlled by the actions of inhibin and activin, 
which belong to the transforming growth factors β (TGF-β) family. Activins are 
homodimers of inhibin βα and/or βB-subunits. Three different forms have been 
described according to the combination of these β subunits: activin (βA-βB), activin A 
(βA-βA) and activin B (βB-βB).  
Two forms of inhibin have been identified, namely inhibin A and B, which consist of a 
common α subunit and the βA (inhibin A) or βB (inhibin B) subunit. Inhibin is produced 
by both the testis (Sertoli cells) and the ovaries (granulosa cells) and is responsible for 
feedback suppression of FSH secretion. Inhibin binds to and inactivates activin 
receptors in a competitive manner. Inhibin B is the physiologically relevant form of 
inhibin in this context and is a key mediator of FSH feedback regulation (Bilezikjian et 
al., 2006). 
The various components essential for activin signalling are present in the anterior 
pituitary and activins have been reported to exert effects on multiple pituitary cell 
types, the best-characterised of which are the gonadotrophs. Bilezikjian et al (2004) 
demonstrated expression of inhibin/activin α and β-subunit mRNAs in anterior pituitary 
cells, together with the corresponding secretion of activins A and B. In the rat, activin 
B produced by rat pituitary cells has been reported to serve as a positive signal locally 
driving the expression of FSH-β and the secretion of FSH in vitro, and to mediate the 
hypersecretory FSH response to ovariectomy, in vivo (Corrigan et al. 1991, DePaolo et 
al. 1992). Through a paracrine mechanism, activin A originating from other pituitary 
cell types, including folliculostellate cells, may also participate in modulating the 
responses of gonadotrophs (Bilezikjian et al. 2003). Activins are permissive for the 
actions of GnRH on FSH production. In turn, GnRH pulse frequency can alter activin B 
production by modulating inhibin/activin βB mRNA levels (Weiss et al. 1992, Burger et 
al. 2002). Transcriptional studies of FSH-β and GnRH receptor promoters in αT3-1 and 
LβT2 cell lines demonstrated that both are modulated by activin (Fernandez-Vazquez 
et al. 1996, Duval et al. 1999, Pernasetti et al. 2001, Norwitz et al. 2002, Suszko et al. 
2003, Bernard 2004) and involves the Smad2/3 pathway used by activin (Pernasetti et 
al. 2001, Norwitz et al. 2002, Suszko et al. 2003, Bernard 2004). Activin modulates 
gonadotroph sensitivity to GnRH by facilitating the action of GnRH to promote FSH-β 
and GnRH-R gene transcription (Pernasetti et al. 2001, Gregory et al. 2005).  
Raising evidence suggests stimulatory effects, rather than inhibitory, of androgens on 
FSHβ gene transcription in rodents. Previous studies demonstrated that T increases 
FSHβ mRNA levels in GnRH antagonist-treated rats, whereas α-GSU and LHβ-subunit 
mRNA levels are decreased (Paul et al., 1990; Dalkin et al., 1992). Furthermore, T 
selectively induces FSHβ mRNA in both male and female primary rat pituitary cell 
cultures (Garhib et al., 1990; Winters et al., 1992; Leal et al., 2003).  Furthermore, 
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GnRH-R levels in rodent pituitaries are modulated by androgens which in turn may alter 
responsiveness of FSHβ to GnRH (Marchetti et al., 1982; Jegou et al., 1985; Kaiser et 
al., 1993).  
Follistatins are activin-binding proteins that irreversibly bind to activins and prevent 
them from binding to their receptors (Michel et al. 1993, Phillips and deKretser 1998, 
Balemans and Van Hul 2002, Shimasaki et al. 2004). Although first identified as FSH-
inhibitory components of gonadal fluids, follistatin is also expressed in many other 
tissues, including most cell types of the anterior pituitary (Bilezikjian et al. 2004). 
Androgens have been shown to modulate levels of follistatin in the rat pituitary in vivo 
and both activin and follistatin in cultured rat pituitary cells (Kaiser et al., 1993; 
Bilezikjian et al., 1996; Leal et al., 2003). The above described data suggest that the 
mechanism of androgen action on FSHβ-su might be indirect, through modulation of the 
activin/follistatin system in the pituitary. 
Interestingly, activins were also able to enhance LHβ-su gene expression in mouse 
primary pituitary cells and LβT2 cells. This effect was mediated through binding of 
smad proteins, being cellular mediators of the activin receptor signalling pathway, with 
specific smad binding elements (SBE), present in the promoter region of the LHβ-su 
gene (Yamada et al., 2004). Furthermore, these proteins were able to interact with 
transcription factors such as Otx-1 and Ptx1, both being important mediators of LHβ-su 
gene transcription (Coss et al., 2005). 
Recently, it has been demonstrated that glucocorticoids and activin were able to 
synergistically enhance FSH-βsu gene expression in LβT2 cells (McGillivray et al., 2007). 
Other factors, which are not discussed in this work, that may influence gonadotropin 
secretion through modulation of GnRH release by hypothalamic neurons include 
kisspeptin, neuropeptide Y, galanin-like peptide (GALP) and proopiomelanocortine 
(Crown et al., 2007). 
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1.2 Estrogens 
This chapter describes the physiology of the estrogens and their general mechanisms of 
action. We also discuss the cross-talk between ERs and growth factors and their 
importance at the level of reproductive tissues. In the last part of this chapter, a short 
overview is given of compounds, present in the environment, which may exert or 
interfere with estrogenic action in both humans and animals. 
  
1.2.1 Physiology 
Estrogens are naturally occurring cyclopentanophenanthrene compounds, derived from 
the precursor cholesterol. The most potent and dominant estrogen in humans is 17-β-
estradiol (E2), but the weaker estrogens estrone (E1) and Estriol (E3) are also present.  
In premenopausal women, E2 is the primary sex hormone and is responsible for growth 
of the breast and reproductive epithelia, bone maturation and the development of the 
secondary sexual characteristics. The ovaries are the main source of E2 with secondary 
production by the adrenal glands and conversion of steroid precursors into estrogens in 
peripheral tissues, in particular fat tissue (Hadley, 1996e). Both in the ovaries and the 
peripheral tissues, estrogens are the result of aromatisation of androgen precursors by 
the CYP19 enzyme aromatase.  
Estrogens have always been considered as female sex hormones but their role in the 
development and the maintenance of the reproductive system in males is emerging 
(Carreau et al., 2006). In the male, the testes account for 15% of circulating estrogens 
(Lew et al., 2003); the remaining is produced in the peripheral tissues, mainly at the 
level of the fat tissue. Both intratesticular and peripheral estrogen production occurs 
through the conversion of androgens into estrogens by CYP19 enzyme aromatase 
(Simpson et al., 1994). In the reproductive system of males, aromatase expression has 
been demonstrated in spermatocytes and spermatids. Furthermore, a role for estrogens 
in the regulation of epididymal function has been suggested (Lambard et al., 2005). 
Estrogen production, either intratesticular or extragonadal, is of physiological 
significance throughout adult life.  
Estrogens are not only critical for both male and female reproduction; they also play an 
important role in the regulation of other physiological processes. In bone, estrogen 
production appears to be as vital for the maintenance of bone mineralisation and 
prevention of osteoporosis in men as it is in women (Simpson and Davis, 2001; 
Compston, 2002). Individuals with a mutation of the gene encoding for ERα or a 
mutation in CYP19 display failure of epiphysial fusion, osteopenia and delayed bone 
age (Gennari et al., 2004). Furthermore, in humans, estrogens may also exert a 
protective role in the cardiovascular system and against neurodegenerative diseases 
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such as stroke, Alzheimer’s disease and Parkinson’s disease, although reports on these 
effects have not been univocal (Nilsson and Gustafsson, 2002). 
 
1.2.2 Estrogen receptors 
Estrogens act through binding to specific estrogen receptors (ERs) localised 
intracellularly at the cytosolic and nuclear level. There are two functional ER isoforms, 
namely ERα and ERβ, which are encoded by the genes ESR1 and ESR2, respectively. 
Both genes are located on distinct chromosomes (locus 6q25.1 and locus 14q22-24, 
respectively) and comprise eight exons which are separated by seven intronic 
sequences. The human ERα gene ESR1 encodes a protein of 595 amino acids with a 
molecular weight of about 66 kDa, while ERβ has 530 amino acids and an estimated 
molecular mass of about 54 kDa (Walter et al., 1985; Green et al., 1986; Kuiper et al., 
1996; Mosselman et al., 1996).  
ERα and ERβ are expressed in a variety of tissues such as reproductive tissues (e.g. 
breast, uterus, ovary, prostate, bladder, seminal vesicles and in the testis), the 
cardiovascular system, bone, liver (only ERα), the urogenital tract and the 
gastrointestinal tract (only ERβ). The highest expression of ERβ was seen in the 
prostate, the ovary and the lungs (Enmark and Gustafsson, 1999; Nilsson et al., 2001; 
Nilsson and Gustafsson, 2002). 
Both receptors consist of six functional domains sharing the common structure of 
steroid/thyroid hormone nuclear receptors (Kumar et al., 1987; Truss and Beato, 
1993). Between the two receptors, the N-terminal domain (A/B) is the less conserved 
with only 18% homology. The C domain is strongly conserved (97% homology) between 
both receptor isoforms and consists of two zinc fingers forming a helix–loop–helix motif 
to bind DNA hormone responsive elements. The D domain functions as a hinge region 
and contains signals for nuclear localisation of ER, while the E domain is responsible for 
ligand binding. Both ER isoforms bind E2 with high affinity, although they share only 
58% of homology in this domain (Tsai and O'Malley, 1994; Mangelsdorf et al., 1995; 
Kuiper et al., 1998c; Osborne and Schiff, 2005). The structure of both human ER 
isoforms is illustrated in figure 1.1. 
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Figure 1.1: Structure of human estrogen receptor α (hERα) and β (hERβ).  
Human ERα and ERβ share common structural domains. The A/B domain contains activation 
function 1 (AF-1), which constitutively contributes to ER transcriptional activity. This domain is 
one of the least conserved domains between ERα and ERβ, showing only a 30% identity. The DNA 
binding domain, or C domain, is the most highly conserved region between ERα and ERβ, with 
97% identity. For this reason, both receptors can bind to similar target sites. The D domain, or 
hinge region, is not well conserved (24%) between the receptors and it contains the nuclear 
localisation signal. Finally, the E/F region encompasses the ligand binding domain (LBD), a 
coregulator binding surface, the dimerisation domain, a second nuclear localisation signal, and 
activation function 2 (AF-2). In contrast to AF-1, AF-2 is a ligand-dependent activation function. 
The E/F domains of ERα and ERβ exhibit a sequence identity of 58% (adapted from Hall and 
McDonnell, 2005). 
 
Analysis of the binding affinities of a variety of synthetic or naturally occurring 
estrogenic compounds (including phytoestrogens and environmental estrogenic 
compounds) has shown that the relative binding affinities for both differ for only some 
compounds. Genistein and other phytoestrogens have a significantly higher binding 
affinity for ERβ when compared to ERα (Kuiper et al., 1997; Kuiper et al., 1998a). 
In contrast, Schaefer and colleagues demonstrated that 8-prenyl-naringenin (8-PN), 
isolated from hops, shows higher affinity for ERα in comparison to ERβ. These data 
were confirmed by experiments performed in our laboratory, whereby human, cervical 
Hela cells were transiently transfected with either human ERα or ERβ, in the presence 
of the estrogen-driven ERE-Luc reporter plasmid (data not shown). 
Many messenger RNAs (mRNAs) have been identified for ERβ, whereby two splicing 
variants (ERβ1 and ERβ2) have been characterised (PriceJr et al., 2000; Price et al., 
2001; Poola et al., 2002). ERβ2 shows a lower affinity for E2, presumably due to the 18 
amino acids insertion in the ligand binding domain (LBD). The ERβ2 isoform seems to 
act as a suppressor of ERα and ERβ1 transactivating activity (Zhao et al., 2005). 
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1.2.3 Estrogens: mechanisms of action 
The main mechanism of action of estrogens is through estrogen receptors, which act as 
signal transducers and ligand-activated transcription factors. Following ligand-binding, 
the ligand-ER complex interacts with hormone response elements, present in the 
regulatory region of target genes and alters target gene transcription in a positive or 
negative manner. ERs are also able to regulate target gene expression through protein-
protein interactions with other transcription factors. Furthermore, raising evidence 
demonstrates rapid, non-genomic actions of estrogens. In the next chapters, both 
genomic and non-genomic actions of estrogens are described in detail.  
 
1.2.3.1 “Classical” mechanism of action of estrogens 
The classical mechanism of action of estrogens involves the ER, its ligands and its 
coregulatory proteins. In the absence of estrogens, the ER is associated with heat-
shock proteins (including hsp70 and hsp90) in a transcriptionally inactive state. Binding 
of E2, its natural endogenous ligand, or another agonist induces conformational 
changes, hereby promoting homo- or heterodimerisation and subsequent nuclear 
translocation (Truss and Beato, 1993; Mangelsdorf et al., 1995).  
The N-terminal activating function 1 (AF-1) domain and the C-terminal AF-2 domain are 
essential for the transcriptional activity of both estrogen receptors. The ligand-
independent AF-1 domain is the least conserved region among nuclear receptors, both 
in size and sequence. Consequently, the activation capacity of AF-1 domains has been 
shown to vary considerably between different nuclear receptors. The AF-1 domain is a 
site-specific phosphorylation region, containing serine (Ser) residues at specific 
positions, which can be phosphorylated by cellular kinases. Following binding of E2, ERα 
becomes predominantly phosphorylated on Ser-118 and to a lesser extent on Ser-104 
and Ser-106. Activation of the mitogen-activated protein kinase (MAPK) pathway, for 
example by growth factor receptor signalling, stimulates phosphorylation of Ser-118 
and Ser-167. Phosphorylation of Ser-118 leads to an increased association with known 
ERα co-activators. The mechanism by which Ser-104, Ser-106 and Ser-167 
phosphorylation enhances ERα-mediated transcription remains unknown (Lannigan et 
al., 2003).  
The ligand-dependent AF-2 domain is important for the interaction with co-regulators 
in a ligand-dependent manner (Kumar et al., 1987; Krauset al., 1995; McInerney and 
Katzenellenbogen, 1996; McInerney et al., 1996).  
The AF-1 domain in ERα is very active in the stimulation of reporter-gene expression 
from various estrogen response elements (ERE)-reporter constructs in different cell 
lines (Walker et al., 1984; Klein-Hitpa et al., 1986). In contrast, the activity of the ERβ 
AF-1domain is negligible (Cowley and Parker, 199). For example, both ER isoforms show 
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a distinctive response to synthetic estrogenic ligands such as the selective estrogen 
receptor modulators 4-hydroxytamoxifen (4-OH-Tam) and raloxifene. Differences in the 
N-terminal regions of ERα and ERβ is one possible explanation for the difference 
between the two receptors in their response to various ligands. In ERα, two different 
parts of the AF-1 domain are required for the agonism of E2 and the partial agonism of 
4-OH-Tam, respectively. In ERβ, this dual function of the AF-1 domain is missing. For 
this reason, the role of the AF-1 domain in ERβ transcriptional activity remains to be 
clarified (McDonnell et al., 1995; McInerney and Katzenellenbogen, 1996; Paech et 
al.,1997). 
Ligand-activated ERs interact with an ERE-sequence, present in the regulatory regions 
of target genes.  
The consensus palindromic element ERE (5’-GGTCAnnnTGACC-3’) is based on the 
estrogen-responsive sequence of the vitellogenin A2 promoter of the Xenopus laevis 
and functions in an orientation and distance-independent manner. This consensus 
sequence was established by comparing all known ERE-sequences, whereby the most 
common nucleotide at each position within these sequences was chosen and placed at 
the corresponding position in the consensus sequence. (Klein-Hitpa et al., 1986; 
Ponglikitmongkol et al., 1990). Furthermore, several ERE half sites have been described 
but ER DNA binding remains controversial. It is important to mention that only a 
fraction of the known mammalian estrogen-responsive palindromic EREs reflect this 
consensus. Many target genes contain response elements that share little similarity to 
consensus EREs (Kato et al., 1992; Porter et al., 1996; Porter et al., 1997). It has been 
demonstrated that the sequence of the response element affects the affinity of the 
receptor for binding DNA. This explains, at least in part, how the sequence of the 
response element is an important determinant of the transactivation capacity of ERs. 
Furthermore, consensus and imperfect EREs also influence the relative ability of ERs to 
bind to cofactors (Klinge, 2000; Loven et al., 2001a; Loven et al., 2001b).  
The genomic mechanism of action of estrogen receptors has been illustrated in figure 
1.2. 
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Figure 1.2: Classical, genomic action of estrogen receptors. 
In the absence of estrogens, the estrogen receptor (ER) is transcriptionally inactive and forms 
complexes with heat shock proteins (HSP). Following ligand-binding, ER dimerises (either homo- 
or heterodimers), bind to an estrogen response element (ERE) in estrogen-responsive target 
genes and modulate target gene transcription either positively or negatively following 
interaction with compounds of the transcription machinery. 
 
Despite ERs bind E2 and SERMs with similar affinity and interact with the same EREs, 
the transcriptional activity of ERs is distinct. Because of the homology in their AF-2 
domains, one should expect that both ERα and ERβ recruit co-activators in a similar 
manner; however, differences have been reported. For instance, E2 generally 
stimulates greater transcriptional activity via ERα than through ERβ (McInerney et al., 
1998; Cowley and Parker, 1999; Hall and McDonnell, 1999). More marked differences 
are observed with SERM-bound ERs. For ERE-dependent gene expression, 4-OH-Tam is a 
partial agonist of ERα but is generally not capable to stimulate ERβ transcriptional 
activity (Barkhem et al., 1998; McInerney et al., 1998; Hall and McDonnell, 1999). 
Conversely, when assessing ER activity on activating protein 1 (AP-1) containing 
reporter genes, 4-OH-Tam will stimulate ERα and ERβ transcriptional activity in a cell-
dependent fashion (Paech et al., 1997). 
Following binding to an ERE, the ligand-ER complex interacts with basal transcription 
factors and with coregulators to regulate gene expression. These coregulators can 
affect the magnitude of gene stimulation or repression and can alter the dose-response 
profile to a specific ligand. The magnitude of stimulation or repression of receptor 
transcriptional activity is determined by the nature of the ligand, which controls the 
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recruitment of coregulators to the ligand-receptor complex. Coregulators can be 
divided in coactivators and corepressors. These proteins do not bind to DNA, but 
interact indirectly through association with other DNA-binding proteins (Horwitz et al., 
1996; McKenna et al., 1999; McKenna and O'Malley, 2002). 
Agonist-bound ERs recruit co-activators. In the last years, more than 50 co-activators 
have been identified. The first identified co-activator family, also called steroid 
receptor co-activator (SRC) consists of three related members:  
 
• SRC-1 (p160-1, N-CoA1) 
• SRC-2 (TIF-2, GRIP-1, N-CoA2)  
• SRC-3 (named ACTR, AIB, P/CIP, PRIP) 
 
These transcription factors are recruited in a ligand- and AF-2-dependent manner 
through a distinctive common signature motif termed the nuclear receptor (NR)-box 
which contains the core consensus sequence LxxLL (where L is leucine and x is any 
amino acid) (Leo and Chen, 2000; Xu and Li, 2003).Several reports have postulated that 
differences in the activities between ERα and ERβ could be due to differences in their 
ability to interact with co-regulatory proteins. 
SRC not only interact with nuclear receptors, such as the ER, progesterone receptor 
and thyroid receptor (Takeshita et al., 1997; Han et al., 2006; Ying et al., 2005), but 
also with other transcription factors, including activator protein-1 (1 (AP-1) nuclear 
factor-κB (NFκB) and signal transducer and activator of transcription (STAT) (Lee et al., 
1998; Werbahj et al., 2000; Arimura et al., 2004). Binding of SRC to transcription 
factors results in the recruitment of other chromatin modification factors, such as 
acetyltransferases and methyltransferases. Furthermore, SRCs can modify the 
chromatin structure and activate transcription of their target genes. In other words, 
intracellular changes of SRC concentrations may greatly affect the expression levels of 
many genes and, as a consequence, influence a variety of cellular processes (Chen et 
al., 1999; McKenna et al., 2002) 
 There are differences between the affinity of ERα and ERβ for members of the SRC co-
activator family. In the presence of E2, ERα was shown to bind with greater affinity 
when compared to ERβ, to NR-box regions of the SRC family co-activators (Wong et al., 
2001). There exists also a different affinity of full-length SRC family members for ERs 
(SRC-3 > SRC-1 > SRC-2) (Bramlett et al., 2001; Bramlett and Burris, 2002). In addition, 
the nature of the ligand influences the relative affinity of ER for particular NR-boxes. 
For example, the interaction of the E2-bound ERβ is approximately two times greater 
than genistein-bound ERβ to SRC-2 NR-box1, whereas genistein-bound ERβ binds 
approximately five times better to SRC-2 NR-box-3 than the same receptor bound to E2. 
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In conclusion, the preferential binding of certain co-activators to ERα or ERβ is an 
important determinant for E2 signalling (Routledge et al., 2000). 
While the role of coactivators for ERα is well recognised, the importance of 
corepressors remains unclear at this moment, as the main mechanism of ERα differs 
from that of other NRs, such as the thyroid hormone (TR) and the retinoic acid 
receptor (RAR). The latter can bind to DNA in the absence of ligand and actively 
repress transcription. In the presence of ligand, corepressors are released from 
TR/RAR, coactivators are recruited, and transcription is initiated (Taggart et al., 
1992). In contrast, it is generally believed that ERα only binds to DNA in the presence 
of ligand, eliminating the requirement of corepressors. However, several studies have 
demonstrated that the antagonist-ER complex recruits corepressors including REA (ER-
selective repressor of ER activity), together with Nuclear Receptor Corepressor (NCoR) 
and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT: 
silencing mediator of RAR and TR) (Montano et al., 1999; Delage-Mourroux et al., 2000; 
Perissi et al., 2004). Figure 1.3 illustrates the effects of coregulatory proteins on ER-
functioning in the absence or presence of different ER ligands. In figure 1.4, an 
overview is given of all coregulators which are responsible for the regulation of ER 
transcriptional activity. 
It is important to mention that the balance between coactivators and corepressors is an 
important determinant of the agonist/antagonist activity of for example SERMs in a 
variety of tissues such as the breast (Dobrzycka et al., 2003).  
In conclusion, the regulation of the ER transcriptional activity is complex and depends 
on different factors, including the type of ligand, the tissue-specific expression of both 
ER isoforms and the presence of coregulatory proteins. 
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Figure 1.3: Estrogen receptor interactions with coregulatory proteins.  
This represents a hypothetical schematic of the exchange of coregulators involved in ER-
mediated gene activation. Following interactions of coregulatory proteins with ERα may occur: 
A. In the presence of a SERM such as tamoxifen (T), the receptor interacts with a complex of 
corepressor proteins, including SMRT and/or NCoR, which maintains the gene in an inactive 
state. B. In the absence of ligand, ERα may bind to either corepressor or coactivator complexes. 
Intracellular signalling can influence the extent of interaction with these complexes and 
therefore the relative magnitude of basal receptor activity: less active when bound to 
corepressor complexes and more active when the equilibrium is shifted to coactivator complex 
interaction. C–E, estrogen (E) binding activates the receptor and initiates coactivator complex 
formation, which is necessary for target gene transcription. This process involves histone 
acetylation, which is modulated by histone acetylases (HDAC) such as CBP/p300 and SRCs). Next, 
a complex consisting of BRG-1/BAF57, unwinds DNA and remodels the chromatin in order to 
initiate gene transcription by interactions with cofactor complexes. The latter may include SRC-
1 or other members of the SRC-1 family. After initiation, transcription is further carried out by 
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other protein complexes, which, in turn, interact with RNA polymerase II. Finally, coactivator 
complexes and the receptor itself are turned over at the promoter by ubiquitin-proteasome-
dependent processes. This turnover leads to down-regulation of receptor/coactivator levels, and 
is also required for efficient continued transcription of the gene (adapted from Smith and 
O'Malley, 2004). 
 
Figure 1.4: Regulation of transcriptional activity of ER target genes by coactivators 
and corepressors (adapted from: Girault et al., 2006). 
 
1.2.3.2 Protein-protein interactions with transcription factors 
The regulatory regions of several estrogen-responsive target genes do not contain ERE-
sequences and are therefore not able to directly interact with ERs. The promoters that 
lack any ERE-like sequences require a second DNA-binding transcription factor to 
mediate ER association with the DNA, whereby ERs stabilize the DNA binding of that 
transcription factor. Of the human genes in which indirect binding of ER can result in 
estrogen regulation, stimulating protein 1 (Sp1) is the predominant mediator response 
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to estrogenic stimulation. Sp1 binds to the estrogen-responsive DNA-regulatory region, 
with ER enhancing the binding of Sp1 to the DNA and contributing to co-activator 
recruitment (Porter et al., 1997; Duan et al., 1998; Sun et al., 1998). Other 
intermediary factors through which ER can associate with promoter/enhancers include 
activating transcription factor (ATF)-2/c-jun, ATF-2/CREB and nuclear transcription 
factor-Y (Karin, 1995; Wang et al., 1999). Both ERα and ERβ can interact with the 
fos/jun transcription factor complex on activator protein 1 (AP-1) sites to stimulate 
gene expression (Umayahara et al., 1994; Webb et al., 1999; Kushner et al., 2000).  
It has been suggested that AP-1-mediated estrogen-responsive genes contribute to the 
tissue-specific responses to estrogen analogs, via differential activation of ERα and 
ERβ. In the presence of ERα, E2 and Tam acts as full agonists in the AP-1 pathway, 
whereas raloxifene only partially activated ERα at AP-1. In contrast, in the presence of 
ERβ, 4-OH-Tam and raloxifene behave as fully competent agonists in the AP-1 pathway, 
while E2 acts as an antagonist, inhibiting the activity of both 4-OH-Tam and ral (Paech 
et al., 1997). 
Another important example of the indirect effects of estrogen receptors on gene 
transcription is the modulation of cyclin D1 gene expression. Cyclin D1 is important for 
progression of cells through the G1 phase of the cell cycle and is a well-defined target 
for E2-bound ERα action in mammary carcinoma cells (Arnold and Papanikolaou, 2005). 
No ERE-like sequences have been identified in the cyclin D1 promoter (Herber et al., 
1994). However, deletion of AP-1 and Sp1 responsive elements resulted in a decrease 
of promoter responsiveness to E2. Unlike ERα, E2-bound ERβ represses cyclin D1 
expression and blocks ERα– E2-mediated induction when both receptors are present (Liu 
et al., 2002).  
In conclusion, the protein-protein interactions of ERs with other transcription factors 
play an important role in the regulation of target genes, of which the promoter region 
does not contain ERE-like sequences.  
 
1.2.3.3 Non-genomic effects of estrogens 
The genomic effects of estrogens, described above, occur after a time-interval of at 
least two hours following E2 exposure and explain a variety of hormone functions in 
physiological and pathological situations. However, rapid estrogenic actions have also 
been described in several reproductive tissues, including the breast, the uterus and the 
ovary (Aronica et al., 1994; Tesarik and Mendoza, 1997; Lobenhofer et al., 2000; Song 
et al., 2002). These effects could not be contributed to genomic actions, as 
demonstrated by the inability of transcription and translation inhibitors to repress 
these effects (Losel et al., 2003). Rapid non-genomic actions have been observed at 
concentrations varying from the picomolar to high micromolar range and are mediated 
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by membrane-located ERs. The exact structure of these receptors is yet to be fully 
elucidated. Some reports suggested that these effects are mediated through 
completely different receptors. In particular, the ability of E2 to activate G-proteins 
through an orphan G-protein-coupled receptor-30 (GPR30) has been reported (Ahola et 
al., 2002; Maggiolini et al., 2004). GPR30 shows low capacity of E2, with a modest 
generation of cyclic adenosine monophosphate (cAMP) (Filardo et al., 2002). However, 
raising evidence indicates that the membrane-localised ER is the same protein as the 
NR, transported to the plasma membrane by unclear mechanisms (Pappas et al., 1995; 
Razandi et al., 2004). ERα appears to be the primary endogenous mediator of rapid E2 
actions. Less information is available concerning the role of the E2-ERβ complex to 
activate rapid non-genomic mechanisms. A limited number of studies suggested a 
possible role for ERβ in the regulation of rapid non-genomic effects. For example, in 
Chinese hamster ovary cells, ERβ is capable of activating IP3 production, extracellular-
regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and c-Jun kinase 
phosphorylation (Norfleet et al., 1999; Razandi et al., 1999). Another study 
demonstrated that the ERβ- E2 complex stimulated p38/MAPK signalling in human colon 
cells (Acconcia et al., 2005). These data strongly indicate that also ERβ could initiate 
signal transduction cascades through non-genomic actions. 
Non-genomic effects of estrogens include calcium channel opening and calcium influx 
or mobilisation within seconds of binding receptors expressed in target tissues (Thomas 
et al., 2006). E2 rapidly generates cAMP, phospholipase C, and inositol triphosphate 
(IP3). These effects are mediated through G-protein activation, and these early signals 
result into the rapid stimulation of protein kinase C, protein kinase A, MAPK, and 
phosphatidyl inositol 3-kinase (PI3K) (Morley et al., 1992; Lobenhofer et al., 2000; 
Perret et al., 2001). Membrane ER physically associate with and activate various G-
protein α-subunits, including Gαs and Gαq (Hermans, 2003). G-protein activation 
explains how ER generates cAMP (Gαs function) or inositol 1, 4, 5-triphosphate and 
calcium (Gαq function). 
G-protein coupling enables membrane ERs to initiate signal transduction at the cell 
surface in different cell types. For example, a rapid activation of the cAMP/PKA 
pathway has been demonstrated in hippocampal neurons (Gu and Moss, 1996) as well as 
in duodenal cells (Picotto et al., 1996), pulmonary vascular smooth muscle cells 
(Farhat et al., 1996) and rat adrenal gland cells (Chen et al., 1998). Other rapid 
estrogenic effects have been reported, including nitric oxide synthase in endothelial 
cells (Chambliss et al., 2005), phospholipase (PL) C-dependent inositol triphosphate 
(IP3) production, calcium influx, and PKCα activation in cultured endometrial cells 
(Perret et al., 2001), liver-derived HepG2 cells (Marino et al., 1998) and aortic smooth 
muscle cells (Incerpi et al., 2003).  
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Estrogens can also interact with MAPK signalling pathways, either in a direct or indirect 
manner. For example, E2 rapidly stimulates the activation of MAPK pathways in 
neuroblastoma cells (Watters et al., 1997), mammary tumor-derived MCF-7 cells 
(Castoria et al., 2001) and bone cells (Jessop et al., 2001). Furthermore, MAPK 
signalling pathways are activated by many growth factor receptors. An example of 
indirect action of ERα is the activation of the insulin-like growth factor 1 (IGF-1) 
receptor by E2-activated ERα, hereby leading to activation of the receptor and the 
corresponding activation of the MAPK signalling pathway (Kahlert et al., 2000). This 
will be further discussed in the next chapter.  
In conclusion, emerging data indicate the importance of the non-genomic, rapid 
actions of estrogens in different types of cells. However, the responses may vary in a 
cell-specific manner, as the set of signal transduction molecules and downstream 
targets, present in the target cells, will determine the final outcome following 
estrogen exposure. 
 
1.2.4 Cross-talk of estrogen receptors with growth factor receptors 
Growth factors are important mediators of cellular proliferation and/or differentiation. 
These proteins bind to specific high-affinity, low-capacity receptors on the cell surface 
of responsive cells. Many growth factors are quite versatile, stimulating cellular 
division in different cell types, while others are specific to a particular cell-type. An 
intrinsic characteristic of growth factor receptors is their tyrosine kinase activity. 
Ligand-binding induces receptor dimerisation and conformational changes, hereby 
inducing transphosphorylation of discrete tyrosine residues, present in the kinase 
domain of the receptor. Following receptor activation, proteins of signalling 
transduction pathways are phosphorylated and activated as well. Such proteins include 
nonreceptor tyrosine kinases such as Src family members, or Grb and SOS family 
proteins (Herbst, 2004; Scaltriti and Baselga, 2006). In figure 1.5, an example of the 
insulin signalling pathway is illustrated. 
Two important examples of growth factors, which are expressed in reproductive tissues 
are insulin-like growth factor I (IGF-I) and epidermal growth factor (EGF). In the 
uterus, E2 stimulates the production of EGF and activates the EGF receptor (EGFR), 
hereby enhancing cell growth (Mukku and Stancel, 1985). Upregulation of EGF may 
explain the strong growth effect of E2 on uterine epithelium, an action which can be 
prevented by the administration of an EGF antibody (Nelson et al., 1991). Increased 
synthesis of EGF by E2 confirmed the observation that the latter hormone induces EGF 
secretion from breast cancer cells and associates this interaction in the proliferation of 
hormonally responsive cancer (Dickson et al., 1986). 
Interactions between growth factors and ERs have been extensively investigated in 
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reproductive tissues. Ligand-activated growth factor receptors stimulate 
phosphorylation and activation of the nuclear ER through MAPK. Growth factor 
receptor-activated MAPK (ERK) phosphorylates serine residue 118 (Ser-118) in the A/B 
domain of the nuclear ERα. This results in an increased ER-related transactivation of 
genes that are up-regulated by growth factors (Ali et al., 1993; Kato et al., 1995). 
 
 
Figure 1.5: Insulin receptor signalling pathway.  
Schematic overview of the signal transduction pathways, which are activated following binding 
of insulin to its receptor (Adapted from Cell Signalling Technology, www.cellsignal.com). 
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Cross-talk between growth factor receptors and ERα requires the A/B domain (Ignar-
Trowbridge et al., 1996). In addition, several kinases can phosphorylate additional 
amino acid residues within ERα, resulting in increased transcriptional activity of the 
nuclear receptor (Joel et al., 1998; Chen et al., 2002; Lee and Bai, 2002). Thus, the 
effects of growth factor receptor-ER interactions depend upon the signalling 
environment within a particular cell that differentially phosphorylates several residues 
in the nuclear ER. An example of cross-talk between ERα and the IGF-IR is shown in 
figure 1.6. 
 
Figure 1.6: Cross-talk between IGF-1R and ERα in the uterus (Adapted from: Klotz 
et al., 2000). 
 
Another mechanism through which growth factor-induced signalling modulates ER 
transcriptional activity is via coregulator protein phosphorylation. For example, EGF 
induces extracellular signal-regulated kinase (ERK) phosphorylates serine 736 of 
glucocorticoid receptor interacting protein (GRIP) 1, resulting in increased activity of 
this nuclear receptor nonspecific coactivator protein (Lopez et al., 2001). EGF-
enhanced Src and Jnk activation may have a similar function for the cAMP response 
element-binding protein (Feng et al., 2001). Other coactivator proteins that are 
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important and specific to ER function could be similarly activated or recruited through 
signalling-induced post-translational modifications. 
In addition, growth factor receptors can also modulate cyclin D1 production, hereby 
promoting G1/S phase cell cycling (Wiepz et al., 1997). Cyclin D1 activates ER 
transcriptional function and interacts with the coactivator proteins, SRC-1 and cAMP 
response element-binding protein/p300, as an additional mechanism to amplify nuclear 
ER action (Zwijsen et al., 1997). 
Several G-protein-coupled receptors (GPCRs) signal to ERK through the transactivation 
of the EGFR (Daub et al., 1996). In the chapter on non-genomic, rapid effects of 
estrogens, we have discussed the activation of G-proteins via the membrane ER. The 
latter may also interact with the membrane EGFR. For example, in breast cancer cells, 
estrogens rapidly stimulate the EGFR, leading to cAMP and ERK up-regulation. E2 
induces the activation of matrix metalloproteinases (MMPs) 2 and 9, which enhance the 
release of heparin binding EGF (HB-EGF). In turn, the latter binds and activates the 
EGFR (Prenzel et al., 2001).  
The full extent of membrane-initiated signalling by E2/ER and its dependence on 
growth factor receptors remains to be defined, and the in vivo significance remains 
unclear. However, EGF antibodies were able to prevent E2-induced vaginal and uterine 
growth, implying that cross-talk from ER to the EGFR at the membrane may be 
physiologically important (Nelson et al., 1991). For example, ERα directly associates 
with the membrane-tethered p85 subunit of PI3K. E2 rapidly activates the latter, 
leading to the generation of nitrous oxide (NO) and the rescue of rats from ischemia-
reperfusion injury of the muscles (Simoncini et al., 2000). 
The bidirectional cross-talk between ER and growth factor receptors indicates a potent 
method for augmenting E2 or growth factor action. In a specific cell type, there may be 
an important contribution from one of these pathways, essential to the cell biology. 
For example, in breast cancer, tamoxifen is effective in preventing the reoccurrence of 
ER-positive breast cancer, in part because it inhibits aspects of E2 and EGFR signalling 
(Guvakova and Surmacz, 1997). In ER-negative breast cancer, there is possibly less 
control on EGFR signalling to cell proliferation or survival in the absence of ER 
antagonism, thereby contributing to a more aggressive phenotype. In human breast 
cancer, ER and EGFR concentrations are inversely correlated, and ER seems to repress 
the EGFR gene (deFazio et al., 2000; Wilson and Chrysogelos, 2002). Increased EGFRs in 
ER-negative breast cancer may also contribute to the more active growth and invasive 
behavior of these tumors (Bucci et al., 1997).  
Little information is available concerning the effects of growth factors such as IGF-I on 
gonadotropin production. Several in vivo studies in rats have demonstrated the 
enhancement of GnRH and LH release following IGF-1 treatment in animals. For 
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example, intraventricular administration of small doses of IGF-1 to immature juvenile 
or peripubertal rats increases plasma LH levels. Furthermore, immunoneutralisation of 
hypothalamic GnRH inhibited the increase in LH released after the third ventricular 
injection of IGF-1, thus demonstrating in vivo that IGF-1 acts, via a centrally mediated 
mechanism, to stimulate LH release (Hiney et al., 2004).  
Other groups reported the presence of IGF-1 immunoreactivity specifically in GnRH 
neurons of rats and mice, showing co-expression of IGF-1 in GnRH perikarya of adult 
female rats, hereby indicating that IGF-1 may directly regulate GnRH neuronal function 
(Longo et al., 1998; Miller and Gore, 2001; Daftary and Gore, 2004). 
IGF-1 can also exert actions on the hypothalamo-pituitary-gonadal (HPG) axis through 
the pituitary gonadotrophs. Expression of IGF-1, its receptor and IGF-1 binding proteins 
was demonstrated in the anterior pituitary gland. The main site of action of growth 
factors are the somatotrophs (Tannenbaum et al., 1983; Bach and Bondy, 1992), 
nevertheless, there is also evidence for effects on gonadotrophs (Lackey et al., 1999). 
For example, in a primary culture of anterior pituitary cells, IGF-1 significantly 
increases LH, FSH, and GnRH-stimulated gonadotropin secretion (Kanematsu et al., 
1991; Pazos et al., 2004). Furthermore, the gonadotropin-stimulating effects of IGF-1 
are suppressed by administration of anti–IGF-1 and anti–IGF-1R antibodies, indicating 
that IGF-1 also acts at the level of the anterior pituitary to stimulate gonadotropin 
secretion (Pazos et al., 1999).  
In conclusion, pituitary gonadotrophs are also a site at which IGF-1 may influence HPG 
function, whereby this growth factor reaches the gonadotrophs through the portal 
capillary vasculature or via the general circulation after being released from the liver. 
 
1.2.5 Xenoestrogens and phytoestrogens 
Via the food chain, the air and the water as well as during fetal development, man and 
wildlife are exposed to many agents of anthropogenic or natural origin, which can 
interact with the endocrine system. The largest body of evidence exists for compounds 
that are estrogenic in nature, but the amount of experimental data on other types of 
interactions, especially anti-androgenic, steadily increases (Akingbemi and Hardy, 
2001). Many animal studies provided evidence that several of these chemicals can 
disturb sexual development and differentiation (Skakkebaek et al., 2001). Because of 
the growing public and scientific concern, epidemiological studies have been initiated 
to analyse the short and long-term effects of endocrine disruptors (Eertmans et al., 
2003). 
The US Environmental Protection Agency (US-EPA) has defined endocrine disruptors as 
“exogenous agents that interfere with the production, release, transport, metabolism, 
binding, action, or elimination of the natural hormones in the body for the 
 
37
  
maintenance of homeostasis and the regulation of developmental processes.” (Kavlock 
et al., 1996). An increasing number of chemical compounds in the environment have 
been identified as endocrine disruptors using in vitro and in vivo bioassays. These 
include pesticides, industrial chemicals, pharmaceuticals and natural hormones acting 
as ligands for the estrogen-, androgen- or arylhydrocarbon receptor or exerting a 
combined action (Norgil et al., 2002). 
Much research has been performed concerning the effects of endocrine disrupting 
chemicals with estrogenic effects on male fertility.  
Epidemiological data suggest that worldwide, since the 1940s a decrease in sperm 
quality may have occurred with ensuring regional differences in sperm quality and/or 
concentrations (Carlsen et al., 1992; Ohlson and Hardell, 2000). The latter differences 
indicate the involvement of environmental factors. A decrease of ejaculate volume, of 
sperm concentration and of the percentage of normal motile spermatozoa was 
reported in sons of women, who were treated with diethylstilbestrol (DES) during 
pregnancy (Bibbo et al., 1978). Other reports described an inverse correlation between 
the concentration of polychlorinated biphenyls (PCB) metabolites in blood and seminal 
plasma and sperm motility (Dallinga et al., 2002). It became obvious from these studies 
that, in a number of cases, negative effects could be linked to exposure to 
environmental contaminants (beside genetic predisposition), when the latter occurred 
during a well-defined sensitive life stage, the so-called “critical window of exposure” 
(Andersen et al., 2000; Anderson et al., 2000). 
Beside decreased sperm quality, the incidence of testicular cancer, one of the most 
common malignant tumors in young males, increased during the last decades 
(Dearnaley et al., 2001). The obvious regional differences in incidence and the 
association with birth cohorts has suggested possible involvement of environmental 
factors in the development of testicular cancer (McKiernan et al., 1999). Furthermore, 
an increase in cryptorchidism and hypospadias cases was reported by several groups 
(Weidner et al., 1998; Hosie et al., 2000). It is important to mention that the 
prevalence values of these disorders are sometimes difficult to interpret, due to 
differences in screening techniques. Although the latter differences hamper cross-study 
comparison, there are clear indications of a rise in incidence in a number of European 
countries, the United States and Japan (Jensen et al., 1995; Paulozzi et al., 1997; 
Dearnaley et al., 2001).  
 
1.2.5.1 Xenoestrogens 
Among the endocrine disruptors, xenoestrogens have received most of researchers’ 
attention until now. Xenoestrogens are synthetic substances that differ chemically 
from estrogens produced by living organisms but mimic or enhance the estrogen 
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effects. The estrogenic stimulation is an unintended side-effect of these agents or their 
metabolites.  
They differ from phytoestrogens (estrogenic substances from plants), mycestrogens 
(estrogenic substances from fungi) (Branham et al., 2002), and pharmacological 
estrogens (estrogenic action is intended). Exogenous estrogen substances from a 
variety of sources may have a cumulative effect upon living organisms, and 
xenoestrogens may be part of a larger picture of a process of estrogenisation of the 
environment. Xenoestrogens have only recently been introduced into the environment, 
as produced by industrial, agricultural, and chemical companies. These compounds 
show a high structural diversity and can be categorised by usage (herbicides, 
fungicides, insecticides) or chemical structure (PCBs, dioxins, organochlorines and 
alkylphenols) (Dhooge et al., 2001; Eertmans et al., 2003).  
 
1.2.5.2 Phytoestrogens 
Phytoestrogens are a group of biologically active plant substances which are estrogen-
like compounds that occur naturally in many plants and fungi, with a chemical 
structure showing similarities to that of E2 (Ibarreta et al., 2001). This structural 
similarity accounts for the ability of these compounds to bind to ERs and exert various 
estrogenic or antiestrogenic effects. There are three main classes of phytoestrogens: 
isoflavones, coumestans, and lignans, which occur in either plants or their seeds 
(Kurzer and Xu, 1997; Duncan et al., 2003). The isoflavones genistein, daidzein and 
their precursor's biochanin A and formononetin, are present in high amounts in soy 
seeds and have received most attention in the literature (Reinli and Block, 1996). 
Together with coumestrol, present in a number of Cruciferae, these compounds were 
the most potent phytoestrogens known so far (Kuiper et al., 1998b). However, recently 
a newly identified phytestrogen has been isolated from hops (Humulus lupulus), 
namely 8-prenylnaringenin (8-PN) (Rong et al., 2000). This compound belongs, together 
with 6-prenylnaringenin and isoxanthohumol to the group of prenylated flavanones 
(Milligan et al., 1999). Several in vitro studies have identified 8-PN as one the most 
potent phytoestrogens, with a potency equivalent to, or greater than that of other 
established phytoestrogens, including genistein and coumestrol (Milligan et al., 2000; 
Milligan et al., 2002; Matsumura et al., 2005). Currently, there is little data available 
concerning the in vivo effects of 8-PN. Daily beer intake can result in levels which fall 
within the range of biological activity (Possemiers et al., 2006).  Another study 
demonstrated that 8-PN was able to inhibit angiogenesis both in vitro and in vivo 
(Pepper et al., 2004). However, a recent study demonstrated that 8-PN affects 
mammalian sperm function much more than E2, hereby suggesting the involvement of 
mechanisms other than ER binding (Fraser et al., 2006).  
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Several phytoestrogens including for example genistein, are claimed to help prevent or 
exert beneficial effects on a multitude of human disorders, including cancers, 
cardiovascular diseases, osteoporosis, and postmenopausal symptoms (Goldwyn et al., 
2000; Morton et al., 2002). However more studies are required to confirm their 
possible health promoting potential and to trace possible adverse effects. 
Phytoestrogens are able to interact with ERs, showing higher affinity to ERβ than ERα 
(Kuiper et al., 1998a). Variable effects may be observed, as ER distribution is cell- and 
tissue dependent (reviewed in 2.2). Other mechanisms have also been described, 
including the inhibition of protein tyrosine kinases (Akiyama et al., 1987; Uckun et al., 
1995), repression of angiogenesis (Fotsis et al., 1998; Pepper et al., 2004; Kiriakidis et 
al., 2005) and inhibition of cell cycle progression (Hewitt and Singletary, 2003; 
Shenouda et al., 2004; Handayani et al., 2006). They are also able to alter ER cellular 
levels (Cappelletti et al., 2006) and sex steroid hormone binding globulin (SHBG) 
concentrations (Mousavi and Adlercreutz, 1993; Pino et al., 2000).  
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Chapter 2 The Study of Estrogenic Effects in  
   Pituitary Gonadotrophs 
In this chapter, we describe the potential in vitro models for the study of estrogenic 
effects at the level of the pituitary, together with their advantages and disadvantages. 
For a summary, we refer to table 2.1 at the end of this chapter. 
2.1 Cell cultures 
2.1.1 Tissue explants and primary cell cultures 
Currently, several culture methods are available to evaluate the effects of compounds 
in a cell- or tissue-specific manner. The oldest method is the usage of tissue explants, 
whereby the target tissue or organ is isolated from laboratory animals or humans. 
Primary cell cultures can be prepared from these target tissues or organs, whereby 
cells are cultured directly following isolation. However, these cultures can contain 
mixed cell types or consist predominantly of a single cell type. Given the complex 
interrelationships of cells in any organ or tissue, primary cultures rarely consist 
exclusively of a single cell type. The cell type of interest can be further purified using 
enzymatic methods or by physical dissociation. Alternatively, primary cultures can be 
maintained in conditions chosen to positively select for the survival of only one cell 
type. 
Primary cell and organ cultures have the advantage in that they are recently removed 
from the in vivo situation and might therefore be expected to more closely resemble 
the function of that cell or tissue in vivo. The disadvantage is that these cultures are 
reacting to a constantly changing environment over the first days or weeks in vitro, 
including the changes in the mix of cell types in the culture, changes in cell shape, 
changes in cell associations, and changes in the factors secreted from the cells and the 
receptors and other cell surface proteins present on the cells. In addition, when 
different cell types are present in the culture, cellular interactions can complicate the 
interpretation of the observed effects. Other drawbacks are the requirement of the use 
of living animals or the availability of fresh tissues and the fact that preparation is 
mostly time consuming. Furthermore, there can be considerable variation from one 
preparation to another. Other disadvantages are a limited lifespan, potential 
contamination problems and a limited growth potential. This is important to take into 
consideration in determining how long primary cultures can be studied and in 
interpreting the results obtained (Merchant et al., 1964; Freshney, 1983).  
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2.1.2 The pituitary 
The aim of the present work is to study estrogenic effects at the level of the pituitary 
gonadotrophs. As the adenohypophysis consists of 5 different hormone secreting cell 
types namely gonadotrophs, lactotrophs, thyrotrophs, somatotrophs and corticothrops 
(reviewed in 1.3.1), interpretation of gonadotroph-specific manner is complicated by 
several factors. First of all, the percentage of gonadotrophs in the pituitary is quite 
low, varying between 10-15% (Wang, 1988). Furthermore, interactions between 
gonadotrophs and lactotrophs or somatotrophs are described in the literature and, 
albeit at least in part of these interactions are physiologically relevant; they also may 
also complicate the interpretation of the obtained data (Cheung, 1983; Denef and 
Andries, 1983; Andries et al., 1995).  
The ultimate goal of our project is to study potential interfering effects of estrogenic-
active compounds such as xenoestrogens and phytoestrogens on reproductive function, 
especially through alterations of gonadotropin secretion. Therefore, we have 
preferentially studied models which reflect as closely as possible characteristics of 
mature pituitary gonadotrophs. In this particular context, the strategic choice was 
made to use immortalised, gonadotropic cell lines. Other potential alternatives for the 
analysis of estrogenic effects at the level of the pituitary, such as the use of 
lactotroph-related models, were not considered in this work. 
 
2.1.3 Immortalised cell lines  
The second type of cell culture is the culture of established or immortalised cell lines. 
A vast majority of these are derived from tumors (e.g., HeLa) or from cells transformed 
in vitro, although some cell lines were established from normal embryonic tissue (e.g., 
3T3, CHO). These cell lines have been developed with the aim of maintaining a 
representative phenotype combined with the ability to grow the cell, or its precursor, 
indefinitely in culture. This can be accomplished using conditional transformation or by 
establishing the cell line from stem cell or precursor cells, which can then be induced 
to differentiate into a terminally differentiated cell type in culture. 
More recently, transgenic animals have been produced that widely express 
transforming genes such as the Simian Virus (SV) 40 T antigen (Tag) (Ali and DeCaprio, 
2001). Tissues from these animals can be used to more easily establish cell lines in 
vitro. Other transgenic animals have been created with targeted expression of 
transforming genes that predictably form tumors in specific tissues or cell types or with 
gene deletions that predictably lead to tumor formation in specific tissues (Neufeld et 
al., 1987; Heath et al., 1989).  
Immortalised or transformed cell lines are extremely valuable but it is important to 
keep in mind that they are transformed and will therefore have properties significantly 
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different from those of the normal tissue from which they are derived. These 
differences will frequently involve changes in the growth regulation of these cells 
types. 
In the literature, several immortalised cell lines showing gonadotropic properties have 
been described, including the LβT2, αT3-1, LH2, HP75 and RC-4B cell lines. 
The murine, gonadotropic LβT2 and αT3-1 cell lines differ in their stage of 
differentiation and are derived from pituitary tumors which were isolated from male, 
transgenic mice. An 1800 bp fragment of the regulatory region of the rat LHβ-subunit 
(LβT2 cell line) respectively the rat common α-subunit gene (αT3-1 cell line), was 
linked to the coding region of the oncogene SV40 T antigen (Windle et al., 1990; Alarid 
et al., 1996). This initiated a transformation process that immortalised pituitary cells 
at the stage when specific regulatory regions become active. During embryonic 
development, the earliest marker of anterior lobe differentiation is the glycoprotein 
hormone α-subunit, which is expressed at embryonic day 11.5 (E11.5) in mice. In the 
days between E11.5 and E16.5, other cell types of the anterior pituitary will 
differentiate, including corticotrophs, thyrotrophs and somatotrophs. The 
gonadotrophs are the last cells which differentiate, showing two stages, marked by 
expression of the β-subunits of either LH (E16.5) or FSH (17.5) (Windle et al., 1990; 
Alarid et al., 1996).  
According to the literature, the LβT2 cell line shows characteristics of mature 
gonadotrophs iin vivo, including the expression of a functional GnRH-R, the expression 
of both gonadotropin subunits and GnRH-enhanced LH secretion (Turgeon et al., 1996). 
Initially, it was assumed that these cells were not able to secrete FSH. However, 
Graham and colleagues (1999) reported that FSHβ-subunit expression and the 
corresponding FSH release is induced by activin A treatment. Additional studies have 
demonstrated stimulatory actions of  activin and steroids (including androgens and 
glucocorticoids) on FSHβ-expression in LβT2 cells (Pernasetti et al., 2001; Bailey et al., 
2004; Spady et al., 2004; Thackray et al., 2006;  McGillivray et al., 2007). 
As androgens and estrogens are important regulators of gonadotropin secretion, the 
LβT2 cell line served as an in vitro model for the study of their regulatory effects. LβT2 
cells show expression of a functional androgen receptor (AR) (Curtin et al., 2001; 
Lawson et al., 2001; Okada et al., 2003; Spady et al., 2004). Furthermore, a limited 
number of publications described the presence of ER expression and estrogenic 
regulatory effects on LH synthesis, storage and secretion (Turgeon et al., 1996; 
Schreihofer et al., 2000; Nicol et al., 2002; Kowase et al., 2007). Other reports 
describe the importance of  transcription factors such as steroidogenic factor 1 (SF-1), 
early growth response protein (Egr1) and pituitary homeobox 1 (Ptx1) in the regulation 
of LHβ-subunit gene expression (Dorn et al., 1999; Rosenberg and Mellon, 2002; Buggs 
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et al., 2006; Lawson et al., 2007). 
The αT3-1 cell line shows expression of the GnRH-R and the common α-subunit but 
lacks gonadotropin hormone β-subunit expression (Alarid et al., 1996). Many groups 
used this cell line to analyse the GnRH-R signalling pathway (McArdle et al., 1996; 
Garrel et al., 1997; Kakar et al., 1997; Reiss et al., 1997; Brinkmeier et al., 1998; 
Poulin et al., 1998; Rose et al., 2004). The regulation of the common α-subunit gene 
expression and the involvement of transcription factors including SF-1 and Ptx1, has 
been extensively studied in αT3-1 cells (Tsujii et al., 1995; Attardi et al., 1998; Burin 
et al., 1998; Tremblay et al., 1998; Wood et al., 1998; Bryan et al., 1999; Fowkes et 
al., 2002; Harris et al., 2003; Xie et al., 2005; Aikawa et al., 2006). Several reports 
described the presence of the AR (Okada et al., 2003; Burger et al., 2007) and ER 
(Schreihofer et al., 1999; Schreihofer et al., 2000; Williams et al., 2000; Demay et al., 
2001; Schreihofer et al., 2001). 
The LH2 cell line was generated by stably transfecting αT3-1 cells with the 
complementary DNA (cDNA) encoding for the rat LHβ-subunit. LH2 cells expressed the 
rat LHβ subunit and were shown to secrete LH following GnRH challenge. The authors 
used this cell line to investigate the effects of secretagogues on LH secretion (Yonahara 
et al., 2003).  
The human HP-75 cell line was derived from gonadotroph tumour cells from a clinically 
non-functioning human pituitary adenoma. HP-75 cells expressed chromogranin A, both 
gonadotropins and enzymes (proconvertases) which are involved in chromogranin 
processing, hereby reflecting properties of differentiated gonadotrophs in vivo. HP-75 
cells have been mostly used to analyse the effects of growth factors and leptin at the 
level of the pituitary (Tsumanuma et al., 2000; Onguru et al., 2004). 
The rat RC-4B cell line was derived from a pituitary adenoma and consists of all five 
pituitary cell types (Berault et al., 1990; Polkowska et al., 1991). These cells show 
morphological characteristics of differentiated anterior pituitary cells. Following 
immunocytochemical analysis, a part of these cells (20% and 8.6% respectively) 
appeared to be positive for both gonadotropin subunits and the GnRH-R. Other present 
cell types expressed prolactine, growth hormone, the thyroid stimulating hormone β 
(TSHβ) subunit and adrenocorticotropic hormone (ACTH), respectively (Berault et al., 
1990). Because of the presence of all these hormone-secreting cell types, 
interpretation of obtained data is more complex.  
In summary, we have retained the LβT2 and αT3-1 cell lines for the further 
investigation of estrogenic effects at the level of the pituitary gonadotrophs because 1) 
for both cell lines indications of estrogen responsiveness were available in the 
literature and 2) they were the best established gonadotroph-related cell lines in the 
literature. A summary of the characteristics of both cell lines in relation to mature 
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gonadotrophs in vivo, based on the available literature is shown in table 2.2. Finally, 
the properties of the LH2 and HP-75 cell lines make them potentially interesting 
alternative models for the LβT2 and αT3-1 cell lines. However, at the time that our 
work was already in a more advanced stage, we did not have access to the LH2 cell 
line. Furthermore, to the best of our knowledge, as to date neither for these cells nor 
for HP-75 cells are literature data available showing estrogenic responsiveness.  
In conclusion, we have chosen to use the immortalised LβT2 and αT3-1 cell lines for our 
experiments. In view of the ultimate goal of this project, being the development of an 
approach for analysis of estrogenic actions of compounds specifically at the level of in 
a gonadotrophs, gonadotropic cell lineages appeared to be the most appropriate in 
vitro study model. Nevertheless, it should be pointed out that this is a strategic choice 
in a particular context and that for other purposes, such as the study of some aspects 
of the physiological regulation of gonadotropin secretion and gonadotroph function, 
primary cell cultures and/or tissue explants can be preferable in vitro models.  
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Table 2.1: Advantages and disadvantages of different culture models. 
 Advantages Disadvantages 
Organ 
culture 
 
• Maintained tissue 
architecture 
 
• Normal physiological 
functions and interactions 
are maintained 
 
• Cells remain fully 
differentiated 
 
• Limited growth potential & 
viability 
 
• Fresh explantation is required 
for every experiment 
 
• Rather large number of 
animals needed 
 
• Potential for variability 
depending on animal status at 
sacrifice(e.g. stress, health 
status) 
 
Tissue 
culture 
 
• Some normal functions are 
maintained 
 
• Cells remain fully 
differentiated 
 
 
 
• Variable & limited duration of 
viability 
 
• Labour intensive and 
relatively expensive 
 
• Rather large number of 
animals needed 
 
Primary cells 
 
• Differentiated 
characteristics of cell in vivo 
 
• Normal physiological 
functions are maintained to 
various degree according to 
type of culture (e.g. 3D 
reaggregation allows analysis 
of interactions between 
different pituitary cell 
types) 
 
 
 
• Loss  of normal tissue 
architecture (partially 
compensated in 3D 
aggregates) 
 
• Initally heterogeneous but 
later dominated by fibroblasts 
 
• Variable & limited duration of 
viability 
 
• Rather large number of 
animals needed 
 
Immortalised 
cell lines 
 
• Continuous use / longer 
viability 
 
• 
 
• Absence of normal 
physiological, intercellular 
interactions 
 
• 
No interference of other cell 
types Potential loss of cell-specific 
characteristics / 
dedifferentiation 
 
• Reduction of animal use 
 
• 
 
Standard procedures 
facilitating interlabora
• Physiological relevancy of 
observed responses? tory 
reproducibility   
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Table 2.2: Properties of the gonadotropic LβT2 and αT3-1 cell lines as compared to 
mature gonadotrophs, according to literature data (see text; NK: not known). 
Mature Gonadotrophs LβT2 αT3-1 
 
• Gonadotropin-releasing hormone receptor 
• α-glycoprotein hormone subunit 
• Luteinizing hormone β subunit (LHβ-su) 
• Follicle Stimulating Hormone β-subunit (FSHβ-su) 
• Luteinizing hormone (LH) secretion 
• Follicle stimulating hormone (FSH) secretion 
• Estrogen receptor α (ERα) mRNA 
• Estrogen receptor β (ERβ) mRNA 
• Truncated estrogen receptor product 1 (TERP-1) 
mRNA 
• TERP-1 protein 
• ERα protein 
• ERβ protein 
• Androgen receptor expression (mRNA/protein) 
• Glucocorticoid receptor (mRNA/protein)  
• Pituitary homeobox factor 1 (Ptx1) 
• Steroidogenic factor I (SF-I) 
• Early growth response protein 1 (Egr1) 
• Activin receptors (ActR IA, IB, IIA, IIB) 
• Smad proteins 
• Chromogranin A (CgA)expression (mRNA/protein) 
• Secretogranin II (SgII; mRNA/protein) 
  
+ + 
+ + 
- + 
- + 
- + 
- + 
+ + 
+ + 
+ + 
  
Variable Variable 
+ + 
NK NK 
+ + 
NK + 
+ + 
+ + 
+ + 
+ + 
+ + 
NK + 
NK + 
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Chapter 3 Methodology 
3.1 Introduction 
In this section, we describe the general methodology of our studies on estrogenic 
effects in the murine, gonadotropic αT3-1 and LβT2 cell lines.  
In the first part of the experimental section, we have evaluated the effects of 
estrogens on LH synthesis and secretion in the differentiated LβT2 cell line using 
transient transfection studies, the real time (or quantitative) polymerase chain 
reaction (PCR) technique and a commercial radioimmunoassay (RIA).  
In the second part of our work, we have analysed the interactions between the IGF-IR 
and ER in the immature αT3-1 cell line. Proliferation experiments, transient 
transfection studies and Western blot analysis were performed to test our hypothesis. 
In the final part of the discussed experimental section, we present some preliminary 
data on the growth modulatory effects of 8-prenylnaringenin (8-PN) and naringenin 
derivatives on αT3-1 cell proliferation. ER selectivity of 8-PN and these derivatives 
were tested in a human, cervical carcinoma cell line (Hela), transiently transfected 
with an estrogen-responsive reporter plasmid, in the presence of an expression vector 
encoding for either hERα or hERβ.  
All applied techniques will be discussed in detail in the next sections. The choice of 
these procedures is based on standard techniques, as described in the literature. 
3.2 Receptor expression 
3.2.1 Reverse-transcription polymerase chain reaction (RT-PCR) 
Two different techniques have been used to determine receptor expression in our 
gonadotropic cell lines, i.e. reverse transcriptase PCR (RT-PCR) and Western Blot 
analysis. First, the expression of the messenger RNA (mRNA), which encodes for a 
specific protein, has been investigated using the reverse transcriptase PCR (RT-PCR) 
technique. Total RNA is extracted from a fixed number of cells, using a commercial 
RNA extraction kit (RNeasy mini kit), according to the instructions of the manufacturer 
(Qiagen Benelux, Venlo, The Netherlands). RNA concentration is then determined 
following spectrophotometrical analysis at 260 nm (A260) using the following formula: 
dilution factor * A260 * 40 μg/mL (50 μg/mL for DNA). However, RNA (or DNA) extracts 
may be contaminated with proteins or phenol during the extraction protocol. To check 
for purity, for each sample the ratio of A260 and A280 is assessed. Values above 1.8 (or 
1.9 for DNA) suggest that the samples are free of these contaminants. Next, extracts 
are diluted using RNase and DNase free water to obtain a stock concentration of 1 
μg/μL. Total RNA is then reverse transcribed to its complementary DNA (cDNA) using a 
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commercial kit (RevertAid First Strand cDNA Synthesis Kit), according to the 
manufacturers instructions (Fermentas GMBH, St. Leon-Rot, Germany).  
Next, the obtained cDNA is amplified using specific primer sets for each amplicon of 
interest. These primers are developed using primer design software, taking into 
account parameters such as primer length, melting temperature, GC-content and 
amplicon length. The reference sequences, encoding for the protein of interest, are 
described in the Nucleotide database of the National Centre of Biotechnology 
Information (NCBI; http://www.ncbi.nlm.nih.gov) and the gene databases of Ensembl 
(www.ensembl.org).  
Preliminary experiments are performed to determine the optimal PCR conditions for 
each primer set, including RNA concentration, annealing temperature and primer 
concentration. In the final PCR run, both positive and negative controls have been 
included beside the RNA extracts of interest. RNA extracted from cells, showing 
expression of the protein of interest, served as a positive control, while cells, lacking 
the presence of this protein were used as an alleged negative control. PCR efficiency 
was controlled by amplifying a housekeeping gene (e.g. β-actin). 
Following PCR amplification, electrophoresis was performed whereby amplicons are 
separated on a 2% agarose gel according to their size and electric charges. A DNA size 
marker, consisting of several amplicons of different lengths, served as a reference to 
determine the length of each amplicon. Finally, amplicons were visualised under 
ultraviolet light following ethidium bromide staining (Sambrook J, 1989). 
 
3.2.2 Western Blot 
RT-PCR is an excellent tool to determine mRNA expression. However, mRNA has to be 
translated in order to produce the corresponding protein. In addition, post-
translational processes can modify the final protein structure. In order to analyse 
protein expression, we have used the Western blot analysis technique (Burnette, 1981).  
First, cell lysates are prepared using Laemmli buffer, which consists of a buffer (mostly 
Tris base), a sulfhydryl compound (typically β-mercapto-ethanol), an anionic lipophilic 
detergent (sodium dodecyl sulphate (SDS) and glycerol. Then, samples are boiled, 
which allows denaturation and complete unfolding of proteins. SDS, present in the 
Laemmli buffer, will surround the protein with a negative charge, while β-mercapto-
ethanol prevents the reformation of disulfide bonds. The glycerol is necessary to 
increase the density of the sample in order to facilitate sample loading.  
The proteins of the sample are separated according to molecular weight using gel 
electrophoresis. Following electrophoresis, proteins are transferred from the gels onto 
nitrocellulose or polyvinylidene fluoride (PVDF) membranes by electroblotting. The 
charged proteins move from within the gel onto the membrane while maintaining the 
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organisation they had within the gel. Protein binding is based upon hydrophobic 
interactions, as well as charged interactions between the membrane and protein. Next, 
the membrane is incubated in a solution of bovine serum albumin (BSA) or non-fat dry 
milk, containing a small percentage of detergent (e.g. Tween 20) in order to prevent 
non-specific protein interactions between the membrane and the antibody used for 
detection of the target protein. 
After blocking, a primary antibody is incubated with the membrane under gentle 
shaking. Typically, the solution is comprised of buffered saline solution with a small 
percentage of detergent and with powdered milk or BSA. The antibody can be 
incubated for a period varying from 30 minutes to overnight. After rinsing the 
membrane to remove unbound primary antibody, it is exposed to another antibody, 
directed to a species-specific portion of the primary antibody. This is known as a 
secondary antibody, and due to its targeting properties, tends to be referred to as 
"anti-mouse," "anti-goat," etc. Antibodies come from animal sources (or animal sourced 
hybridoma cultures); an anti-mouse secondary will bind to just about any mouse-
sourced primary antibody.  
The secondary antibody is usually linked to biotin or to a reporter enzyme such as 
alkaline phosphatase or horseradish peroxidase. This step confers an advantage in that 
several secondary antibodies will bind to one primary antibody, providing enhanced 
signal. 
Most commonly, a horseradish peroxidase-linked secondary is used in conjunction with 
a chemiluminescent agent, and the reaction product produces luminescence in 
proportion to the amount of protein (Constantine et al., 1994; Lischke et al., 1996; Liu 
et al., 1997). A sensitive sheet of photographic film is placed against the membrane, 
and exposure to the light from the reaction creates an image of the antibodies bound 
to the blot. 
In the second part of the results section, phosphorylation of the serine residue at 
position 118 (Ser118) in the activating function 1 (AF-1) domain of ERα was investigated 
following exposure to E2 and growth factors. Cells were treated for 4h with test 
compounds and lysates were prepared as described above. A primary antibody was 
used that only detects ERα when the receptor is phosphorylated at Ser118, and not at 
serine residues, located at other positions in the AF-1 domain. Furthermore, this 
antibody does not cross-react with phospho- ERα. Next, blots were stripped and stained 
for total ERα, using a primary antibody that recognizes both phosphorylated and non-
phosphorylated ERα (total ERα). Following densitometric analysis using specialised 
image analysis software (Digimizer, Mariakerke, Belgium), the ratio of phospho-ERα 
over total ERα was made for each treatment group and corrected for β-tubulin, serving 
as a loading control. 
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3.3 LH synthesis and secretion in the LβT2 cell line 
The differentiated gonadotropic LβT2 cell line is able to produce both gonadotropins 
LH and FSH (Thomas et al., 1996; Turgeon et al., 1996). In our work, the effects of 
GnRH alone or in combination with E2 on LH biosynthesis were investigated at three 
different levels. LH consists of a common α-subunit and a specific β-subunit which 
determines the biological activity of the hormone (Gharib et al., 1990). As LHβ-subunit 
production is the rate-limiting parameter of LH synthesis, we have focused on LHβ -su 
gene expression. 
 
3.3.1 Transient transfections 
We have performed transient transfections to analyse the promoter activity of the rat 
LHβ-subunit gene following test compound treatment. In transfections, foreign DNA is 
introduced into eukaryotic cells. Experimentally, this is most often done as a transient 
transfection, in which the transfected gene is expressed only transiently, only for a 
short period of time. This process is usually used to test how various genetic 
modifications affect the functioning of particular genes. In transient transfection, the 
introduced gene can be lost from the cell at any time depending on environmental 
factors. At the latest, the transient gene will be lost during cell mitosis; neither 
daughter cell will retain the transient gene. In order to retain the introduced gene in 
the cell’s genetic material, stable transfections must occur. 
Cells can be transfected using different methods. The foreign DNA can be introduced 
into the cells through microinjection or using chemical or biological reagents such as a 
calcium ion or liposome that creates a "gate" in the cell allowing the uptake of the 
foreign DNA. 
In our experiments, all transient transfections were performed using the commercial 
Lipofectamine 2000 reagent, which consists of cationic lipids. These lipids will complex 
DNA and allow a better uptake into the cells, as these lipids can easily merge with the 
cell membrane (Dalby et al., 2004). 
In the present work, LβT2 cells were transiently transfected with a reporter plasmid, 
consisting of an 1800 bp fragment of the regulatory region of the rat LHβ-su gene, 
coupled to a gene encoding for the enzyme luciferase (Rosenberg and Mellon, 2002). 
When transfected cells are exposed to GnRH, the GnRH-R signalling transduction 
cascade will be activated in the cells, resulting in enhanced transcription of GnRH-
target genes, including the LHβ-subunit gene. As our reporter construct consists of the 
latter’s regulatory region, luciferase expression will be stimulated by GnRH. Following 
exposure to test compounds, cells are lysed using a specific lysis buffer by adding 
luciferin. The latter is the enzyme substrate, which produces light at a wavelength of 
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562 nm when it reacts with the enzyme luciferase in the presence of oxygen and ATP. 
This enzyme catalyzes a light-emitting (chemiluminescent) reaction whereby the 
intensity of the response depends on the amount of luciferase produced in the cells. 
This reaction is measured using a luminometer (Gould and Subramani, 1988). This 
reaction is measured using a luminometer.  
It is important to mention that transfection efficiency may vary between experiments. 
For this reason, the cellular protein content, which is an indication for the number of 
cells, can be determined using standard protein assays, such as the bicinchoninic acid 
(BCA) (Walker, 1994) or Lowry assay (Waterborg and Matthews, 1994). Luciferase 
values are then corrected for protein content. Another method is the co-transfection of 
a reporter plasmid, encoding for a gene that is constitutively expressed such as the 
house-keeping genes β-galactosidase (β-gal) and glyceraldehyde-3-phosphate 
dehydrogenase (GADPH). These enzymes also catalyze light-emitting reactions in the 
presence of a specific substrate. Luciferase values are then normalised for β-gal or 
GADPH values, hereby by-passing the differences in transfection efficiency. 
 
3.3.2 LHβ-subunit mRNA expression in the LβT2 cell line 
Activation of the promoter region of a target gene results in enhanced gene 
transcription and corresponding mRNA expression. In the LβT2 cells, we have evaluated 
LHβ-subunit mRNA expression following test compound exposure. For this purpose, we 
have used real-time PCR analysis based on the Taqman® assay (Watson and Li, 2005). 
This assay is based on a classic PCR reaction; however, the reaction mix also contains a 
specific probe that binds to the amplicon of interest. This probe is designed in parallel 
with the choice of the primer set, using specific primer design software for real-time 
PCR analysis. It consists of two types of fluorescent labels. While the probe is attached 
or unattached to the template DNA and before the polymerase acts, the quencher (Q) 
fluorophore (usually a long-wavelength colored dye, such as red) reduces the 
fluorescence from the reporter (R) fluorophore (usually a short-wavelength colored 
dye, such as green). It does this by the use of Fluorescence Resonance Energy Transfer 
(FRET), which is the inhibition of one dye caused by another without emission of a 
proton. The reporter dye is found on the 5’ end of the probe and the quencher at the 
3’ end. Once the TaqMan® probe has bound to its specific piece of the template DNA 
after denaturation (high temperature) and the reaction cools, the primers anneal to 
the DNA. Taq polymerase then adds nucleotides and removes the Taqman® probe from 
the template DNA. This separates the quencher from the reporter, and allows the 
reporter to emit its energy. The more times the denaturing and annealing takes place, 
the more opportunities there are for the Taqman® probe to bind and, in turn, the more 
emitted light is detected. The light emitted from the dye in the excited state is 
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received by a computer and shown on a graph display showing PCR cycles on the X-axis 
and a logarithmic indication of intensity on the Y-axis.  
In theory, DNA of RNA can be amplified infinitely. However, it is important to mention 
that, in practice, this does not occur. PCR amplification shows a sigmoid pattern, 
reaching a plateau when the number of PCR cycles rise. The more RNA or DNA is 
present in a sample, the faster the amplification curve will reach its plateau phase.  
To analyse the obtained real-time PCR data, a predetermined threshold value is chosen 
in such a manner that it intersects with all PCR amplification curves during their 
exponential phases. When the threshold value is set, CT-values can be determined for 
all samples. This value corresponds to the intersection of the threshold and the PCR 
amplification curve. This means that the more mRNA of interest is present in a sample, 
the lower the number of PCR cycles is necessary to achieve a plateau and the lower the 
CT-value will be.  
Finally, CT-values for each sample are quantified against a standard curve, prepared by 
a serial dilution (1/10) of a fixed amount of total RNA. Furthermore, the CT-values for 
the housekeeping gene β-actin, which was amplified in parallel with the amplicon of 
interest, were quantified against a separate standard curve, identically prepared as 
described above. For all samples, the corresponding dilutions were determined from 
both standard curves and the dilution ratio for LHβ-su and β-actin was then calculated.  
 
3.3.3 Luteinising hormone secretion in the LβT2 cell line 
Two different stimulation protocols, varying in the time of exposure, were applied to 
evaluate the effects of GnRH, alone or in the presence of E2, on LH secretion in the 
LβT2 cell line. Following stimulation, medium samples were collected and stored at -
20°C until analysis. Rat LH concentrations were determined using a commercial radio-
immunoassay (RIA) according to the instructions of the manufacturer (Amersham 
Pharmacia (GE Healthcare, Diegem, Belgium). The detection limit of the assay was 0.8 
ng/mL. The concentration range of the kit was between 0.8 and 50 ng/mL. 
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3.4 Estrogenic responses in the αT3-1 cell line 
The response to estrogens was evaluated in the αT3-1 cell line using two different 
techniques, namely transient transfection studies and proliferation experiments. Both 
techniques are described in the next two sections. 
 
3.4.1 Transient transfection studies 
In the second and final part of the results section, αT3-1 cells were transiently 
transfected with two different estrogen-responsive reporter constructs. The ERE-TK-
Luc vector consists of the vitellogenin ERE sequence coupled to the thymidine kinase 
promoter. The 3X-ERE-TATA-Luc reporter plasmid contains three copies of the 
vitellogenin ERE in the pGL2-TATA-Inr plasmid (Kalkhoven et al., 1998). It has been 
demonstrated that estrogenic effects not only depends on the type of ERE-sequence, 
but also in a promoter-dependent manner. Despite the fact that both reporter 
constructs contain a different type of promoter, the luciferase response to E2 was 
identical when transfected into the αT3-1 cell line.  
Exposure of transfected αT3-1 cells to estrogens results in the activation of the 
estrogen receptor, which will dimerises and interact with the ERE-sequence, present in 
our reporter constructs. This results in enhanced luciferase gene transcription, 
dependent on the type and concentration of the estrogenic ligand.  
The transfections in the αT3-1 cell line were performed under identical conditions as 
for the LβT2 cell line, as described in paragraph 3.3.1. 
 
3.4.2 Proliferation experiments 
In the present work, we have used the sulforodamine B (SRB) assay to assess growth 
modulatory responses following treatment with test compounds. The SRB-assay was 
developed in 1990 and is a rapid, colorimetric screening assay (Skehan et al., 1990). It 
relies on the ability of SRB to bind to protein components of cells that have been fixed 
to tissue-culture plates by trichloroacetic acid (TCA). SRB is a bright-pink 
aminoxanthene dye with two sulfonic groups that bind to basic amino-acid residues 
under mild acidic conditions, and dissociate under basic conditions. As the binding of 
SRB is stoichiometric, the amount of dye extracted from stained cells is directly 
proportional to the cell mass. The strong intensity of SRB staining allows the assay to 
be carried out in a 96-well format. The assay can detect densities as low as 1,000–
2,000 cells per well, and with a signal-to-noise ratio of 4.83 at a density of 5,000 cells 
per well. This level of sensitivity is comparable to those of fluorescent dye-staining 
methods, and is superior to those of other protein-staining methods using conventional 
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visible dyes (Skehan et al., 1990). In addition, the SRB method has proven to be 
practical, because after the TCA-fixed and SRB-stained cell monolayers are dried they 
can be stored indefinitely. Color extracted from SRB-stained cells is also stable. With 
its high level of sensitivity, adaptability to the 96-well format and endpoint stability, 
the SRB assay is well suited to large-scale screening applications, as well as research.  
The effectiveness of the SRB assay is frequently compared to that of another method 
using the tetrazolium dye 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT). The MTT assay requires cellular metabolic activity to convert the 
colorless tetrazolium to the purple-colored formazan dye; therefore, it detects only 
viable cells, whereas the SRB method does not distinguish between viable and dead 
cells. This difference, however, does not compromise the ability of the SRB assay to 
detect cytotoxic effects of a drug. Studies undertaken by several groups showed that 
results from the SRB assay correlated well with those of the MTT assay, although the 
IC50 values of compounds tested using the SRB method were slightly higher. However, 
the SRB assay has several advantages over the MTT assay. For example, some 
compounds can directly interfere with MTT reduction without having any effects on cell 
viability, while SRB staining is rarely affected by this type of interference. 
Furthermore, SRB staining is independent of cell metabolic activity; therefore, fewer 
steps are required to optimize assay conditions for specific cell lines than in the MTT 
assay (Rubinstein et al., 1990; Keepers et al., 1991; Griffon et al., 1995; Haselsberger 
et al., 1996). 
In conclusion, the SRB-assay is an efficient and sensitive tool to assess cell 
proliferation.  
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Chapter 4 Experimental work 
4.1 Estrogen Receptor Signaling is an Unstable Feature of the 
Gonadotropic LβT2 cell line 
 
Molecular and Cellular Endocrinology 273 (1-2): 16-24 (2007) 
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Estrogen receptor signaling is an unstable feature of the
gonadotropic LT2 cell line
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bstract
The murine, gonadotropic LT2 cell line was assessed as a potential in vitro model to analyze estrogen receptor (ER)-mediated regulation of
uteinizing hormone (LH) synthesis and secretion. In agreement with limited literature data, repeated exposure to (sub) physiological concentrations
f gonadotropin-releasing hormone enhanced LH-subunit gene expression, being the rate-limiting step of LH synthesis, and the corresponding LH
ecretory response. However, in the same subclone of the LT2 cell line, we observed that LH production was not affected following exposure to
2, which is in contrast to previously reported weak or modest effects. One explanation may be the absence of measurable ER protein expression
n the one hand and impaired ER signal transduction on the other. Furthermore, an alternative ER mRNA splicing variant was detected in the
T2 cell line, which (theoretically) encodes for a protein that may alter ER transcriptional activity, depending on the cellular context.
The studied LT2 subclone did not show a generalized impairment of nuclear receptor function, as we observed androgen- and glucocorticoid-
nduced gene transcription, together with enhanced LH secretory response following dexamethasone treatment.
Since its development, the gonadotropic LT2 cell line served as a reference model to study gonadotroph-specific effects because of its mature
roperties. Nevertheless, this cell line does not seem to be a suitable in vitro model for the study of estrogenic regulatory effects at the level of the
ituitary gonadotrophs in view of the unstable nature of ER signaling in LT2 cells.
2007 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
Reproductive competence depends on the interplay between
he different compartments of the hypothalamic–pituitary–
onadal axis. The episodic release of hypothalamic gonado-
ropin-releasing hormone (GnRH) results in a pulsatile pat-
ern of luteinizing hormone (LH) secretion by the pituitary
onadotrophs (Wildt et al., 1981). Luteinizing hormone is
esponsible for the synthesis and the release of gonadal steroids,
hich in turn alter gonadotropin secretion through feedbacknteractions at the level of the hypothalamus and the pituitary
Belchetz et al., 1978; Haisenleder et al., 1994; Bousfield et
l., 1994). In males, both testosterone (T) and its aromatiza-
∗ Corresponding author. Tel.: +32 92403414; fax: +32 92403886.
E-mail address: frank.eertmans@ugent.be (F. Eertmans).
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ion product 17--estradiol (E2) contribute to the regulation of
H secretion (Hayes et al., 2000; Tilbrook and Clarke, 2001).
n females, E2 exerts a negative feedback on LH release for
he greater part of the ovarian cycle, at least in part through
irect actions at the pituitary level. This inhibitory action is tran-
iently reversed into marked facilitation of pituitary LH secretion
uring the mid-cycle LH surge (Knobil, 1988; Herbison, 1998;
erdelhue´ et al., 2002; Moenter et al., 2003).
The role of E2 in the GnRH-mediated regulation of LH
elease by pituitary gonadotrophs has been extensively investi-
ated using primary pituitary cell cultures and isolated perifused
ituitaries (Emons et al., 1989; Ortmann et al., 1992a, 1992b)
owever, gonadotrophs represent only 10–15% of the anterior
ituitary cell population (Wang, 1988) It has been established
hat paracrine interactions between gonadotrophs and other pitu-
tary cell types, including lactotrophs and somatotrophs, may
nfluence basal or GnRH-induced LH secretion (Cheung, 1983;
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enef and Andries, 1983; Andries et al., 1995; Gregory et al.,
004), hereby complicating data interpretation. The need for in
itro models to study estrogenic effects at the pituitary level is
urther emphasized by the increasing interest for the therapeutic
se of phytoestrogens and the development of selective estro-
en receptor modulators on the one hand and growing concern
or potentially disrupting effects of chemical pollutants with
strogenic actions on reproductive function on the other hand
Eertmans et al., 2003).
The murine, gonadotropic LT2 cell line shows important
imilarities with mature gonadotrophs in vivo, including the
xpression of the GnRH receptor (GnRH-R) and the produc-
ion of both gonadotropins LH and follicle stimulating hormone
FSH) (Mellon et al., 1991; Alarid et al., 1996; Thomas et al.,
996; Graham et al., 1999) Therefore, this cell line is a use-
ul in vitro model to unravel cellular mechanisms involved in
H synthesis and secretion and thus potentially also for the
tudy of estrogen-specific regulation at the level of the pituitary
onadotrophs.
In the present study, LH secretion and the corresponding
H-subunit (LH-su) gene expression were assessed in the
T2 cells following exposure to GnRH alone or in combination
ith E2.
. Materials and methods
.1. Plasmids, chemicals and materials
The reporter plasmid rLH-Luc (Rosenberg and Mellon, 2002) was kindly
rovided by Dr. D. Coss (University of San Diego, La Jolla, CA, USA). The
RE-tk-Luc vector (Harnish et al., 2000) was a kind gift of Dr. W. Vanden
erghe (Ghent University, Ghent, Belgium). The pSG-hER66 (HEGO) vector
Green et al., 1994), encoding for the human estrogen receptor  (hER) was a
ind gift of Dr. J.A. Gustafsson (Karolinska Institute, Stockholm, Sweden). The
MTV-Luc reporter plasmid (De Vos et al., 1993) was kindly provided by Dr. F.
laessens (Faculty of Medicine, University of Leuven, Leuven, Belgium). The
SV--Gal vector, encoding for the enzyme -galactosidase, was purchased
rom Promega (Leiden, The Netherlands). Gonadotropin-releasing hormone
GnRH), 17--estradiol (E2), dexamethasone (Dex) and primary antibodies
gainst-tubulin were obtained from Sigma (Bornem, Belgium). All cell culture
roducts and lipofectamine Plus were purchased from Invitrogen (Merelbeke,
elgium). The rat LH RIA, the anti-mouse and anti-rabbit secondary antibod-
es conjugated to horseradish peroxidase and ECL Western Blotting Detection
eagents were from Amersham Biosciences (Roosendaal, The Netherlands).
NAlater solution and the RNeasy mini-kit were purchased from Westburg
Leusden, The Netherlands). The Taqman PCR core reagent kit was obtained
rom Applied Biosystems (Lennik, Belgium). The RevertAid First Strand cDNA
ynthesis Kit was from Fermentas (Sint Leon-Rot, Germany). PCR primers were
urchased from Operon (Leiden, The Netherlands). Primary antibody against
R (NCL-L-ER-6F11) was from Novocastra (Newcastle, United Kingdom).
.2. Cell culture
The murine, gonadotropic T3-1 and LT2 cell lines were kindly provided
y Dr. P. Mellon (University of San Diego, La Jolla, CA, USA). The human
ervical Hela cell line and the human breast cancer cell line MCF-7 (subclone
Z) were a gift from Dr. P. Briand (Jack Bell Research Center, British Columbia,
anada). Lung fibroblasts and pituitaries, isolated from C57BL/6 mice, were
rovided by Dr. K. Vermaelen (Ghent University Hospital, Ghent, Belgium).
ll cell lines were grown as a monolayer in a 5% CO2, humidified atmosphere
37 ◦C) and weekly passaged in Dulbecco’s Modified Eagle Medium (DMEM)
ontaining 10% fetal calf serum (FCS), 100 units/ml penicillin G and 100g/ml
treptomycin, except for the murine Sertoli TM4 cell line, which was grown
3
a
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n DMEM: Nutrient Mix F12 supplemented with 5% horse serum, 2.5% FCS,
00 units/ml penicillin G and 100g/ml streptomycin.
.3. LH secretion studies
LT2 cells (5 × 105 cells/well) were seeded in 24-well plates and incubated
or 48 h, after which culture medium was replaced by phenol red-free DMEM:
utrient Mix F12 supplemented with 5% dextran-coated charcoal (DCC) treated
CS and antibiotics, containing GnRH (0.1–1000 nM), alone or in combination
ith E2 (0.2 nM) and Dex (20 nM), either alone or combined. Two stimulation
etups were used whereby in a first approach, a 15 min exposure was followed by
75 min collection period in GnRH-free vehicle. In the second protocol, the cells
ere incubated continuously for several hours (1–6 h). “Conditioned medium”
as collected at the end of each incubation and stored at −80 ◦C until analysis.
ells were washed and incubated overnight in fresh steroid-free medium or
edium containing one or both steroid hormones. Both stimulation protocols
ere repeated for the next two days. At day 5 (third day of stimulation), following
edium collection, cells were counted and then stored at −80 ◦C in a mixture
f 50l of phosphate-buffered salines (PBS) and 250l of RNAlater solution
ntil total RNA extraction. For all experiments, experimental medium containing
.1% ethanol, served as vehicle control, indicated by C in the figures. LH was
easured using a commercial RIA (Amersham Biosciences, Roosendaal, The
etherlands) according to the manufacturer’s protocol.
.4. RNA isolation, real time PCR analysis and reverse
ranscription PCR
Total RNA was extracted from LT2 and TM4 cells, and from lung fibrob-
asts and total pituitaries, freshly isolated from C57BL/6 mice using the RNeasy
ini-kit, treated with DNase and frozen at −20 ◦C until analysis.
Quantitative expression of LH-subunit (LH-su) messenger RNA (mRNA)
ith mouse -actin as the internal standard was performed using the Taqman®
eal-time analysis method on a Perkin-Elmer ABI Prism 7700 sequence detec-
ion system (Applied Biosystems, Lennik, Belgium). A LH-su-specific 120 bp
ragment was amplified using forward primer (fp) 5′-CATCACCTTCACCA-
CAGCAT-3′ and reverse primer (rp) 5′-GAGGCGAAGCGCAGCTC-3′, in
ombination with the TaqMan® probe 5′-FAM-CCTCCCGTGCCTCAGCC-
GTGT-TAMRA-3′. A mouse -actin specific 138 bp fragment was
mplified using fp, 5′-AGAGGGAAATCGTGCGTGAC-3′ and rp, 5′-
AATAGTGATGACCTGGCCGT-3′, in combination with Taqman® probe
′
-FAM-CACTGCCGCATC CTCTTCCTCCC-TAMRA-3′. All primer/probe
ets were developed using the Primer Express software (Applied Biosys-
ems, Lennik, Belgium), based on genbank entries NM 012858 (LH-su) and
M 007393 (-actin). PCR conditions were as follows: a reverse transcription
tep at 48 ◦C for 30 min and an initial denaturation step at 91 ◦C for 10 min,
ollowed by 40 cycles consisting of a denaturation step at 91 ◦C for 1 min, a
min annealing step at 65 ◦C and a 2 min extension step at 72 ◦C. An elongation
tep of 10 min at 72 ◦C finalized the amplification. LH-su mRNA levels were
uantified against a standard curve, prepared by a serial dilution (1/10) of 50 ng
otal RNA extracted from LT2 cells; -actin mRNA was quantified as a refer-
nce gene against a separate standard curve. Threshold cycle (CT) values for the
H-su and -actin were obtained for each sample, the corresponding dilutions
ere determined from both standard curves and the dilution ratio for LH-su
nd -actin was calculated. Values for treated cells are expressed relative to the
ontrol (untreated cells), set to 100%.
For qualitative reverse transcription PCR analysis of the androgen
eceptor (AR), the glucocorticoid receptor (GR) and the ER pituitary-
pecific variant truncated estrogen receptor product 1 (TERP-1), total RNA
as reverse transcribed using the RevertAid First Strand cDNA Syn-
hesis Kit, according to the manufacturer’s instructions. The following
CR primers were used (fp = forward primer, rp = reverse primer): a 203
p-specific amplicon for AR fp, 5′-CTCTTCTTCCTGGCATACTCTCTT-
′
, AR rp 5′-CTGGTGGAGTTGTGAACAGAGTAC-3′, a 461 bp-specific
mplicon for the GR fp, 5′-GCCTGGTGTGCTCCGATGAA-3′, GR
p, 5′-CACTGCGGCAATCACTTGGC-3′,a 370 bp-specific amplicon for
ERP-1, TERP-1 fp, 5’-CCATTTCTTGAGCTTGTTGAACAG-3’, TERP-
rp, 5’-GTGTCTGTGATCTTGTCCAGGAC-3’ (adapted from Schreihofer
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t al., 2000) and a 238 bp-specific amplicon for -actin fp, 5′-
TGGCACCACACCTTCTA-3′,-actin rp, 5′-GGGCACAGTGTGGGTGAC-
′
. Primers were based on genbank entries NM 013476, NM 008173,
M 007956 and NM 007393 for AR, GR, ER respectively -actin. Two
icrolitres of cDNA were amplified as follows: an initial denaturation step at
2 ◦C for 10 min was followed by 40 cycles consisting of a denaturation step
t 92 ◦C for 30 s, a 30 s annealing step (58◦) and a 45 s extension step at 72 ◦C.
n elongation step of 10 min at 72 ◦C finalized the amplification. PCR products
ere analyzed using a 2% agarose gel electrophoresis, followed by ethidium
romide staining.
Expression of full length ER and possible ER mRNA splicing variants
as analyzed using two primer sets. The first primer set was taken from Swope
t al. (2002) and consists of a common FP and two different RPs, which are able
o distinguish between full length ER (516 bp) and a variant message (480 bp).
ollowing RT-PCR analysis and agarose gel electrophoresis, densitometric anal-
sis was performed using Digimizer image analysis software (Medcalc Software,
ariakerke, Belgium) to quantify full length ER and the variant messages. The
atio of full length ER to the variant message was calculated for each tested
ell line and corrected for -actin, which was amplified in parallel and served as
control for PCR efficiency on the one hand and as loading control on the other.
he murine, gonadotropic T3-1 cell line and the murine TM4 Sertoli cell line
erved as a positive control, while mouse lung fibroblasts served as an alleged
egative control.
The second primer set (fp, 5′-GTCTGGTCCTGCGAAGGCTGC-3′ and
p 5′-TGACGTAGCCAGCAACATGTCAAAG-3′), adapted from the one
escribed by Pasqualini et al. (1999) in the rat, yields an amplicon of 702 bp
or full length ER, while alternative splicing messages correspond to an ampli-
on of 585 bp (exon 4 deletion), 366 bp (exon 5 deletion) and 249 bp (exons
and 5 deletion), respectively. PCR conditions were similar to the conditions
escribed above, differing only in annealing temperature of the reverse primer
55 ◦C instead of 45 ◦C).
.5. Western blot
Lysates were prepared of MCF-7 cells (untransfected) and of LT2 and
ela cells, prior to and following transfection with a human estrogen receptor 
hER) expression vector (50 ng). Cells were washed twice with PBS and lysed
n Laemmli buffer (0.25 M Tris, 1.92 M glycine and 1% sodium dodecyl sul-
hate in aqueous solution). Lysates were centrifuged at 14,000 rpm for 30 min
t 4 ◦C, and protein concentration was determined by Lowry assay. All sam-
les were diluted with sample buffer (62 mM Tris–HCl, pH 6.8, 10% glycerol,
.0% -mercaptoethanol, 2.0% SDS, 0.0012% bromophenol blue) and heated
t 94 ◦C for 5 min. A total of 25g of protein was loaded for each sample.
lectrophoresis was carried out on a 10% separating gel at 100 V for 1 h in a
ini-Protean II electrophoresis system (BioRad). After electrophoresis, proteins
ere transferred from polyacrylamide gels onto nitrocellulose membranes by
lectroblotting (0.8 mA/cm2 constant current, 60 min, room temperature). Fol-
owing transfer, membranes were blocked with 5.0% dehydrated nonfat milk in
BS-T (20 mM Tris–HCl, pH 7.4, 137 mM NaCl, 0.10% Tween-20) for 60 min at
oom temperature. Membranes were then washed three times in fresh TBS-T fol-
owed by a 1 h incubation with primary antibody. Following washing (3× TBS-T,
min), membranes were incubated for 1 h in secondary antibody. Immunode-
ection was performed with an enhanced chemiluminescence (ECL) system
ccording to manufacturer’s specifications. Chemiluminescence was captured
n photographic film. Each Western blot was exposed for 15, 30 and 60 s to
uarantee linearity of the film.
.6. Transient transfection studies
Cells were grown in 24-well plates at a density of 1.25 × 105 cells per well
LT2 cell line) respectively 3 × 104 cells per well (Hela and TM4 cell lines) in
dentical conditions as for the secretion experiments. Following overnight incu-
ation, cells were transfected with rLH-Luc (250 ng) or MMTV-Luc (50 ng)
sing Lipofectamine Plus according to the instructions of the manufacturer.
he ERE-TK-Luc (250 ng) reporter plasmid was transfected in LT2 cells,
lone or in combination with the HEGO expression vector, encoding for the
ER (50 ng). In each experiment, a reporter plasmid, encoding for the enzyme
s
(
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-galactosidase (-gal; 20 ng) was co-transfected in order to control for trans-
ection efficiency. Twenty-four hours later, cells were treated for 16 h with test
ompounds. After cell lysis, luciferase and -gal activities were determined
sing a Packard Lumicount Microplate luminometer (Packard Instrument Com-
any Inc., Meriden, CT, USA). Luciferase values were normalized for -gal
alues and the obtained results for treated cells were expressed relative to the
ontrol (untreated cells), set to 100%.
.7. Statistical analysis
Values in the figures are presented as the average ± S.D. Curve analysis
four parameter logistic regression) was performed using Sigmaplot 8.0 (SPSS
nc., Chicago, USA). Statistical analysis was carried out by oneway ANOVA
sing the SPSS 11 statistical package (SPSS Inc., Chicago, USA). Significant
ifferences were determined by the Dunnet’s post hoc test; statistical significance
as inferred at P< 0.05.
. Results
.1. LH secretion and LHβ-subunit (LHβ-su) gene
xpression following GnRH challenge
A short pulse setup was applied to investigate the LH secre-
ory response of LT2 cells following repeated GnRH treatment.
T2 cells were exposed to 15 min GnRH, followed by a 75 min
ollection of GnRH-free medium. On the first treatment day,
H secretion, as measured by RIA, was not induced by rais-
ng concentrations of GnRH (0.1–1000 nM). On treatment day
, LH release was significantly induced, reaching a plateau at
0 nM of GnRH. At day 3, maximal induction of secretion was
hown at 10 nM of GnRH followed by a declining LH response
t higher GnRH concentrations, the secretion at 1M being no
onger different from the blank. When investigating the effect
f varying the duration of GnRH exposure from 1 h up to 6 h,
timulation for 4 h was found to result in the largest differ-
nce between stimulated and unstimulated cells. Despite the fact
hat LH medium concentrations were approximately 1.55-fold
igher for cells treated with GnRH for 4 h in comparison to
T2 cells exposed for 15 min, no differences were observed in
he LH release profile between both stimulation setups (Fig. 1A
nd B).
In a next series of experiments, the short pulse setup was
sed to investigate the effects of E2 (0.2 nM) and Dex (20 nM)
n LH secretion as assessed on the third day of repeated
xposure to GnRH. 17--Estradiol alone did not alter cell num-
er or the LH secretory response. In contrast, a significant
P< 0.001) decrease of 20% in cell number was observed in
ex-exposed LT2 cells, with a significant (P= 0.002) increase
n LH release, corrected for cell number, when compared to cells
xposed to GnRH (10 nM) alone. We observed a comparable
9% reduction in cell number (Fig. 2) and a borderline sig-
ificant (P= 0.06) induction of LH secretion, corrected for cell
umber, in LT2 cells, treated with both E2 and Dex, in compari-
on to cells treated with GnRH (10 nM) alone. Results are shown
n Fig. 3.LH-subunit (LH-su) messenger RNA (mRNA) expres-
ion, as determined using real-time PCR, was significantly
P< 0.05) induced by GnRH in a dose-dependent manner; at
M of GnRH, mRNA levels were approximately three-fold
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Fig. 1. Gonadotropin-releasing hormone (GnRH)-induced luteinizing hormone
(LH)-secretion in the LT2 cell line. LT2 cells were exposed daily to GnRH
(0.1–1000 nM) during three consecutive days using a short pulse setup (Fig. 1A;
15 min GnRH–75 min collection of GnRH-free medium) or a 4 h exposure
setup (Fig. 1B). Values for treated cells were corrected for cell number and
are expressed relative to vehicle control (experimental medium containing 0.1%
ethanol), set at 100%. Results are presented as the mean ± S.D. from three
separate experiments. *P< 0.05 vs. vehicle control (C).
Fig. 2. Effect of E2 (0.2 nM) and/or Dex (20 nM) treatment on cell proliferation
in the LT2 cell line. At the end of the LH secretion experiments (third day of
repeated exposure to GnRH), cell number was determined using the trypan blue
exclusion method. Results were expressed relative to vehicle control (C), set at
100%. Results are presented as the mean ± S.D. from three separate experiments.
*P< 0.05 vs. vehicle control (C).
Fig. 3. Effects of different steroid treatments on LH secretion following repeated
exposure to 10 nM of GnRH. LT2 cells were exposed daily to 10 nM of GnRH
during three consecutive days using a short pulse setup (15 min GnRH–75 min
collection of GnRH-free medium) in the absence or presence of 0.2 nM E2 and
20 nM Dex, alone or combined. At treatment day 3, LH medium concentrations
were determined and corrected for cell number. Shown are also controls (in
absence of GnRH). Values are expressed relative to vehicle control (experimental
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fedium containing 0.1% ethanol), set at 100%. Results are presented as the
ean ± S.D. from three separate experiments. *P< 0.05 vs. vehicle control.
igher compared to the control. In the presence of E2 and Dex,
H-su mRNA levels remained unchanged in comparison to
ells treated with GnRH alone (Fig. 4). The expression of mouse
-actin mRNA, which served as an internal standard, was not
ffected by any treatment (data not shown).
Finally, LH-su promoter activity was studied following
reatment with GnRH using the reporter plasmid rLH-Luc.
uciferase activity was dose-dependently induced by GnRH,
hile co-incubation with E2 and Dex did not affect promoter
unctioning (Fig. 5).
ig. 4. Dose-dependent stimulation of rat LH-subunit (LH-su) mRNA
xpression by GnRH in the LT2 cells. LT2 cells were exposed daily to GnRH
0.1–1000 nM), alone or in the presence of E2 (0.2 nM) and Dex (20 nM) dur-
ng three consecutive days. At the final day, LT2 cells were harvested and
otal RNA was extracted for real-time PCR analysis. Values for treated cells
re expressed relative to their respective control (experimental medium contain-
ng 0.1% ethanol and experimental medium supplemented with E2 (0.2 nM)
nd Dex (20 nM), respectively), set at 100%. Results are presented as the
ean ± S.D. from three separate experiments. *P< 0.05 vs. respective control
C); GnRH-induced LH-su mRNA expression was not significantly altered
ollowing treatment E2/Dex-treatment.
60
20 F. Eertmans et al. / Molecular and Cellular Endocrinology 273 (2007) 16–24
Fig. 5. Modulation of rLH-su promoter activity by GnRH. LT2 cells were
transiently transfected with the rLH-Luc construct (250 ng), which consists
of an 1800 bp fragment of the 5′ flanking region of the rLH-su gene, cou-
pled to a gene encoding for the luciferase enzyme. LT2 cells were exposed to
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Fig. 6. Reverse-transcription PCR analysis of ER expression in the LT2
cell line. Fig. 6A: the expression of ER and an alternative splice variant was
investigated using reverse transcriptase polymerase chain technique (RT-PCR).
Full length ER and the alternative message correspond to an amplicon of 516
and 480 bp, respectively. The estrogen-responsive TM4 Sertoli cell line and the
gonadotropic T3-1 cell line served as a positive control, while lung fibroblasts
were used as an alleged negative control. (B) RT-PCR was applied to analyze
the expression of alternative ER mRNA splicing variants, which contains an
exon 3 and/or exon 4 deletion. Full length ER mRNA corresponds to a 702 bp
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cell line. For all amplicons of interest, all primer sets yielded
negative results when applied to mouse fibroblast mRNA which
served as an alleged negative control. Mouse -actin expression
was used to control for PCR efficiency (data not shown).
Fig. 7. Western Blot analysis of ER expression in the LT2 and the Hela cellnRH (0.1–10,000 nM), alone (full line) or in combination (dashed line) with
2 (0.2 nM) and Dex (20 nM) for 16 h. Results are presented as the mean ± S.D.
rom three separate transfections.
.2. Gonadotropin subunits and hormone receptor
xpression
Expression of the mRNAs encoding for the GnRH-receptor
nd the gonadotropin subunits was demonstrated in our subclone
f the LT2 cell line and in C57BL/6 mouse pituitaries, serving
s a positive control (data not shown).
Expression of full length ER and possible ER mRNA
plicing variants was analyzed in LT2 cells using different
rimer sets. The first primer set distinguishes between full length
R (516 bp) and a variant message (482 bp), which results from
nappropriate splicing at the 3′-end of exon 4. The levels of full
ength ER were 1.6-fold higher in comparison to the variant
essage. In contrast, the ratio of full length ER to the variant
essage was significantly (P< 0.05) higher (3.7- and 3.5-fold,
espectively) in the murine, gonadotropic, T3-1 cell line and in
he murine, TM4 Sertoli cell lines, both serving as a positive con-
rol. No bands could be detected in the mouse, lung fibroblast.
n example of a representative gel electrophoresis is illustrated
n Fig. 6A.
In a second series of experiments, a primer set was used
hich is able to detect both full length ERmRNA and splicing
ariants, which result from deletion of exon 4, exon 5 or the
ombination of both exons. Following RT-PCR analysis, only
ull length ER was amplified, while no splicing variants could
e detected in the LT2 cell line. Observations were identical in
he T3-1 and TM4 cell lines, showing higher expression of full
ength ERmRNA when compared to the LT2 cells (Fig. 6B).
urthermore, we were unable to demonstrate expression of the
ituitary-specific truncated estrogen receptor product-1 (TERP-
) in the LT2 cell line, while positive results were obtained
sing C57BL/6 mouse pituitaries (data not shown).Following Western analysis, neither ER protein (Fig. 6)
or the (theoretically) expected protein of 42.3 kDa could be
etected. Similar negative results were obtained for the demon-
tration of full length ER (66 kDa) in LT2 cells which were
l
(
t
s
amplicon. Sample 1 and 2 represent two different RNA extracts of the LT2 cell
ine. Samples 3 and 4 correspond to the T3-1 and TM4 cell lines, respectively.
urine, lung fibroblast RNA (lane 5) served as an alleged negative control.
rown in DMEM containing varying concentrations (1–10%) of
ither non-treated or DCC-treated FCS, respectively (data not
hown).
Transfection with an expression vector, encoding for the
uman ER (HEGO), strongly induced receptor expression.
ysates from human MCF-7 breast cancer cells and from human
ervical Hela cells, transfected with the HEGO expression vec-
or, served as a positive control (Fig. 7). In contrast to the low
R mRNA abundance, the glucocorticoid receptor (GR) and
he androgen receptor (AR) were strongly expressed in the LT2ine. Lysates were prepared from LT2 and Hela cells, without (−) and with
+) prior transfection with a human ER expression vector, and analyzed for
he presence of ER protein (66 kDa fragment). The human MCF-7 cell line
erved as a positive control. Mouse tubulin (Tub.; 50 kDa fragment) was used
s loading control.
61
F. Eertmans et al. / Molecular and Cellular Endocrinology 273 (2007) 16–24 21
Fig. 8. Assessment of estrogen receptor (ER)-mediated gene transcription in the
LT2 and the Hela cell line. LT2 and Hela cells were transiently transfected
with the ERE-tk-Luc construct alone, or in combination with a human ER
expression vector. The ERE-tk-Luc reporter plasmid consists of two copies of
the Xenopus laevis vitellogenin A2 ERE (58-GGTCACAGTGACC-38), linked
to the thymidine kinase (tk) promoter and coupled to a gene encoding for the
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Fig. 9. Differential response of the MMTV-promoter in the LT2 and TM4 cell
lines. Both cell lines were transiently transfected with the AR- and GR-driven
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duciferase enzyme. Cells were exposed to E2 (10 and 1000 nM for LT2 cells;
.1 and 10 nM for Hela cells) for 16 h. Results are presented as the mean ± S.D.
rom three separate transfections. *P< 0.05 vs. vehicle control (C).
.3. Assessment of hormone receptor-mediated gene
xpression
No response could be observed in LT2 cells, transiently
ransfected with an ER-driven reporter construct (ERE-TK-
uc), following exposure to E2 (16 h; 10 pM to 1M). In
ddition, LT2 cells did not respond to E2 following co-
ransfection with an expression vector encoding for the human
R. As a positive control, the human Hela cell line was trans-
ected in parallel. E2 was able to stimulate luciferase activity
n a dose-dependent manner, with an EC50 of 1.68 pM. At
he highest concentration of E2 (10 nM) tested, ER-mediated
uciferase induction was 22.55-fold in comparison to vehicle
ontrol. Results are presented in Fig. 8.
AR- and GR-mediated gene transcription was investigated in
T2 cells using a MMTV-Luc reporter construct. At a con-
entration of 1M, MMTV promoter activity was significantly
P< 0.05) stimulated by dihydrotestosterone (DHT) and Dex
1.83- and 2.5-fold, respectively, in comparison to vehicle con-
rol) in the LT2 cell line. As a positive control, the mouse Sertoli
M4 cell line was transfected in parallel. Luciferase activity
howed a significant (P< 0.05) 2.21- and 4.56-fold increase
hen compared to vehicle control following treatment with DHT
nd Dex respectively. Results are shown in Fig. 9.
. Discussion
Whereas the results of the present study confirm that the
urine, gonadotropic LT2 cell line displays characteristics of
ature gonadotrophs in vivo with gonadotropin-releasing hor-
one (GnRH) inducible luteinizing hormone (LH) secretion, in
ur hands, extensive experiments failed to demonstrate regula-
ory effects of 17--estradiol (E2).
t
d
s
tMTV-Luc reporter plasmid and treated with Dex (1M) or dihydrotestos-
erone (DHT; 1M) for 16 h. Results are presented as the mean ± S.D. from
hree separate transfections. *P< 0.05 vs. vehicle control (C).
Using a short pulse setup, daily repeated exposure to (sub)
hysiological concentrations of GnRH enhanced LH release by
T2 cells, except on the first treatment day, showing lack of
ecretory response following GnRH challenge. These findings
uggest that the previously well-documented self-priming effect
f GnRH (Aiyer et al., 1974; Waring and Turgeon, 1980) was
reserved in the LT2 cell line. Turgeon et al. (1996) and Nicol et
l. (2002) also reported increased responsiveness of LT2 cells,
lthough there was already a significant response on day 1. In
ur experiment, increasing the exposure time to 4 h, although
esulting in higher basal medium LH concentrations, still failed
o show a significant response to GnRH challenge on day 1. In
ddition, the LH secretion pattern in response to GnRH, seen
n the following treatment days was identical for the short and
onger stimulation setups.
On the third day of exposure, we observed a maximal effect
t 10 nM of GnRH, while higher concentrations resulted in
decreased secretory response, which is in agreement with
he findings of Nicol et al. (2002). Currently, the mecha-
ism underlying the latter phenomenon remains unknown, but
ost-transcriptional processes or vesicle storage of LH may
e impaired in the LT2 cell line at these supraphysiological
nRH concentrations. Indeed, in our experiments, a dimin-
shed response to higher GnRH concentrations was not seen for
H-subunit (LH-su) promoter activity and the corresponding
essenger RNA (mRNA) expression, which were both dose-
ependently stimulated by GnRH, hereby reaching a maximal
ffect at 1M.
On the third day of repeated exposure to 10 nM of GnRH, we
id not observe any changes in cell number and the LH secre-
ory response of LT2 cells in the presence of E2. In contrast,
examethasone (Dex) treatment decreased cell number while
timulating the LH secretory response. Results for the combina-
ion of both steroids were similar as for Dex alone. Turgeon and
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olleagues reported that a significant effect of E2 was seen only
n the fourth day of repeated exposure. Furthermore, in their
xperiments, the GnRH-induced secretory response to Dex was
pproximately two-fold higher in comparison to the E2-treated
roup and was comparable to the effects they observed in E2- and
ex-treated (E2/Dex) cells (Turgeon et al., 1996). In contrast, at
ay 3 of repeated exposure, Nicol and colleagues reported that
H secretion was significantly stimulated by all steroid treat-
ents, with a stronger induction in the Dex-group in comparison
o E2-treated cells (Nicol et al., 2002). Similar to the observa-
ions of Turgeon et al. (1996) the combination of both steroids
ad no additional effects above the Dex-mediated response.
In our hands, the combination of E2 and Dex did not influence
nRH-induced LH-su gene expression, being the rate-limiting
tep of LH synthesis (Evans, 1999; Yamada et al., 2004). Our
ata are in agreement with the findings of Turgeon et al. (1996),
ut are at variance with the observations of Nicol et al. (2002),
howing inconsistent effects on LH-su mRNA expression. The
ack of estrogenic response in our LT2 cell line may plausi-
ly be attributed to the rather weak abundance of the mRNA
ncoding for the ER and the absence of demonstrable recep-
or protein. Similar findings were reported by the group of
iswender (2006), who transfected ER in the LT2 cell line
ecause of the absence of the receptor (Colorado AES Projects
OL00220; ref. 32).
Our data are conflicting with the observations of another
roup, reporting strong ER mRNA and protein expression in
he LT2 cells (Schreihofer et al., 2000). In our hands, differ-
nt culture conditions did not affect ER mRNA and protein
xpression. Furthermore, we demonstrated that our LT2 cell
ine preserved the main properties of mature gonadotrophs in
ivo, including mRNA expression of the GnRH receptor (GnRH-
) and the gonadotropin subunits, which is in agreement with
ther reports (Turgeon et al., 1996; Lawson et al., 2001). LT2
ells also showed a strong expression of the mRNAs encoding
or the androgen receptor (AR) and the glucocorticoid receptor
GR).
Dedifferentiation in function of time and passage number
ay be a possible explanation for the loss of ER expression
n our subclone. This phenomenon was reported by Kim et al.
2000) in immortalized hepatocytes, which were generated using
imian virus 40 (SV40) T-antigen oncogenesis. The authors
emonstrated that dedifferentiation was caused by chromoso-
al damages, induced by raising T-antigen levels following
ontinuous passages. As SV40 T-antigen oncogenesis was used
o develop the LT2 cell line (Alarid et al., 1996), we cannot
xclude that similar effects occurred in these cells, resulting
n the loss of cell characteristics, including ER expression.
nother explanation could have been overexpression of the trun-
ated estrogen receptor product 1 (TERP-1) in our cell line. This
ituitary-specific ER-isoform is able to modulate E2-mediated
ene transcription, depending on the ER over TERP-1 concen-
ration ratio (Resnick et al., 2000). However, TERP-1 expression
ppeared to be also absent in our LT2 cell line. Furthermore,
nother group reported that TERP-1 expression in the LT2
ells was considerably lower when compared to ER and also
aried between experiments (Schreihofer et al., 2000).
m
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Although we were not able to demonstrate TERP-1 expres-
ion in the LT2 cell line, we did show the expression of an
lternative ERmRNA, which results from inappropriate splic-
ng at the 3′-end of exon 4, whereby an intronic sequence is
ncorporated at this 3′-end and downstream exons are deleted.
heoretically, this mRNA variant encodes for a protein of
2.4 kDa, which lacks most of the ER ligand binding domain
LBD) (Swope et al., 2002). In the mouse, the exact function of
his protein remains currently unknown but a similar variant has
lready been described in humans, where it was able to enhance
r inhibit full length ER transcriptional activity, depending on
he cellular context (Bollig and Miksicek, 2000). Although we
ere not able to demonstrate the expression of this truncated
rotein in the LT2 cell line with the applied primary antibody,
ne can postulate that the observed lack of estrogenic effects in
he LT2 cell line might be related to the low ratio of full length
R to the variant message. These findings are in contrast to
ur observations in the gonadotropic T3-1 and TM4 Sertoli
ell lines, which are both estrogen-responsive. In the latter cell
ines, substantially higher levels (3.7- and 3.5-fold) of full length
R in comparison to the variant message were measured.
In the rat, Pasqualini et al. (2001) have described ER splic-
ng variants showing deletions of exon 3 and/or exon 4, which
an alter ER transcriptional activity either positively or nega-
ively. Furthermore, these variant mRNAs were expressed in a
tage- and region-specific manner (Pasqualini et al., 1999) in
he presence of full length ER mRNA. We have analyzed the
xpression of corresponding ER splicing variants in the LT2
ell line. One important difference is the fact that the rat ER
ene contains only 8 exons, which is in contrast to the mouse
ene, which consists of nine exons. In other words, the murine
R gene exons 4 and 5 correspond to rat exons 3 and 4. We
ave performed RT-PCR analysis using a primer set which was
erived from the one described by Pasqualini and colleagues
1999). However, no ER splicing variants were detected in
he LT2 cell line nor in the other two tested murine cell lines
T3-1 and TM4 cell line)
In order to by-pass the apparent absence of ER protein,
T2 cells were transiently transfected with an expression
ector encoding for the human ER in combination with
n ER-driven reporter construct (ERE-tk-Luc). Despite strong
xpression of ER protein, as demonstrated using Western blot
nalysis, E2 treatment still failed to stimulate estrogen response
lement (ERE)-mediated luciferase expression. In contrast, Dex
nd dihydrotestosterone (DHT) were able to stimulate the mouse
ammary tumor virus (MMTV) promoter, which is under tran-
criptional control of the GR and the AR. These observations,
ogether with the demonstrated mRNA expression of both recep-
ors, suggest a specific problem of ER signaling in the LT2 cell
ine, rather than a generalized impairment of nuclear receptor
unctioning.
It should be noticed that we transfected human ER into a
urine cell line, and thus that a species-specific incompatibility
ight underlie our negative transfection results in the LT2 cell
ine. However, similar experiments were performed in the mouse
M4 Sertoli cell line, whereby transfection with a HEGO vector
nd ERE-LUC resulted in a significant increase in estrogenic
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esponse above cells, transfected with ERE-Luc alone (data not
hown).
Recently, Turgeon and Waring (2006) demonstrated that pro-
esterone receptor (PR) A and B expression in LT2 cells
as not affected by E2, which was in contrast to their obser-
ations in rat and mouse pituitary cultures, showing increased
xpression of both PR isoforms following E2-exposure. Another
roup reported a decrease in GnRH-induced aromatase promoter
ctivity in LT2 cells treated with E2 (Galmiche et al., 2006),
owever at a 50,000-fold higher concentration (10M) in com-
arison to our and other experiments (Turgeon et al., 1996; Nicol
t al., 2002).
The present results indicate the importance of careful analy-
is of data, obtained in highly specific cell lines. In the case of the
T2 cell line, the previously reported estrogenic effects were
ather modest or weak (Turgeon et al., 1996; Nicol et al., 2002)
oreover, variable outcome may occasionally be observed even
or cell lines yielding much more robust estrogenic responses
han those previously described for LT2 cells, such as in the
uman MCF-7 breast cancer cell line, which has been widely
sed in validated in vitro assays to assess estrogenic effects
Rasmussen and Nielsen, 2002). One can postulate that ER-
ediated signaling is an unstable feature of the LT2 cell line,
hich is vulnerable to dedifferentiation.
In conclusion, in our hands, extensive investigations failed to
emonstrate any regulatory effect of E2 on the GnRH-induced
H secretory response and the corresponding LH-su gene
xpression in the LT2 cell line. Underlying causes appear to
e situated at different levels involved in ER signal transduction,
ncluding rather weak ER mRNA expression, the absence of a
unctional ER protein and lack of estrogenic response follow-
ng co-transfection with an ER expression vector. Furthermore,
he relative strong expression of an ERmRNA splicing variant
n comparison to full length ERmRNA suggests a possible role
or this variant in abnormal ER signaling in the LT2 cell line. In
iew of the inconsistencies between laboratories or subclones in
he expression of ER-mediated signaling, the LT2 cell line does
ot seem to be a suitable in vitro model for the study of estrogen
egulation of gonadotropin synthesis and secretion. It seems rel-
vant to point out this limitation in view of the unique position of
he LT2 cell line as an immortalized cell line reflecting essen-
ial properties of mature gonadotrophs and a well established
nd useful model for in vitro studies of gonadotropin regulation.
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In reproductive tissues such as the breast and the uterus, cell proliferation and differentiation is strongly regulated by complex interactions
between estrogen receptor a (ERa) and growth factor receptors. In the present study, we investigated the potential occurrence of such
cross-talk in the murine, gonadotropic aT3-1 cell line, which expresses ERa and the IGF-I receptor (IGF-IR). Under estrogen-free
conditions, basal cell proliferation and ER-mediated gene transcription was strongly inhibited by the selective estrogen receptor
modulator (SERM) 4-hydroxy-tamoxifen (4-OH-Tam) and by the pure anti-estrogen ICI 182,780 (ICI). These effects can be reversed by
either 17-b-estradiol (E2) or insulin-like growth factor I (IGF-I), both exerting modest mitogenic effects in the aT3-1 cell line.
Furthermore, IGF-I enhanced both basal and E2-induced ER-driven gene transcription. This may be explained, at least in part, by enhanced
phosphorylation of ERa at serine 118, a prerequisite for the transactivation capacity of the receptor. Finally, the IGF-I-induced response on
cell growth and ER-mediated transactivation can be inhibited with either ICI or 4-OH-Tam. In conclusion, our data indicate IGF-IR and ER
interactions in the aT3-1 cell line, an in vitro model for the pituitary gonadotrophs, hereby suggesting a role of IGF-I in the regulation of
gonadotropin synthesis and secretion.
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DOI: 10.1002/jcp.21053Estrogens play an important role in the neuroendocrine
regulation of gonadotropin synthesis and secretion by
modulating the release of the hypothalamic gonadotropin-
releasing hormone (GnRH) on the one hand and by direct
interaction with the pituitary gonadotrophs on the other
(Knobil, 1988; Tilbrook and Clarke, 2001; Burger et al., 2004;
Malyala et al., 2005).
Several studies have demonstrated protective effects of
17-b-estradiol (E2) in the nervous system (Dluzen and
McDermott, 2000; Mendez et al., 2005; Manthey and Behl,
2006), an action that appears to involve estrogen receptor (ER)
and growth factor receptor interactions in neural cells (Singer
et al., 1999; Topalli and Etgen, 2004). Likewise, such cross-talk
has been demonstrated in extensive studies in reproductive
tissues, for example, in the female breast and the uterus,
demonstrating that E2 and growth factors such as insulin-like
growth factor I (IGF-I) and epidermal growth factor (EGF) act
together in order to regulate cell differentiation and
proliferation (Ruan et al., 1995; Richards et al., 1996; Lee et al.,
1999; Klotz et al., 2000; Oesterreich et al., 2001).
In the absence of estrogens, agonist-bound growth factor
receptors can enhance ER transcriptional activity through
kinase signaling pathways which induce phosphorylation of the
receptor at specific serine residues (Kato et al., 1995; Kahlert
et al., 2000; Chen et al., 2002).
In the central nervous system, IGF receptors (IGF-R) are
widely expressed, whereby many brain cells show additional
co-expression of the ER (Cardona-Gomez et al., 2001). In
particular, several authors report the presence of the IGF-IR
not only at the level of the hypothalamus (Daftary and Gore,
2004, 2005) but also in the pituitary (Xia et al., 2001; Weiss
et al., 2003; Rose et al., 2004).
A limited number of studies have investigated the effects of
IGF-I on gonadotropin secretion by the pituitary gonadotrophs.
In ovariectomized female rats, E2 and IGF-I were shown to
interact at the hypothalamic level to modulate luteinizing
hormone (LH) secretion (Hiney et al., 2004). Furthermore, 2 0 0 7 W I L E Y - L I S S , I N C .IGF-I was not only able to stimulate GnRH release from the
median eminence but also to enhance LH release by male rat
pituitary cells (Soldani et al., 1995). Another report
demonstrated additive effects of E2 and IGF-I on GnRH-induced
LH secretion in female rat pituitary cells (Xia et al., 2001). These
observations indicate that ER and IGF-IR interactions at the
level of the hypothalamus and the pituitary gonadotrophs may
contribute to the regulation of gonadotropin synthesis and
secretion. However, little information is available concerning
the degree of cross-talk between ER and growth factors at the
level of the pituitary gonadotrophs. In the present study, we
have investigated possible interactions in the murine,
gonadotropic aT3-1 cell line, which expresses the GnRH
receptor (GnRH-R) and the gonadotropin common a-subunit,
but not theirb-subunits (Mellon et al., 1991; Alarid et al., 1996).
We report for the first time the existence of ERa interaction
with the IGF-IR, but not the EGF-R inaT3-1 cells, as revealed by
cell proliferation assays, reporter gene studies and Western
analysis.
Materials and Methods
Plasmids, chemicals and materials
The ERE-tk-Luc vector (Harnish et al., 2000) was a kind gift of Dr. W.
Vanden Berghe (Ghent University, Ghent, Belgium). The pSV-b-Gal67
584 E E R T M A N S E T A L .vector, encoding for the enzyme b-galactosidase, was purchased from
Promega (Leiden, The Netherlands); 17-b-estradiol (E2), tamoxifen
(Tam), 4-hydroxy-tamoxifen (4-OH-Tam), insulin-like growth factor I
(IGF-I), epidermal growth factor (EGF), the mitogen-activated protein
kinase (MAPK) kinase inhibitor PD 98059, trichloroacetic acid (TCA),
sulforodamine B (SRB), trizma base and primary antibodies against
a-tubulin were obtained from Sigma (Bornem, Belgium); ICI 182,780
was purchased from AstraZeneca (Macclesfield, UK). All cell culture
products and Lipofectamine Plus were from Invitrogen (Merelbeke,
Belgium). Activated charcoal was from Merck (Darmstadt, Germany).
Dextran T70 was obtained from Pharmacia (Uppsala, Sweden).
Antibodies against ERa (NCL-L-ER-6F11) and EGF receptor (EGF-R)
were from Novocastra (Newcastle, United Kingdom). The antibody
for the detection of phosphorylated ERa (at serine residue 118) was
obtained from Cell Signaling Technology (Leiden, The Netherlands).
Antibodies against insulin-like growth factor I receptor (anti-IGF-IRa;
SC-712) were from Santa Cruz (Heidelberg, Germany). The enhanced
chemiluminescence (ECL) Western Blotting Detection Reagents and
secondary anti-mouse and anti-rabbit antibodies conjugated to
horseradish peroxidase were from Amersham Biosciences
(Roosendaal, The Netherlands).
Cell culture
The murine, gonadotropic aT3-1 cell line was kindly provided by Dr. P.
Mellon (University of San Diego, La Jolla, CA, USA). The human cervical
HeLa cell line and the human breast cancer cell line MCF-7 (subclone
AZ) were a gift of Dr. P. Briand (Department of Tumor Endocrinology,
Danish Cancer Society, Copenhagen, Denmark). Lung fibroblasts and
pituitaries, isolated from C57BL/6 mice, were provided by Dr. K.
Vermaelen (Ghent University Hospital, Ghent, Belgium). All cell lines
were grown as a monolayer in a 5% CO2, humidified atmosphere
(378C) and weekly passaged in growth medium (Dulbecco’s Modified
Eagle Medium (DMEM) containing 10% fetal calf serum (FCS), 100 units/
ml penicillin G and 100 mg/ml streptomycin. The murine Sertoli TM4
cell line was grown in DMEM: Nutrient Mix F12 supplemented with 5%
horse serum, 2.5% FCS, 100 units/ml penicillin G and 100 mg/ml
streptomycin.
Removal of sex steroids from fetal calf serum (FCS)
Sex steroids were removed from FCS by dextran-coated charcoal
(DCC) treatment. Briefly, a mixture of 10% activated charcoal and 1%
Dextran T70 (50/50) was prepared in a volume equal to that of the
serum to be treated. The mixture was centrifuged (15 min, 4,000 rpm),
the supernatant removed, and the pellet combined with the serum and
mixed by rotation overnight at 48C. The next day, the mixture was
centrifuged (15 min, 4,000 rpm), the supernatant was combined with a
freshly prepared pellet and rotated for 8 h. Following centrifugation (15
min, 4,000 rpm), the supernatant was ultracentrifuged (20,000 rpm, 30
min, 48C) and filter-sterilized (0.2 mm) before use.
RNA isolation and reverse transcription PCR
Using the RNeasy mini-kit, total RNA was extracted from aT3-1 cells,
TM4 cells and from lung fibroblasts, freshly isolated from C57BL/6
mice, treated with DNase and frozen at 208C until analysis.
For reverse transcription PCR analysis of the estrogen receptor a
(ERa), total RNA was reverse transcribed using the RevertAid First
Strand cDNA Synthesis Kit, according to the manufacturer’s
instructions. The following PCR primers were used (fp, forward
primer; rp, reverse primer): a 320 bp-specific amplicon for ERa fp,
50- TGGCGCTCCATGGAACACC-30, ERa rp, 50-
TGCTGCAGAGTCAGGCCAGAT-30 . Total RNA from TM4 cells
was used as a positive control, while mouse fibroblast total RNA served
as an alleged negative control. To check for PCR efficiency, a 238 bp-
specific amplicon for gene b-actin was amplified using fp, 50-
CTGGCACCACACCTTCTA-30 and rp, 50-
GGGCACAGTGTGGGTGAC-30. Primers were based on GenBank
entries NM_007956 and NM_007393 for ERa and b-actin,
respectively. Two microlitres of cDNA were amplified as follows: an
initial denaturation step at 928C for 10 min was followed by 40 cycles
consisting of a denaturation step at 928C for 30 sec, a 30 sec annealing
step 508C, and a 45 sec extension step at 728C. An elongation step of 10
min at 728C finalized the amplification. PCR products were analyzed
using a 2% agarose gel electrophoresis, followed by ethidium bromide
staining.JOURNAL OF CELLULAR PHYSIOLOGY DOI 10.1002/JCPProliferation assay, sulforodamine B (SRB) assay
Optimal growth conditions, including cell density, serum
concentration and exposure time (3, 5, and 7 days) were extensively
investigated resulting in the following protocol:aT3-1 cells (5,000 cells/
well) were seeded in growth medium in 96-well plates. After 48 h,
culture medium was replaced by 200 ml of experimental medium
phenol red free DMEM: Nutrient Mix F12 supplemented with 5% DCC
FCS, 100 units/ml penicillin G and 100 mg/ml streptomycin containing
the test compounds. Experimental medium containing 0.1% ethanol
served as vehicle control. Cell number was assessed using the
colorimetric SRB assay, according to the protocol, described by Skehan
and colleagues (Skehan et al., 1990) after 5 days, found to be an optimal
incubation period when compared to the 3 and 7 days exposure period,
respectively.
Briefly, cells were fixed by adding 50 ml of a 50% TCA solution to
each well, incubated for 1 h at 48C, subsequently washed five times with
water and air-dried. Next, 100 ml of a 0.4% solution (w/v) SRB in 1%
acetic acid solution was added to each well and incubated for 30 min.
Plates were washed with 1% acetic acid solution and air-dried.
Cell-bound SRB was solubilized with 100 ml Trizma base (10 mM) and
the absorbance (492 nm) was determined directly in the 96-well plates
using a Multiskan EX microplate reader (Thermo Labsystems, Brussels,
Belgium). The absorbance at 620nm was used for background
correction. A standard curve, prepared using a serial dilution (1/2) of
16 104 cells/well, was used to calculate cell number. Data are
expressed as a percentage of vehicle control.
Reporter gene studies
aT3-1 cells and TM4 Sertoli cells were seeded in 24-well plates at a
density of 2 105, respectively, 3 104 cells per well in growth
medium. Following overnight incubation, cells were transfected with
ERE-tk-Luc (250 ng) using Lipofectamine Plus according to the
instructions of the manufacturer. In each experiment, a reporter
plasmid, encoding for the enzyme b-galactosidase (b-gal; 20 ng) was
co-transfected in order to control for transfection efficiency. Twenty-
four hours later, cells were incubated for 16 h in experimental medium
containing test compounds. Experimental medium containing 0.1%
ethanol served as vehicle control. For the experiments with the
selective MAPK kinase (MEK) inhibitor PD98059, aT3-1 cells were
preincubated for 2 h with 50 mM of the inhibitor, prior to 16h
stimulation with E2 (100 pM) or IGF-1 (100 ng/ml), in the presence of
PD 98059. After cell lysis, luciferase and b-gal activities were
determined using a Packard Lumicount Microplate luminometer
(Packard Instrument Company Inc., Meriden, CT, USA). Luciferase
values were normalized for b-gal values and the obtained results for
treated cells were expressed relative to the control (untreated cells),
set to 100%.
Western analysis
Lysates were prepared of aT3-1 cells and MCF-7 cells (either vehicle-
or test compound-treated for 4 h), using Laemmli buffer (0.25 M Tris,
1.92 M glycine and 1% sodium dodecyl sulphate (SDS) in aqueous
solution). Lysates were centrifuged at 14,000 rpm for 30 min at 48C,
and protein concentration was determined by Lowry assay. All samples
were diluted with sample buffer (62 mM Tris–HCl, pH 6.8, 10%
glycerol, 5.0% b-mercaptoethanol, 2.0% SDS, 0.0012% bromophenol
blue) and heated at 948C for 5 min. A total of 25 mg of protein was
loaded for each sample. Electrophoresis was carried out on a 10%
separating gel at 100 V for 1 h in a Mini-Protean II electrophoresis
system (BioRad, Nazareth-Eke, Belgium). After electrophoresis,
proteins were transferred from polyacrylamide gels onto
nitrocellulose membranes by electroblotting (0.8 mA/cm2 constant
current, 60 min, room temperature). Following transfer, membranes
were blocked with 5.0% dehydrated non-fat milk in TBS-T (20 mM
Tris–HCl, pH 7.4, 137 mM NaCl, 0.10% Tween-20) for 60 min at room
temperature. Membranes were then washed three times in fresh
TBS-T followed by incubation (1 h) with primary antibody. Following
washing (3 TBS-T, 5 min), membranes were incubated for 1 h in
secondary antibody. Immunodetection was performed with an
enhanced chemiluminescence system (Amersham Biosciences,
Roosendaal, The Netherlands) according to manufacturer’s
specifications. Chemiluminescence was captured on photographic film.
Each Western blot was exposed for 15 sec, 30 sec and 60 sec to
guarantee linearity of the film.68
Fig. 1. Hormone receptor expression in the murine,
gonadotroph-derived aT3-1 cell line. The expression of estrogen
receptor a (ERa) was investigated using the reverse-transcriptase
polymerase chain technique (RT-PCR) using a specific primer set,
yielding an amplicon of 320 bp. The ER-positive TM4 Sertoli cell line
served as a positive control, while lung fibroblasts were used as an
alleged negative control. Western blot analysis was performed to
confirm the presence of ERa protein and to analyze the expression of
the insulin-like growth factor I receptor (IGF-IR) and the epidermal
growth factor receptor (EGF-R). Mouse a-tubulin served as a protein
loading control. Lysates fromthehumanMCF-7/AZbreast cancer cell
line were used as a positive control.
E R a A N D I G F - I R C R O S S - T A L K I N a T 3 - 1 C E L L S 585To determine the phosphorylation status of ERa, densitometric
analysis was performed using Digimizer image analysis software
(Medcalc Software, Mariakerke, Belgium). Briefly, immunoreactive
bands at 66 kDa were quantified following incubation with specific
antibodies directed to phosphorylated ERa and non-phoshphorylated
ERa (total ERa), respectively. Values for phosphorylated ERa were
expressed relative to the corresponding values for total ERa and
normalized for a-tubulin. The obtained results for test-compound
treated cells were expressed relative to the control (vehicle-treated
cells), set to 100%.
Statistics
Data are expressed as a mean standard deviation of at least
three independent experiments. Curve analysis (four parameter
logistic regression) was performed using Sigmaplot 8.0 (SPSS
Benelux, Brussels, Belgium). Statistical analysis was carried out by
one-way ANOVA using the SPSS 12 statistical package (SPSS).
Significant differences were determined by the Dunnet’s post hoc
test.
Results
Hormone receptor expression
The expected RT-PCR product (320 bp) for ERa messenger
RNA (mRNA) was detected in the murine, gonadotropicaT3-1
cell line and in murine Sertoli TM4 cells but not in mouse
fibroblast mRNA, which was used as an alleged negative
control.
In aT3-1 cells, Western analysis showed the presence of a
66 kDa protein, with immunoreactivity towards an ERa
specific antibody. Following incubation with an insulin-like
growth factor I receptor (IGF-IR)-specific antibody, two bands
were found at 130 kDa and 200 kDa. No bands were
detected using an antibody directed to the epidermal
growth factor receptor (EGFR). In contrast, the human breast
cancer MCF-7 cell line, which served as a positive
control, expressed all three receptors. Results are
presented in Figure 1.
Effects of 17-b-estradiol (E2), growth factors and
anti-estrogens on basal cell growth
Optimal growth conditions were obtained using 5% DCC-FCS,
while lower serum concentrations resulted in retarded cell
growth (data not shown). E2 and IGF-I, but not EGF,
dose-dependently stimulated cell proliferation in theaT3-1 cell
line, showing a maximal induction of 33% (100 pM; Fig. 2A) and
82% (100 ng/ml; Fig. 2B), respectively, relative to vehicle
control, set to 100%. IGF-I exerted additive effects on
E2-induced proliferation, reaching a maximum effect of 74%
above the estrogen response (Fig. 3A). Conversely, in aT3-1
cells treated with a fixed concentration of IGF-I (100 ng/ml), E2
dose-dependently enhanced cell proliferation, showing a
maximal response of 35% at 100 pM (Fig. 3B).
Next, dose-response experiments were performed with the
selective estrogen receptor modulator (SERM) tamoxifen
(Tam), its metabolite 4-hydroxy-tamoxifen (4-OH-Tam) and
the pure anti-estrogen ICI 182,780 (ICI). ICI and 4-OH-Tam,
but not Tam, dose-dependently inhibited basal cell proliferation
with a 50% inhibitory concentration (IC50) of 216 pM and
1763 pM for ICI and 4-OH-Tam, respectively. Maximal growth
inhibition of aT3-1 cells was larger for treatment with ICI (78%
reduction at 100 nM), compared to 4-OH-Tam (55% reduction
at 100 nM; Fig. 4A).
Growth inhibition, induced by 10 nM of 4-OH-Tam or ICI,
respectively, was dose-dependently reversed by raising
concentrations of E2 with respective EC50 of 56 pM and 1116
pM (Fig. 4B).
IGF-I reversed ICI (10 nM)-induced basal growth inhibition in
a dose-dependent manner. At the highest tested concentration
(1,000 ng/ml), cell number was 3.83-fold increased inJOURNAL OF CELLULAR PHYSIOLOGY DOI 10.1002/JCPcomparison to cells treated with ICI alone (Fig. 5A). IGF-I
exerted similar effects in aT3-1 cells exposed to 4-OH-Tam
(10 nM; Fig. 5B). Conversely, the growth induction, induced by
100 ng/ml of IGF-I (87%), was dose-dependently inhibited by ICI
and 4-OH-Tam, with an IC50 of 166 pM and 1895 pM,
respectively. As expected, EGF was not able to alter anti-
estrogen-mediated growth inhibition (data not shown).
ER phosphorylation
Following test compound treatment (4 h), the phosphorylation
status of ERa at serine residue 118 (Ser-118) was
investigated by Western analysis, using site-specific
anti-ERa-phosphoserine antibodies. In the aT3-1 cell line,
upon E2-exposure, the level of ERa phosphorylation was
2.6-fold increased (P< 0.05) relative to vehicle control. A
similar response was seen following treatment with 4-OH-Tam
or ICI (2.22-fold and 2.5-fold, respectively). IGF-I stimulated
phosphorylation 1.6-fold (P< 0.05), while no significant effects
could be observed following EGF-treatment. In the human
MCF-7 breast cancer cell line, serving as a positive control, E2
induced Ser-118 phosphorylation 4.4-fold (P< 0.05), while
exposure to 4-OH-Tam or ICI resulted in a 3.72-fold and
2.44-fold increase when compared to vehicle control. IGF-I and
EGF stimulated phosphorylation 2.0-fold and 1.7-fold
(P< 0.05), respectively. The combination of IGF-1 and E2
resulted in a synergistic effect on phosphorylation in both cell
lines. Similar effects were seen when MCF-7 cells were exposed
to the combination of E2 and EGF. In contrast, the latter growth
factor did not alter the estrogen-induced phosphorylation
status in the aT3-1 cell line. Results are presented in
Figure 6A, B for the aT3-1 and MCF-7 cell line, respectively.69
Fig. 2. Influence of 17-b-estradiol (E2) and IGF-I on basal cell growth
in the murine, gonadotroph-derived aT3-1 cell line. aT3-1 cells were
treated for 5dayswith eitherE2 (100pM; (A)) or IGF-I (100ng/ml; (B))
and cell proliferation was determined using the SRB assay. Data are
calculated as a percentage of vehicle control, set to 100%, and
expressed as a meanW standard deviation (SD) of at least six
independent experiments. Asterisk (M) designates significant
(P<0.05) differences from vehicle control (B).
Fig. 3. Influence of combined IGF-I and 17-b-estradiol (E2) exposure
on basal growth in the murine, gonadotroph-derived aT3-1 cell line.
aT3-1 cells were treated for 5 days with E2 (100 pM; (A)) or IGF-1
(100 ng/ml; (B)) alone or in combination with raising concentrations
of IGF-I (0.01–100 ng/ml) or E2 (1 pm–10 nM), respectively. Cell
proliferation was determined using the SRB assay. Data are
calculated as a percentage of vehicle control, set to 100%, and
expressed as a meanW standard deviation (SD) of at least six
independent experiments. Asterisk (M) designates significant
(P<0.05) differences from vehicle control (B). Number sign (#)
designates significant (P<0.05) differences from E2-treated cells
(A) or IGF-1-treated cells (B), respectively.
586 E E R T M A N S E T A L .Effects of E2, growth factors and anti-estrogens on
ER-mediated gene transcription
In aT3-1 cells, transiently transfected with an ER-driven
reporter construct (ERE-tk-Luc), E2 dose-dependently induced
luciferase activity (EC50¼ 0.78 pM). At 100 pM, a maximal
induction of 58% was achieved. IGF-I, but not EGF,
dose-dependently enhanced ER-driven luciferase gene
expression, with a 1.9-fold increase at 100 ng/ml relative to
vehicle-treated cells.
IGF-I exerted additive effects on E2 (100 pM)-induced
luciferase activity, showing a maximal induction of 1.7-fold at
10 ng/ml relative to E2-treated cells. At the highest
concentration (100 ng/ml) tested, luciferase activity was only
1.2-fold increased when compared to the estrogen-exposed
aT3-1 cells. The results are presented in Figure 7.
Similar to the growth experiments, the anti-estrogens ICI
and 4-OH-Tam dose-dependently inhibited basal luciferase-
activity, with an IC50 of 349 pM and 802 pM, respectively.
Maximal inhibition, observed at 100 nM, was similar in the
ICI-treated group (67% reduction) and the 4-OH-Tam-treated
group (64% reduction). Under our experimental conditions,
Tam was not able to inhibit basal luciferase activity (Fig. 8).
As a control, TM4 Sertoli cells were transfected in parallel
with the same ER-driven reporter construct. Although E2
induced a maximal response of 14.5-fold at 100 pM, with anJOURNAL OF CELLULAR PHYSIOLOGY DOI 10.1002/JCPEC50 of 12 pM, ICI and 4-OH-Tam were not able to alter the
basal response in the TM4 cell line (data not shown).
In aT3-1 cells, co-incubation with raising concentrations
of E2 dose-dependently reversed the inhibition of basal
luciferase activity, induced by 4-OH-Tam (10 nM) or ICI (10
nM), with EC50 values of 130 pM and 940 pM for cells treated
with 4-OH-Tam and ICI, respectively (data not shown).
Furthermore, IGF-I dose-dependently reversed ICI-induced
inhibition of ER-mediated luciferase activity. At the highest
tested concentration (1,000 ng/ml), luciferase activity was
2.8-fold increased in comparison to cells, treated with ICI alone.
Similar results were observed for IGF-I in 4-OH-Tam-treated
cells (Fig. 9).
Next, we assessed the effects of the mitogen activated
protein kinase (MAPK) kinase (MEK) inhibitor PD 98059 on
ER-mediated luciferase activity in aT3-1 cells, treated with
either E2 (100 pM) or IGF-1 (100 ng/ml). PD 98059 significantly
(P< 0.001) inhibited both E2- and IGF-1-stimulated luciferase
gene expression, by 17% and 65%, respectively. The response
to IGF-1 in PD 98059-exposed cells did not differ from vehicle
control (Fig. 10).
Discussion
In the present study, under estrogen-free conditions, the
pure anti-estrogen ICI 182,780 (ICI) and the selective70
Fig. 4. Anti-estrogen-induced basal cell growth inhibition and
reversal by E2 in the murine, gonadotroph-derived aT3-1 cell line.
aT3-1 cells were exposed to tamoxifen (Tam; 1-100,000 pM),
4-hydroxy-tamoxifen (4-OH-Tam; 1-100,000 pM) or ICI 182,780
(ICI; 1-100,000 pM), either alone (A) or in combination with raising
concentrations of E2 (0.1-100,000 pM; (B)) for 5 days. Cell
proliferation was determined using the SRB assay. Data are
calculated as a percentage of vehicle control (A) or as a percentage
of the values obtained with the highest concentration of E2 and
expressed as a meanWSD of three independent experiments
(B). Asterisk (M) designates significant (P<0.05) differences from
vehicle control (A) or from 4-OH-Tam-treated cells (B). Number
sign (#) designates (P<0.05) significant differences from
ICI-treated aT3-1 cells (B).
Fig. 5. Effect of IGF-I on anti-estrogen-induced growth inhibition in
the murine, gonadotroph-derived aT3-1 cell line. aT3-1 cells were
treated for 5 days with ICI (10 nM; (A)) of 4-OH-Tam (10 nM; (B)),
alone or in combination with raising concentrations of IGF-I
(0.1–1,000 ng/ml). Cell proliferation was determined using the SRB
assay. Data are calculated as a percentage of vehicle control and
expressed as a meanWSD of three independent experiments.
Asterisk (M) designates significant (P<0.05) differences from
anti-estrogen-treated cells.
E R a A N D I G F - I R C R O S S - T A L K I N a T 3 - 1 C E L L S 587estrogen receptor modulator (SERM) 4-hydroxy-tamoxifen
(4-OH-Tam) elicited a dose-dependent inhibition of basal cell
proliferation and estrogen receptor (ER)-mediated gene
expression in the murine, gonadotropic aT3-1 cell line. In
contrast, no effects were seen following treatment with
tamoxifen (Tam), hereby suggesting the lack of cytochrome
P450 isoenzyme CYP2D6 expression, which catalyzes the
conversion of Tam into its active metabolite 4-OH-Tam (Goetz
and Loprinzi, 2003), in theaT3-1 cells. These growth-inhibitory
effects could be reversed by either 17-b-estradiol (E2) or
insulin-like growth factor I (IGF-I), both exerting modest
mitogenic effects in theaT3-1 cell line. Another group reported
a maximal growth induction of 60% following E2-exposure.
Furthermore, growth suppression, induced by the SERM
raloxifen, was dose-dependently reversed by E2 in aT3-1 cells.
The authors suggested that raloxifen may block estrogen
receptor (ER) binding and its corresponding activation by
residual estrogens, present in dextran-coated charcoal
(DCC)-treated fetal calf serum (FCS) (Williams et al., 2000).JOURNAL OF CELLULAR PHYSIOLOGY DOI 10.1002/JCPThey used 2% stripped FCS, consisting of serum which was
DCC-treated for only 25 min. This protocol differs from ours,
whereby FCS was DCC-treated twice for at least 8 h. Although
this does not exclude the possibility that very low residual
estrogen concentrations still induced a cellular response in the
aT3-1 cells, this seems unlikely in view of our parallel
observations for the TM4 Sertoli cell line. These cells were
transiently transfected with the same ER-driven reporter
construct under identical experimental conditions (same
batches of DCC-FCS) as for the aT3-1 cell line. We
observed no effects of ICI and 4-OH-Tam in this highly
estrogen-responsive cell line. In any case, even though it is not
possible to exclude that minimal residual estrogens may
stimulate the highly sensitive aT3-1 cells under our assumed
estrogen-free conditions, this does not change the fact that the
inhibition of basal cell proliferation and basal ER-driven gene
transcription by anti-estrogens was effectively reversed by
both E2 and IGF-1 (Fig. 5A, B).
In reproductive tissues, complex estrogen and growth factor
receptor interactions are involved in the regulation of cell
proliferation and differentiation (Sato et al., 2002; Levin, 2003;
Song and Santen, 2006). Growth factor receptor-activated
mitogen-activated protein kinase (MAPK) enhances
phosphorylation of serine residue 118 (Ser-118), present in the
amino-terminal activation function (AF-1) domain of ERa. We
have demonstrated both ERa and insulin-like growth factor-I71
Fig. 6. Phosphorylation of ERa at serine residue 118 (Ser118). Cells
were exposed to E2 (100 pM), IGF-I (I; 10 ng/ml), EGF (10 ng/ml),
4-OH-Tam (Tam; 10 nM) and ICI (10 nM) for 4 h. In parallel, cells were
treated with the combination of E2 (100 pM) and IGF-I (10 ng/ml),
or EGF (10 ng/ml), respectively. The phosphorylation status at
Ser118 was determined by Western analysis using a site-specific
phospho-ERa antibody. Using densitometric analysis, bands were
quantified and the obtained results for test-compound treated cells
were expressed relative to the control (vehicle-treated cells; (B)), set
to 100%. A and B shows the results for the aT3-1 cell line and the
human MCF-7 breast cancer cell line (subclone AZ; positive control)
respectively. Asterisk (M) designates significant (P<0.05) differences
from vehicle control.
Fig. 7. Influence of E2 and IGF-I on ER-mediated transcriptional
activity aT3-1 cells were transiently transfected with an
estrogen-responsive reporter plasmid (ERE-tk-Luc), in combination
with a control vector encoding for b-galactosidase (b-gal).
Transfected cells were stimulated for 16 h with E2 (100 pM), IGF-I
(100 ng/ml) or the combination of both hormones (10 or 100 ng/ml of
IGF-1), respectively. Luciferase values were normalized for b-gal
values and expressed relative to vehicle control, set to 100%. Asterisk
(M) designates significant (P<0.05) differences from vehicle control.
Fig. 8. Influence of anti-estrogens on ER-mediated transcriptional
activity in the murine, gonadotroph-derived aT3-1 cell line. aT3-1
cells were transiently transfected with an estrogen-responsive
reporter plasmid (ERE-tk-Luc), in combination with a control vector
encoding for b-galactosidase (b-gal). Transfected cells were
stimulated with Tam (1–10,000 pM), 4-OH-Tam (1–100,000 pM) or
ICI (1–10,000 pM) for 16 h. Luciferase values were normalized for
b-gal values and expressed relative to vehicle control, set to 100%.
Asterisk (M) designates significant (P<0.05) differences from vehicle
control.
588 E E R T M A N S E T A L .receptor (IGF-IR) expression, while the epidermal growth
factor receptor (EGF-R) seemed to be absent in the aT3-1 cell
line. The latter observation is supported by the lack of any
response following EGF-treatment. In our hands, Ser-118
phosphorylation was significantly (P< 0.05) stimulated by
both E2 and IGF-I in either aT3-1 or MCF-7 cells, with an
additive effect when both hormones were combined. It has
been demonstrated that Ser-118 phosphorylation resulted in an
increased ER-transcriptional activity (Kato et al., 1995; Bunone
et al., 1996). Indeed, in the aT3-1 cell line, both E2 and IGF-I
stimulated ER-mediated transactivation of an estrogen
response element (ERE), with a further enhancement of the
E2-mediated response by IGF-I. Furthermore, basal and E2- or
IGF-I-induced gene transcription was dose-dependently
inhibited by either ICI or 4-OH-Tam, respectively. It is
important to mention that Ser-118 phosphorylation was also
induced by both anti-estrogens, in agreement with other
experiments, performed in breast cancer cells (Lipfert et al.,
2006).JOURNAL OF CELLULAR PHYSIOLOGY DOI 10.1002/JCPOur findings indicate a key role for ERa in the regulation of
aT3-1 cell proliferation. Furthermore, IGF-I synergistically
enhanced ER-mediated phosphorylation, which is in contrast to
our proliferation and transfection experiments, showing only
additive effects of IGF-I on the E2-induced responses. The exact
mechanisms of action in the aT3-1 cells are yet to be fully
elucidated. However, many reports have demonstrated that
ligand-activated growth receptors can induce Ser-118
phosphorylation through the mitogen-activated protein kinase
(MAPK) pathway (Kahlert et al., 2000; Lannigan, 2003; Levin,72
Fig. 9. Influence of IGF-1 on anti-estrogen-induced inhibition
of ER-mediated transcriptional activity in the murine,
gonadotroph-derived aT3-1 cell line. aT3-1 cells were transiently
transfected with an estrogen-responsive reporter plasmid
(ERE-tk-Luc), in combination with a control vector encoding for
b-galactosidase (b-gal). Transfected cells were stimulated with
4-OH-Tam (10 nM) or ICI (10 nM), alone or in the presence of IGF-1
(1,000 ng/ml) for 16 h. Luciferase values were normalized for b-gal
values and expressed relative to vehicle control, set to 100%. Asterisk
(M) designates significant (P<0.05) differences from vehicle control.
Number sign (#) designates (P<0.05) significant differences from
anti-estrogen-treated aT3-1 cells
E R a A N D I G F - I R C R O S S - T A L K I N a T 3 - 1 C E L L S 5892003). Indeed, in our experiments, the specific MAPK kinase
(MEK) inhibitor PD 98059 was able to significantly inhibit
ER-mediated luciferase gene transcription, induced by either E2
(100 pM) or IGF-I (100 ng/ml). The IGF-1-mediated response
was strongly repressed (66%) by the MEK inhibitor and did no
longer differ from vehicle control, hereby indicating the
involvement of MAPK in the activation of ERa through the
IGF-IR signaling pathway. Furthermore, it is interesting that PD
98059 partly inhibited the E2-mediated response, although, not
as strong as observed for IGF-I. In this regard, it can be noticedFig. 10. Influence of the MEK-inhibitor PD 98059 on E2- and
IGF-1-induced ER-mediated transcriptional activity in the murine,
gonadotroph-derived aT3-1 cell line. aT3-1 cells were transiently
transfected with an estrogen-responsive reporter plasmid
(ERE-tk-Luc), in combination with a control vector encoding for
b-galactosidase (b-gal). Transfected cells were treated with E2
(100 pM) or IGF-1 (100 ng/ml), either alone or in the presence of the
MEK inhibitor PD 98059 (50 mM) for 16 h. Luciferase values were
normalized for b-gal values and expressed relative to vehicle control,
set to 100%. Asterisk (M) designates significant (P<0.05) differences
from vehicle control (B).
JOURNAL OF CELLULAR PHYSIOLOGY DOI 10.1002/JCPthat ER activation in aT3-1 cells may, at least in part, be
regulated by MAPK signaling. Alternatively, the limited decrease
in the E2-mediated response following PD 98059 treatment may
be explained by the inhibition of effects, induced by low
concentrations of IGF-1, present in our experimental medium,
although no inhibitory effect was observed in cells, treated with
this MEK-inhibitor alone.
Recent studies have demonstrated that rapid, non-genomic
effects of estrogens are mediated through the Src/Ras/Raf/
MAPK signaling pathway (Wong et al., 2002; Barletta et al.,
2004).
Coupling between ERa and this pathway occurs through a
newly identified protein, called modulator of non-genomic
activity of ER (MNAR), which facilitates ERa interactions with
members of the Src family in a ligand-dependent manner.
Activation of Src by ERa stimulates the Src/Ras/Raf/MAPK
signaling pathway, resulting in increased phosphorylation of
Ser-118 in the AF1 domain of ERa.
In the present study, we have only analyzed the effects of E2
and IGF-1 on the phosphorylation status of Ser-118. However,
other serine residues (at positions 104, 106, and 167), present
in the AF-1 domain of ERa are also important determinants of
ER transcriptional activity. Barletta et al. (2004) demonstrated
that MNAR was not able to enhance ERa transcriptional activity
when these serine residues (including Ser-118) were mutated
to alanine.
However, ERa transcriptional activity not only depends on
phosphorylation of the ligand-independent AF-1 domain, but
also on interactions of the latter with the hormone-dependent
AF-2 domain, located in the ligand-binding domain (LBD)
(Moggs and Orphanides, 2001). For instance, 4-OH-Tam blocks
AF-2, but allows weak AF-1 activity (Tzukerman et al., 1994;
McDonnell et al., 1995) while other anti-estrogens such as ICI
allow neither AF-1 nor AF-2 activity (McDonnell et al., 1995;
Metzger et al., 1995). Furthermore, cofactor recruitment, their
corresponding phosphorylation and other post-transcriptional
processes such as ligand-dependent proteasome degradation
are parameters which influence ER transcriptional activity
(Moggs and Orphanides, 2001; Nawaz and O’Malley, 2004).
In the present study, we describe interactions between ERa
and the IGF-IR. However, the physiological significance of this
cross-talk at the level of the pituitary gonadotrophs remains to
be established. Our findings support the results of other
reports, demonstrating modulatory effects of either E2 or IGF-I
on pituitary gonadotrophs, in particular on LH secretion
(Soldani et al., 1995; Xia et al., 2001; Hiney et al., 2004). Rose
et al. (2004) demonstrated cross-talk between the GnRH-
receptor (GnRH-R) and the IGF-IR signaling pathways in the
aT3-1 cells. Furthermore, estrogens may interfere with the
GnRH-R signaling pathway in a non-genomic manner.
Several reports demonstrated physical interaction with
and consequent activation of Gas- and Gaq proteins by
membrane-bound ERs (Wyckoff et al., 2001; Levin, 2005; Zhang
and Trudeau, 2006). These G proteins play a key role in the
cellular regulation of cyclic AMP (cAMP), inositol-1,4,5-
triphosphate (IP3) and calcium production (Hubbard and
Hepler, 2006).
It is important to mention that, in pituitary gonadotrophs,
these second messengers mediate the effects of gonadotropin-
releasing hormone (GnRH) following binding to its receptor
(Yuen et al., 2002; Ruf et al., 2003).
All these findings may suggest that estrogenic action on
GnRH-induced gonadotropin production and release may, at
least in part, be realized through complex interactions between
the GnRH-R, the IGF-IR and ERa at the level of the pituitary
gonadotrophs.
In conclusion, our data indicate the occurrence of cross-talk
between the ER and the IGF-IR in the murine, gonadotropic
aT3-1 cell line. Although the physiological significance of this73
590 E E R T M A N S E T A L .phenomenon is yet to be established, rising evidence suggest
the involvement of IGF-I in the regulation of gonadotropin
synthesis and secretion by the pituitary gonadotrophs.
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Chapter 5 Summary and Discussion  
5.1 Background 
To date, extensive research has been conducted on substances of both natural and 
anthropogenic origin, which may affect normal function of the endocrine system. 
Especially in the field of human reproduction, there is growing scientific and public 
concern, as the number of fertility disorders, including decreased sperm quality, 
urogenital tract abnormalities and cancers of reproductive tissues appears to have 
become more prevalent (for review see Eertmans et al., 2003). From this point of 
view, estrogen and androgen receptors represent two main targets of these endocrine 
modulating substances. 
In the current project, we have focused on the effects on the pituitary gonadotrophs of 
compounds showing either estrogenic or anti-estrogenic properties. The importance of 
these effects is emphasized by the widespread occurrence of environmental 
xenoestrogens, the raising intake of phytoestrogens and the growing number of 
pharmaceutical estrogenic compounds (human estrogen-replacement therapy and oral 
contraceptives), selective estrogen receptor modulators (SERMs) used in the 
management of diseases such as osteoporosis, and compounds with predominant anti-
estrogenic action, which are used for the treatment of estrogen-dependent 
malignancies (Singleton and Kahn, 2001; Safe and Papineni, 2006). In table 5.1, we 
present an overview of the clinical use of some SERMs, together with their tissue-
specific effects. 
During recent years, many studies revealed that estrogens are important mediators of 
cell proliferation and differentiation in reproductive tissues such as the breast and the 
uterus (Diel, 2002; Ikeda and Inoue, 2004). In contrast, less information is available 
concerning these regulatory effects at the level of the pituitary gonadotrophs, being 
key players for reproduction. This relative lack of information is surprising, as 
gonadotrophs are responsible for gonadotropin synthesis and secretion, driven by the 
hypothalamic gonadotrophin-releasing hormone (GnRH) (Wildt et al., 1981) and 
modulated by gonadal hormone feedback. In particular, estrogens can alter luteinising 
hormone (LH) and follicle stimulating hormone (FSH) release in either a positive or 
negative manner (for review see Introduction chapter 1.1.3.2.3). 
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Table 5.1: Overview of the clinical use of SERMs and their tissue specificity. 
5.2 The LβT2 cell line: a mature, gonadotropic cell line of 
murine origin 
The original aim of the present work was to develop and validate an in vitro bioassay 
using the murine, gonadotropic LβT2 cell line for the assessment of (anti-)estrogenic 
effects at the level of the pituitary gonadotrophs. This cell line has been developed by 
directing the simian virus 40 (SV40) T antigen oncogene to pituitary gonadotrophs of 
transgene mice using an 1800 bp fragment of the rat LHβ-subunit (LHβ-su) promoter 
region. Following characterisation of clones, isolated from the resulting tumour, LβT2 
cells appeared to closely reflect characteristics of mature gonadotrophs in vivo. They 
expressed a functional GnRH receptor (GnRH-R), together with the common α 
glycoprotein hormone subunit (α-GSU) and the rat LHβ-su (Alarid et al., 1996; Mellon 
et al., 1991; Windle et al., 1990). Under basal conditions, LβT2 cells secrete rat LH, 
while repeated exposure to GnRH enhanced LH release, hereby demonstrating that the 
well-described self priming effect of gonadotrophs in vivo has been preserved (Turgeon 
et al., 1996). However, it was initially presumed that LβT2 cells were not able to 
secrete FSH, as expression of its subunit appeared to be absent. Although, Graham and 
SERM Indication Agonism Antagonism 
Clomifene Male infertility 
 
• Bone 
 
• Hypothalamus 
 
• Breast 
 
• Endometrium 
 
• Cervix 
 
Raloxifene Osteoporosis 
 
• Bone 
 
• Serum lipids 
 
• Breast 
 
• Uterus 
 
Breast cancer 
 
• Endometrium 
Tamoxifene 
 
• Bone 
 
• Cardiovascular 
markers 
 
 
• Breast 
colleagues (1999) demonstrated FSH release following GnRH stimulus in the presence of 
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activin A. 
The mature properties of the LβT2 cell line, together with the scarcity of similar 
5.3 GnRH-enhanced LH secretion in the LβT2 cell line 
cterisation 
r laboratory originates from the laboratory of Dr. 
gonadotropic cell lineages, makes it an important tool for researchers who are 
interested in the regulation of gonadotropin synthesis and secretion. A potential 
advantage of this cell line is the fact that it might replace the use of primary pituitary 
cell cultures, which show a limited lifespan, require labour-intensive preparation and 
are subjected to batch variability. Furthermore, gonadotrophs only represent 10-15% of 
the total pituitary cell population (Wang, 1988), hereby complicating the analysis of 
gonadotroph-specific effects when using primary pituitary cell cultures. For these 
reasons, we have chosen the LβT2 cell line to study estrogenic regulatory mechanisms 
at the level of pituitary gonadotrophs. 
In the present work, the first part of the results section describes the chara
of the LβT2 cell line, followed by the analysis of estrogen-mediated effects on GnRH-
induced LH synthesis and secretion 
The cell line which was used in ou
Mellon (San Diego, California, USA). This batch was directly obtained from her 
laboratory with some (negative) findings being checked in a second directly obtained 
batch. Using the reverse transcriptase polymerase chain reaction (RT-PCR) technique, 
we confirmed the expression of messenger RNA (mRNA) encoding for the GnRH-R, the 
α-GSU and both gonadotropin β subunits (showing variable expression for FSHβ). These 
results indicate that the LβT2 cell line, which was used for our experiments, preserved 
the characteristics of mature gonadotrophs. In table 5.2, we give a short overview of 
hormone (receptor) mRNA expression in the LβT2 cell line, as observed in our 
laboratory.  
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Table 5.2: Overview of hormone (receptor) mRNA and/or protein expression in the 
gonadotropic LβT2 cell line according to literature data, compared to our 
observations. 
Hormone (receptor) mRNA expression in LβT2 cells Expected Results 
 
• Gonadotropin-releasing hormone receptor 
• α-glycoprotein hormone subunit expression 
• Luteinizing hormone β subunit expression 
• Follicle Stimulating Hormone β-subunit  
• Estrogen receptor α mRNA 
• Estrogen receptor β mRNA 
• Estrogen receptor α protein  
• Estrogen receptor β protein 
• Truncated estrogen receptor product 1 mRNA 
• Truncated ERα mRNA (exon 4 deletion) 
• Androgen receptor expression 
• Glucocorticoid receptor expression 
  
+ 
+ 
+ 
variable 
+ 
weak 
+ 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
not determined 
+ 
not determined 
+ 
+ 
 
the third treatment day, the maximal secretory response was observed for cells 
In a next series of experiments, the effects of GnRH alone on LH synthesis and 
secretion have been evaluated in the LβT2 cell line. In order to allow data comparison, 
we have adapted the protocol of Turgeon et al (1994) and Nicol et al (2002). In our 
hands, daily repeated exposure to short pulses of GnRH (15 min) enhanced LH 
secretion, except on the first treatment day. Similar findings were reported by the 
above-mentioned groups. However, in their experiments, GnRH was able to stimulate 
LH release at the first treatment day. These data indicate that LβT2 cells may be naïve 
to GnRH and require self-priming in order to upregulate LH release. Nevertheless, at 
treated with 10 nM of GnRH, while LH release decreased at higher concentrations, in 
agreement with the observations of Nicol and colleagues (2002). It has been well 
described that potent GnRH-R agonists and sustained exposure to GnRH may induce 
GnRH-receptor desensitisation and downregulation. According to our experiments, this 
seems an unlikely explanation for the decrease of LH secretory response during 
exposure to high GnRH concentrations. Indeed, rat LHβ-su promoter activity and mRNA 
expression, as determined following repeated GnRH exposure at treatment day three, 
were dose-dependently stimulated by GnRH, showing maximal induction at 1 μM. In 
addition, when longer exposure periods (1h-6h) were applied, the LH secretory pattern 
was identical in comparison to cells treated according to the short pulse protocol (15 
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min). One possible explanation for the observed decrease in LH release in LβT2 cells 
which were repeatedly exposed to high concentrations of GnRH may be impairment of 
post-transcriptional processes and/or vesicle storage.  
In this first part of the work, we have described the effects of GnRH alone at three 
important levels, involved in LH production, namely rat LHβ-su promoter activity, the 
corresponding mRNA expression and LH secretion. This has shown that LβT2 cells do 
secrete LH in response to GnRH stimulation, display a self priming response to repeated 
exposure to GnRH that is reminiscent of a similar response in vivo, and that impaired 
response of LH during exposure to high GnRH concentrations does not seem to result 
from GnRH receptor desensitisation. Table 5.3 illustrates our results concerning LH 
synthesis and secretion in the LβT2 cells. 
In a next step, we have evaluated LH secretory response following co-incubation with 
17-β-estradiol (E2). 
 
Table 5.3: Overview of the effects of GnRH alone, or in the presence of either E2 or 
Dex, on LH synthesis and secretion in the gonadotropic LβT2 cell line according to 
literature data and compared to our observations. 
LH synthesis/secretion in LβT2 cells Our results 
 
• GnRH-enhanced LHβ-su mRNA expression 
 
 
• GnRH-enhanced LHβ-su gene expression 
 
 
• Dose-dependent LH secretion by GnR 
 
 
 
 
 
• E2 stimulation of GnRH-enhanced LHβ-su gene 
transcription and corresponding LH secretion 
 
• Dex stimulation of GnRH-enhanced LH-secretion 
 
• Dose-dependent activation 
 
 
• Dose-dependent activation 
 
 
• Day 1: No effect 
• Day 2: Dose-dependent 
stimulation 
• Day 3: U-shaped dose-
response curve 
 
• No effects of E2 
 
 
• Stimulatory effect of Dex 
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5.4 Absence of estrogenic effects in the mature, gonadotropic 
LβT2 cell line 
Surprisingly, GnRH-mediated LH synthesis remained unaltered, while Turgeon et al. 
(1994) and Nicol et al. (2002) described significant albeit rather modest effects of 
estrogen exposure on LH secretion. Our negative results cannot be explained by the use 
of a different experimental protocol, as identical culture and experimental conditions 
were applied in our experiments. Moreover, those negative findings were confirmed by 
extensive evaluation of alternative experimental conditions (data not shown) 
In order to evaluate ER functionality in the LβT2 cell line, we have performed cell 
proliferation assays and transient transfection studies using an estrogen-responsive 
plasmid (ERE-tk-Luc). Neither E2 nor anti-estrogens such as the pure anti-estrogenICI 
182,782 (also known as fulvestrant) and 4-hydroxy-tamoxifen (4-OH-Tam), the active 
metabolite of the SERM tamoxifen were able to elicit any effect on cell growth or 
estrogen receptor (ER)-mediated gene transcription (data not shown). 
Analysis of estrogen receptor expression in our LβT2 cell line demonstrated the 
presence of estrogen receptor α (ERα) mRNA, while the ERα isoform transcript 
appeared to be absent. Furthermore, neither ERα nor ERβ protein expression could be 
detected in Western analysis using several specific primary antibodies. The absence of 
any estrogenic response in our LβT2 cells can, at least in part, be explained by the 
absence of both ER isoforms. However, when LβT2 cells were transfected with an 
expression vector, encoding for the human ERα (hERα) in the presence of an estrogen 
responsive reporter plasmid, E2 was not able to enhance ER-mediated gene 
transcription, despite the demonstrated expression of ERα protein using Western blot 
analysis. One could postulate that factors related to species specificity may be 
responsible for the latter negative results. However, parallel experiments, performed 
in the highly estrogen-responsive , murine TM4 Sertoli cell line demonstrated that 
overexpression of hERα enhanced ER-mediated luciferase expression in comparison to 
TM4 cells, transiently transfected with the ERE-tk-Luc vector alone (data not shown). 
The lack of estrogenic response in our LβT2 cell line is not a general nuclear receptor 
problem because androgens and glucocorticoids were able to enhance AR- respectively 
GR-mediated gene transcription, as determined using transient transfection studies 
with the androgen and glucocorticoids responsive MMTV-reporter construct.  
A short overview of the nuclear-receptor mediated effects on gene transcription in the 
LβT2 cell line is presented in table 5.4. 
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Table 5.4: Overview of the nuclear receptor (NR)-mediated gene transcription in 
the gonadotropic LβT2 cell line according to literature data and compared to our 
observations. 
NR-mediated gene transcription in LβT2 cells Our results 
  
• No response 
 
• Estrogen receptor-mediated gene transcription  
 
• Androgen receptor-mediated gene transcription 
(MMTV-promoter) 
• Dose-dependent 
activation 
 
• Glucocorticoid receptor-mediated gene transcription 
(MMTV-promoter) 
 
• Dose-dependent 
activation 
 
 
Furthermore, in our experiments, the glucocorticoid dexamethasone (Dex) enhanced 
GnRH-induced LH secretion, in accordance to the reports by Turgeon et al. (1994) and 
Nicol et. al (2002). The LH secretory response in cells treated with both E2 and Dex was 
identical in comparison to cells exposed to Dex alone.  
Other factors may be responsible for the lack of estrogenic effects in our LβT2 cell 
line. In the literature, many researchers have investigated the existence of ERα mRNA 
splicing variants and their possible effects on full length ERα signalling, especially in 
humans (Poola and Speirs, 2001; Herynk and Fuqua, 2004). These mRNA variants may 
encode for proteins which can either enhance or inhibit ER transcriptional activity. In 
the rat and the mouse pituitary, a specific ERα variant, also called truncated estrogen 
receptor product 1 or TERP-1, has been identified by the group of Schreihofer. TERP-1 
itself is transcriptionally inactive but can interfere with full length receptor activity in 
a positive or negative manner, depending on the ratio of TERP-1 over ERα. (Schreihofer 
et al., 1999; Resnick et al., 2000; Schreihofer et al., 2000). However, we were not 
able to demonstrate TERP-1 expression in the LβT2 cell line, hereby excluding the 
hypothesis that this truncated isoform could negatively modulate ER activity in our 
LβT2 cell line. For this reason, we did screening for other possible ERα mRNA variants. 
Currently, little information is available concerning ER expression during embryonic 
differentiation of the mouse pituitary gonadotrophs. In the chicken, Liu and colleagues 
(2005) demonstrated that ERα expression was already present in an early stage of 
pituitary development and was predominantly found in gonadotrophs. Furthermore, the 
authors reported an increase in ERα expression until the day of birth.  
In the rat, ERβ expression appeared to be higher than that of ERα during embryonal 
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development, showing a reversal around day of birth (Nishihara et al., 2000). As 
mentioned before, ERβ mRNA expression was rather low (αT3-1) or undetectable 
(LβT2), while no receptor protein could be detected in either cell lines following 
Western analysis (data not shown). 
According to our experiments, wild type ERα is already present in an early stage of 
ative ERα 
 of full length ERα mRNA to this mRNA splicing 
g variant in the regulation of ER 
differentiation (E11.5; αT3-1 cells), hereby suggesting an important role of ERα in 
gonadotroph differentiation. However, in a later phase of gonadotroph development 
(E16.5-17.5; LβT2 cells), ERα expression appeared to be completely absent. 
Using a primer set adapted from Swope and colleagues (2002), an altern
mRNA splicing variant was detected in both gonadotropic αT3-1 and LβT2 cell lines. 
According to our knowledge, we describe for the first time the existence of this ERα 
mRNA splicing variant in pituitary gonadotrophs. This alternative message theoretically 
encodes for a 42.4 kDa protein, lacking most of the ER ligand binding domain. 
Although, we were unable to demonstrate the presence of this protein in the αT3-1 and 
LβT2 cell lines following Western analysis. One hypothesis may be that, following 
translation of this mRNA variant, the resulting protein folds in a different way in 
comparison to the wild type ERα. This may result in altered secondary and tertiary 
structures, whereby specific epitopes, to which the applied antibody is directed, are 
oriented differently and may not be recognised. Another possibility is the fact that this 
mRNA splicing variant is highly unstable. It has been demonstrated that unliganded 
nuclear receptors are stabilised by heat shock protein 90 (HSP90) by binding with the 
LBD (Fang et al., 2006). As this variant message encodes for a protein, lacking most of 
the LBD, it is possible that HSP90 is not able to bind this truncated protein, hereby 
resulting in faster protein degradation. 
It is important to mention that the ratio
variant was remarkably lower in LβT2 cells in comparison to the αT3-1 gonadotropic 
and TM4 Sertoli cell lines, being both estrogen-responsive. As described previously, in 
our hands ERα expression was completely absent in the LβT2 cell line. Furthermore, 
following overexpression of ERα in these cells, no ER-mediated gene transcription could 
be demonstrated. These data suggest that, in view of the higher expression of the 
truncated message in comparison to the wild type ERα, the former may influence ERα 
signalling in a negative manner in the LβT2 cell line.  
Our findings suggest an important role for this splicin
signalling at the level of the pituitary gonadotrophs. The relative abundance of full 
length ERα and this variant message depends on the stage of gonadotroph 
differentiation and may determine the degree of estrogenic responsiveness. Future 
studies must reveal whether this truncated protein could act as dominant negative or 
positive transcription factors to modulate the expression of ER target genes and what 
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may be the regulatory mechanisms that regulate its relative abundance. Elucidation of 
these points may ultimately contribute to our understanding of the mechanisms 
underlying the developmental and physiological actions of estrogens in the pituitary 
gonadotrophs. 
5.5 Estrogen receptor-mediated effects in the murine, 
As ou ic effects at the level of the pituitary 
gonadotropic αT3-1 cell line 
r interest pertains primarily to estrogen
gonadotrophs, the LβT2 cell line was not a suitable model for our purposes. For this 
reason, we turned to the αT3-1 cell line as an alternative gonadotropic cell line for the 
study of estrogenic effects. The αT3-1 cell lineage was generated using SV40 Tag 
oncogenesis by the group of Mellon (Mellon et al., 1991; Windle et al., 1990). An 1800 
bp fragment of the promoter region of the α-GSU gene was targeted to the pituitary of 
transgene mice. One of the obtained clones, namely the αT3-1 cell line, corresponded 
to an earlier stage of embryonic differentiation, showing GnRH-R and α-GSU 
expression, while gonadotropin β-su expression and corresponding hormone release 
remained absent. The presence of a functional ER, as described in several reports 
(Williams et al., 2000; Demay et al., 2001; Schausi et al., 2003; Weiss et al., 2003) 
made us decide to choose for the αT3-1 cell line as an alternative for LβT2 cells. The 
cell line, used in our laboratory, expressed mRNAs encoding for ERα and ERβ 
respectively, as demonstrated by RT-PCR. Furthermore, Western blot revealed the 
presence of both ERα and ERβ proteins, showing higher expression for the former 
isoform. Following transient transfection with an estrogen-responsive reporter plasmid 
(ERE-tk-Luc), E2 dose-dependently stimulated ER-mediated gene transcription, hereby 
confirming receptor functionality. In table 5.5, we present an overview of hormone 
(receptor) expression in the αT3-1 cell line. 
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Table 5.5: Overview of hormone (receptor) mRNA and/or protein expression in the 
gonadotropic αT3-1 cell line according to literature data, compared to our 
observations. 
Hormone (receptor) expression in αT3-1 cells Expected Results 
 
• Gonadotropin-releasing hormone receptor 
mRNA 
• α-glycoprotein hormone subunit mRNA 
• Luteinizing hormone β subunit expression 
• Follicle Stimulating Hormone β-subunit  
• Estrogen receptor α mRNA 
• Estrogen receptor β mRNA 
• Estrogen receptor α protein  
• Estrogen receptor β protein 
• Insulin-like growth factor I receptor mRNA 
• Insulin-like growth factor I receptor protein 
• Epidermal growth factor (EGF) 
 
+ 
 
+ 
- 
- 
+ 
+ 
+ 
- 
+ 
Not determined 
Not determined 
 
+ 
 
+ 
- 
- 
+ 
Weak 
+ 
- 
+ 
+ 
- 
 
As estrogens are important mediators of cell growth and differentiation, we have 
performed cell proliferation experiments to evaluate possible mitogenic effects of E2 in 
the αT3-1 cell line. Several parameters, including serum concentration, start cell 
density and exposure time were thoroughly investigated in order to obtain optimal 
culture conditions. Following a five days incubation period, E2 exhibited rather modest 
proliferative effects. Interestingly, under presumed estrogen-free conditions, ICI 
182,780 and 4-OH-Tam appeared to be strong inhibitors of basal cell proliferation. 
Similar results were obtained in αT3-1 cells transiently transfected with the ER-
responsive reporter plasmid ERE-tk-Luc. One could postulate that the presence of 
residual estrogens in the stripped fetal calf serum explains the observed growth 
reduction. For this reason, we have performed parallel experiments in the highly 
estrogen-sensitive TM4 Sertoli cell line. Incubation with raising concentrations of E2 
resulted in a biphasic growth curve, showing either growth stimulation or repression at 
low respectively higher concentrations. In contrast to our findings in the αT3-1 cells, 
ICI 182,780 and 4-OH-Tam were not able to affect basal cell proliferation. 
Furthermore, E2 strongly enhanced ER-mediated gene transcription in TM4 cells which 
were transiently transfected with the ERE-tk-Luc reporter construct.  In similarity to 
the growth experiments, neither of the two anti-estrogens affected basal gene 
transcriptional activity (data not shown). According to these data, we may conclude 
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that the observed growth inhibition in αT3-1 cells exposed to compounds with anti-
estrogenic action is highly unlikely caused by blockade of residual estrogens in our 
incubation system but rather suggests involvement of other factors important for cell 
proliferation and differentiation. 
In summary, this part of our experiments confirmed the presence of a functional ER-
mediated signalling in the αT3-1 cells and showed that cell proliferation is modestly 
stimulated by E2 while, surprisingly, inhibited by anti-estrogens under presumed 
absence of estrogenic stimulation. A short overview of the proliferation and 
transfection experiments, performed in αT3-1 cells, is given in tables 5.6 and 5.7. 
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Table 5.6: Overview of growth modulatory effects of E2, IGF-I, the pure anti-
estrogen faslodex and the SERM 4-OH-Tam in the gonadotropic αT3-1 cell line 
according to literature data, compared to our observations. 
Growth modulatory effects in αT3-1 cells Expected Results 
 
• Stimulatory effects of E2 
 
 
• Stimulatory effects of IGF-I 
 
 
• Inhibitory effects of faslodex (ICI 
182,780) 
 
 
• Inhibitory effects of 4-OH-Tamoxifen 
 
 
• Reversal of faslodex-induced growth 
inhibition by E2 
 
• Reversal of faslodex-induced growth 
inhibition by IGF-I 
 
• Reversal of 4-OH-Tam-induced growth 
inhibition by E2 
 
• Reversal of 4-OH-Tam-induced growth 
inhibition by IGF-I 
 
 
+ 
 
 
+ 
 
 
Not determined 
 
 
 
Not determined 
 
 
Not determined 
 
 
Not determined 
 
 
Not determined 
 
 
Not determined 
 
 
Dose-dependent 
stimulation 
 
Dose-dependent 
stimulation 
 
Dose-dependent 
inhibition 
 
 
Dose-dependent 
inhibition 
 
Dose-dependent 
reversal by E2 
 
Dose-dependent 
reversal by IGF-I 
 
Dose-dependent 
reversal by E2 
 
Dose-dependent 
reversal by IGF-I 
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Table 5.7: Overview of the influence of E2, IGF-I, the pure anti-estrogen faslodex 
and the SERM 4-OH-Tam on ER-mediated signaling in the gonadotropic αT3-1 cell 
line according to literature data, compared to our observations. 
ER-mediated signaling in αT3-1 cells Expected Results 
 
• Stimulatory effects of E2 on ER-
mediated gene transcription 
 
• Stimulatory effects of IGF-I on ER-
mediated gene transcription 
 
• Inhibitory effects of faslodex (ICI 
182,780) on ER-mediated gene 
transcription 
 
• Inhibitory effects of 4-OH-Tamoxifen on 
ER-mediated gene transcription 
 
• Reversal of faslodex-induced inhibition 
of ER-mediated gene transcription by E2 
 
• Reversal of faslodex-induced inhibition 
of ER-mediated gene transcription by 
IGF-I 
 
• Reversal of 4-OH-Tam-induced 
inhibition of ER-mediated gene 
transcription by E2 
 
• Reversal of 4-OH-Tam-induced 
inhibition of ER-mediated gene 
transcription by IGF-I 
 
• ER-phosphorylation (serine 118) by E2 
 
• ER-phosphorylation by IGF-I 
 
 
+ 
 
 
Not determined 
 
 
Not determined 
 
 
 
Not determined 
 
 
Not determined 
 
 
Not determined 
 
 
 
Not determined 
 
 
 
Not determined 
 
 
 
Not determined 
 
Not determined 
 
 
Dose-dependent 
stimulation 
 
Dose-dependent 
stimulation 
 
Dose-dependent 
inhibition 
 
 
Dose-dependent 
inhibition 
 
Dose-dependent 
reversal by E2 
 
Dose-dependent 
reversal by IGF-I 
 
 
Dose-dependent 
reversal by E2 
 
 
Dose-dependent 
reversal by IGF-I 
 
 
+ 
 
+ 
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5.6 Growth factor receptor and estrogen receptor cross-talk 
in the αT3-1 cell line 
In reproductive tissues such as the breast and the uterus, several studies revealed that 
estrogens may elicit their mitogenic effects through complex interactions with growth 
factors such as insulin-like growth factor (IGF) and epidermal growth factors (EGF) 
(Garcia-Segura et al., 2006; Silva and Shupnik, 2007). We demonstrated the presence 
of the transcript encoding for the IGF-I receptor and expression of the corresponding 
protein in the αT3-1 cell line. In contrast, the EGF receptor (EGF-R) appeared to be 
absent, as assessed both at mRNA and protein level. 
In our hands, IGF-I stimulated basal cell proliferation and appeared to be a stronger 
mitogen in αT3-1 cells in comparison to E2. As expected, EGF did not alter αT3-1 cell 
growth. Interestingly, both E2 and IGF-I were able to reverse anti-estrogen-induced 
growth inhibition to a similar extent. In addition, IGF-I stimulated ER-mediated gene 
transcription in αT3-1 cells which were transiently transfected with ERE-tk-Luc. In 
similarity to our observations in the proliferation experiments, this growth factor dose-
dependently reversed anti-estrogen-induced inhibition of basal luciferase activity. 
Conversely, both IGF-I-induced effects on cell proliferation and ER-mediated effects 
were dose-dependently inhibited by the anti-estrogens ICI and 4-OH-Tam. These 
findings are in agreement with other reports, showing that both anti-estrogens 
repressed expression of important mediators of the IGF-IR signalling pathway Pollak et 
al., 1992; Colletta et al., 1994; Chan et al., 2001). 
Our data indicate that interactions between IGF-IR and ER may occur in αT3-1 cells. 
Currently, the mechanisms of action are not completely elucidated, although, there is 
evidence that the estrogen-mediated and growth factor-mediated pathways of cell 
proliferation require common downstream signalling pathways. Growth factors act 
through high affinity tyrosine kinase receptors (Herbst, 2004; Scaltriti and Baselga, 
2006) while estrogen receptors belong to the superfamily of nuclear receptors 
(Mangelsdorf et al., 1995; Truss and Beato, 1993). Many studies have investigated these 
receptor interactions in the breast and the uterus. The main mechanism of action 
involves activation of the mitogen-activated protein kinase (MAPK) signalling pathway 
following ligand binding to the IGF-1R. In turn, activated MAPKs stimulate ERα 
phosphorylation, which finally results in enhanced receptor transcriptional activity, 
even in the absence of estrogens (Chen et al., 2002; Joel et al., 1998; Lee and Bai, 
2002). Interestingly, activation of MAPK pathway is also induced by E2 itself and 
requires mobilisation of intracellular calcium. It appears that a feed-forward system 
exists where E2 activates MAPK, an event that in turn enhances ERα transcriptional 
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activity. This has been extensively described in chapter 1.2.4 of the introduction. 
It is important to mention that cross-talk only occurs between the IGF-IR and ERα, and 
not with ERβ.  These differences may be in part due to different activating function 1 
(AF-1) domains because ERα reveals constitutive AF-1 activity, whereas ERβ lacks 
constitutive AF-1 activity (Mendez et al., 2006). 
Several studies showed that ERα phosphorylation occurs at the amino-terminal A/B 
domain. However, outside of this domain, sites have been identified in the DNA binding 
domain (DBD), in the hinge region and in the ligand binding domain (LBD). Within the 
A/B domain, Ser-104, -106, -118, -154, and -167 were characterised as phosphorylation 
sites in the presence of E2. However, one of the main targets of phosphorylation is Ser-
118 (Ali et al., 1993; Kato et al., 1995). Indeed, in our experiments, using a site-
specific phospho-ERα antibody, we demonstrated that both E2 and IGF-1 induced ERα 
phosphorylation at Ser-118. However, a higher phosphorylation status was observed for 
αT3-1 cells treated with E2 when compared to IGF-I. The combination of both hormones 
resulted in a synergistic effect on ERα phosphorylation. We already mentioned that 
increased ERα phosphorylation resulted in enhanced receptor transcriptional activity. 
However, in our experiments, we observed that both 4-OH-Tam and ICI were able to 
stimulate ERα phosphorylation at Ser-118, while ER-mediated gene transcription dose-
dependently decreased following SERM or pure anti-estrogen exposure. Similar findings 
were reported in breast cancer cells by Le Goff et al. (1994) and Joel et al. (1998). 
However, ERα phosphorylation is mediated by different kinases, depending on agonist 
or antagonist binding. Furthermore, ER transcriptional activity not only depends on its 
phosphorylation status. Other factors, including receptor dimerisation, receptor 
conformation and the binding of coregulators will determine the final outcome 
following ligand binding (see also Introduction chapter 1.2.3.1 for review).  
Our data indicate that MAPK signalling may be involved in cross-talk between ERα and 
the IGF-IR in the αT3-1 cell line. Indeed, the specific MAPK kinase inhibitor PD-98059 
strongly repressed IGF-1-induced luciferase activity in αT3-1 cells transiently 
transfected with ERE-Luc. Interestingly, the effect of E2 was only partially inhibited 
following co-incubation with PD-98059. These data suggest that not only MAPK is 
involved in ERα activation following E2-binding, but that other kinases are involved in 
ERα phosphorylation in the αT3-1 cell line.  
It has long been assumed that estrogens only elicit genomic actions through their 
receptor. However, in recent years, rapid, non-genomic actions of estrogens have been 
reported, whereby the MAPK signalling pathway plays an important role (Dos Santos et 
al., 2002; Xiao-Dong et al., 2007).  
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5.7 Physiological relevance of growth factor and estrogen 
receptor cross-talk in gonadotrophs? 
According to our knowledge, very limited literature data have reported interactions 
between ERα and the IGF-IR at the level of the pituitary gonadotrophs (Kanematsu et 
al., 1991; Adam et al., 2000; Pazos et al., 2004; Weiss et al., 2006). Currently, the 
physiological relevance of this phenomenon remains unclear. However, a limited 
number of studies demonstrated that IGF-I was able to alter LH secretion. 
Furthermore, Rose and colleagues (2004) reported interactions between the GnRH-R 
and the IGF-IR in αT3-1 cells. As extensively described in the introduction (chapter 
1.3.2.1), GnRH elicits its effects through its G-protein coupled receptor. Following 
ligand-binding, the GnRH-R activates second messengers such as cyclic AMP (cAMP), 
inositol-1, 4, 5-triphosphate (IP3) and calcium production. It has been described that 
estrogens may also interfere with this signalling pathway in a non-genomic manner via 
physical interactions between membrane-bounds ERs and Gαs- and Gαq proteins. These 
G-proteins play a key role in the cellular regulation of above mentioned second 
messengers of the GnRH signalling pathway. All these findings together suggest that 
estrogens may, at least in part, elicit their effects on GnRH-mediated LH synthesis and 
secretion through complex interactions with the IGF-IR. However, more research is 
required to further elucidate the exact mechanisms of action behind this cross-talk.  
In summary, we have demonstrated that cross-talk exists between ERα and the IGF-IR 
in the αT3-1 cell line. Both receptors interact with each other through the MAPK 
signalling pathway, which plays a key role in the regulation of cell differentiation and 
proliferation. As previously mentioned, the physiological importance of this 
phenomenon remains unclear at the present. However, a limited number of reports in 
the literature, together with our data, indicate that IGF-I signalling may be an 
important mediator of estrogenic effects at the level of the pituitary gonadotrophs. 
According to our experiments in the more differentiated LβT2 cell line, IGF-IR 
expression remained absent, as determined at mRNA and protein level respectively 
(data not shown). Mellon and colleagues demonstrated that the latter cell line 
corresponds to embryonic day 17.5, while αT3-1 cells reflect an earlier stage of 
differentiation (E11.5) (Mellon et al., 1991; Windle et al., 1990). One could postulate 
that, in mice, IGF-I and ERα may play a crucial role in the differentiation process of 
gonadotrophs during embryonic development, while in a later stage of differentiation, 
IGF-IR and ERα signalling may disappear, as reflected by our observations in LβT2 cells. 
Nevertheless, this seems highly unlikely, as other groups have reported modulatory 
effects of IGF-I on LH secretion in rodent. Moreover, E2 is a well documented regulator 
of gonadotropin secretion at the pituitary level, as shown in vivo in a variety of 
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mammal species. 
A more acceptable hypothesis is the fact that LβT2 cells may not faithfully reflect in 
vivo characteristics of pituitary gonadotrophs, whereby E2 signalling seems to be a less 
stable feature of these cells, being sensitive to dedifferentiation due to presently 
unknown factors. 
Despite the lack of gonadotropin β su expression and the corresponding hormone 
release in the αT3-1 cells, this cell line seems to be an interesting in vitro model for 
the study of estrogenic regulatory effects in pituitary gonadotrophs. 
5.8 The αT3-1 cell line: an in vitro model for the assessment 
of potential estrogenic compounds at the level of pituitary 
gonadotrophs 
In previous parts of this work, we have evaluated estrogen receptor-mediated effects 
in two immortalised, gonadotropic cell lines of murine origin, differing in stage of 
differentiation; only the αT3-1 cell line seems to be potentially suited for the in vitro 
study of estrogenic effects on gonadotrophs in vitro. Despite some limitations, 
including the lack of gonadotropin β-su gene expression, the αT3-1 cell line is a useful 
in vitro tool to assess agents with potential estrogenic properties at the level of the 
pituitary gonadotrophs.  
In ongoing work in our laboratory, potential estrogenic activity of phytoestrogens on 
pituitary gonadotrophs is assessed using the αT3-1 cell line. These kinds of studies are 
needed because of the growing interest in the use of phytoestrogens as estrogen 
replacement therapy in menopausal women. It has been widely demonstrated that 
estrogen withdrawal may play an important role in the onset of typical menopausal 
symptoms such as hot flushes, vaginal dryness and tachycardia. Furthermore, these 
symptoms are correlated with elevated gonadotropin serum levels. For this reason, the 
intake of phytoestrogens may be an alternative for hormonal replacement therapy, as 
these compounds mainly elicit their effects through estrogen receptors. Nevertheless, 
in clinical studies, the observed effects of phytoestrogens, such as isoflavones, on 
menopausal symptoms remain contradictory and therefore inconclusive (Wuttke et al., 
2007).  
The target site of these plant-derived compounds in the central compartment of the 
reproductive axis may be located at the level of the hypothalamus and/or the 
pituitary. However, at present, rather little information is available concerning 
gonadotroph-specific effects of these plant-derived compounds. Therefore, results 
obtained in the above-described study in αT3-1 cells, may provide useful information 
on possible regulatory effects and the corresponding mechanisms of action of these 
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plant-derived compounds at the level of the gonadotrophs. 
As an example, we show in figure 5.1 an example of preliminary data on growth 
modulatory effects in αT3-1 cells exposed to derivatives of 8-prenyl-naringenin (8-PN) 
derivatives. At this moment, 8-PN has been identified as one of the most potent 
phytoestrogens, together with genisteine (Milligan et al., 2000; Milligan et al., 2002). 
8-PN belongs to the group of prenylated flavanones, together with 6-prenylnaringenin 
and isoxanthohumol. These compounds have been isolated from hops (Humulus 
lupulus), a flower which is used as a flavouring agent in the brewing industry (Milligan 
et al., 1999). In our hands, 8-PN dose-dependently induced cell proliferation in a 
similar manner as E2 in the αT3-1 cell line (data not shown). 
Recently, Roelens and colleagues have developed synthetic derivatives of 8-PN by 
substituting the prenyl group at position 8 by alkyl chains, differing in chain length and 
branching pattern (Roelens et al., 2006). In our laboratory, we have investigated ERα 
and ERβ transactivation capacities of 8-PN and its derivatives. For this purpose, human, 
cervical Hela cells were transiently transfected with an estrogen-responsive reporter 
plasmid in the presence of either a human ERα respectively ERβ expression vector. 
Based on the obtained results, we have selected compounds showing ER antagonistic 
properties. These derivatives were characterised by the presence of a long alkyl chain 
(being n-heptyl, n-nonyl respectively n-undecyl) at position 8. Following exposure to 
these naringenin-derivatives, αT3-1 cell proliferation was dose-dependently inhibited, 
showing a similar response as observed with the pure anti-estrogenICI 182,780 and 4-
OH-Tam.  
As mentioned before, these data are preliminary and additional experiments, including 
transient transfections and analysis of growth factor receptor cross-talk, are required 
to further elucidate the effects of phytoestrogens such as 8-PN and its derivatives in 
the αT3-1 cell line. 
5.9 Advantages and disadvantages of gonadotroph cell 
lineages  
The effects of GnRH on gonadotropin release by pituitary gonadotrophs have been well 
described. Nevertheless, the molecular mechanisms of action behind gonadotropin 
synthesis and release are not fully elucidated. Therefore, gonadotropic cell lines such 
as the LβT2 cell line, expressing both LH and FSH β subunits, are welcome in vitro tools 
for this purpose. According to our knowledge, the number of gonadotropic cell lineages 
is very limited. Less differentiated cell lines (for example the αT3-1 cell line) are also 
available, but the lack of β-subunit expression is a limitation for the study of 
gonadotropin regulation. For this reason, Yonehara and colleagues (2003) stably 
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transfected the αT3-1 cell line with the complementary DNA (cDNA) encoding for the 
LHβ-subunit. The obtained clone, the LH2 cell line, was found able to synthesize and 
secrete LH. 
 
Figure 5.1: Growth inhibitory effects of 8-prenyl-naringenin derivatives in the 
gonadotropic αT3-1 cell line. 
Gonadotropic αT3-1 cells were exposed to derivatives of 8-prenyl-naringenin, whereby the 
prenyl group at position 8 was substituted by a long alkyl chain, varying in chain length (C4: 
n-heptyl; C5: n-nonyl; C6: n-undecyl). αT3-1 cells were treated for 5 days with raising 
concentrations (1-10000 nM) of these compounds. Cell proliferation was determined using 
the SRB assay. Data are calculated as a percentage of vehicle control and expressed as a 
mean ± SD of 3 independent experiments (Unpublished results by Eertmans F., Roelens F., 
De Keukeleire D. and Kaufman J.-M.) 
 
However, since its development, the LβT2 cell line served as the golden standard for in 
vitro analysis of gonadotroph-specific effects because of its mature characteristics, 
reflecting physiological properties in vivo. During recent years, a large body of 
research data described different aspects of gonadotropin synthesis, secretion and 
storage in LβT2 cells.  However, caution is required when interpreting data, obtained 
 
93
  
with immortalised cell lines. This is nicely illustrated by the absence of estrogenic 
response in the LβT2 cell line in our hands. Moreover, this finding being at variance 
with prior reports of estrogenic responses in LβT2 cells, although the latter reports are 
rather limited and the reported effects rather weak. Several factors, including 
dedifferentiation and culture conditions may contribute to these observed 
discrepancies.  
Another limitation of studies such as ours in isolated cell lines is the fact that only 
gonadotroph-specific responses have been evaluated. It has been demonstrated that, in 
vivo, gonadotrophs interact with other (secretory and non secretory) pituitary cell 
types, including lactotrophs and somatotrophs (Andries et al., 1995; Cheung, 1983; 
Denef and Andries, 1983). Nevertheless, these interactions may complicate data 
analysis when using tissue explants or primary pituitary cell cultures, which are also 
difficult to standardize. Obviously the choice of experimental model will depend on the 
nature of the questions asked (e.g. screening for modulatory effects of 
pharmacological compounds versus study of complex physiological regulatory 
mechanism) and different models for in vitro study of gonadotropin regulation should 
be regarded as complementary, in vitro study being in turn complementary to in vivo 
approaches.  
In conclusion, notwithstanding the described limitations and the necessity of careful 
data analysis, gonadotropic cell lines such as the αT3-1 and LβT2 cell lines are useful 
tools for the study of gonadotropin synthesis and secretion. In our hands, only the αT3-
1 cell line was found suitable for the purpose of analysing estrogenic effects in 
gonadotrophs. In particular, we expect that in ongoing and future work, this model can 
prove useful to assess potential (anti-)estrogenic effects of phytoestrogens and 
xenoestrogens the gonadotrophs... 
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